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ABSTRACT OF THE DISSERTATION
Magnetic Resonance-guided High Intensity Focused Ultrasound (MRgHIFU) induced
hyperthermia (HT) for treatment of cervical cancer
by
Lifei Zhu
Doctor of Philosophy in Biomedical Engineering
Washington University in St. Louis, May 2021
Michael B. Altman, Ph.D., Chair
Hong Chen, Ph.D., Co-Chair
Hyperthermia (HT), which refers to increasing the temperature of the tumor tissue to 40–45°C
for an extended period of time, has been reported to be one of the most effective sensitizers for
radiation therapy (RT) and/or chemotherapy. High intensity focused ultrasound (HIFU) has been
developed as a non-invasive and non-ionizing tool to induce localized HT. Magnetic resonance
thermometry (MR thermometry) is one of the most reliable methods for non-invasively and
precisely measuring the in vivo volumetric temperature in real time. The integration of MR
thermometry with HIFU has been implemented in commercially available magnetic resonance
guided high intensity focused ultrasound (MRgHIFU) systems. MRgHIFU has been previously
reported to administer HT to both animals’ muscles and rectal cancer in human patients using
MR thermometry and feedback control [1,2].
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Cervical cancer is the fourth most prevalent cancer in women worldwide. Patients with locally
advanced cervical cancer (stage IB3-IVA) have worse survival and higher rates of recurrence
compared to early stage disease. The addition of HT to RT substantially improves local control
and overall survival without affecting treatment-related grade 3–4 toxicity, according to six
phase III/IV clinical trials [3–9].
In previous clinical studies, the HT was induced by microwaves or radiofrequency, which have
limitations including superficial penetration or non-localized heating [10,11]. As a newlyemerged technique, although the feasibility of MRgHIFU induced HT have been evaluated in the
thigh muscle in a porcine model [1,12], no study has evaluated the feasibility of using MRgHIFU
induced HT in various clinically-mimicking pelvic targets. Additionally, no published work has
demonstrated successful implementation using the largest volume HT (diameter, Ø=58 mm) for
either deep or superficial targets. Furthermore, insufficient assessment has been performed for
the targetability of MRgHIFU in primary cervical cancer. However, the above-mentioned
evaluations are all necessary steps prior to the clinical translation. Therefore, to address these
unmet needs before clinical application, the objectives of this dissertation were (1) to review the
available ultrasound-induced HT technology and evaluate published clinical studies combining
ultrasound induced HT with RT in the treatment of neoplasms in different human organ systems,
(2) to evaluate the feasibility and safety parameters of performing MRgHIFU induced HT to an
array of tissue geometries in the pelvis in a porcine model, (3) to characterize the temperature
distribution and tissue damage profile of the largest (Ø=58 mm) HT cell in both deep (i.e., 6-cm)
and superficial (i.e., 2-cm) targets in vivo with different user-definable parameters, (4) to
retrospectively evaluate the percentage of primary lesions and metastatic lymph nodes in late-
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stage cervical cancer (stage IIIB–IVA) patients that can be targeted by a clinical MRgHIFU
device, and to assess optimal patients positioning for the highest targetability rate. In addition,
any statistical correlation between the patients’ anatomical geometries/demographics and
targetability was also explored. Finally, challenges and future directions are also discussed. The
overall goal of the dissertation is to comprehensively evaluate MRgHIFU induced HT, in order
to facilitate, accelerate, and serve as an impetus for the clinical translation of MRgHIFU induced
HT for the late stage cervical cancer.
For the feasibility and safety evaluation, we demonstrated the feasibility of using MRgHIFU to
heat a set of clinically mimicking pelvic targets including the muscle adjacent to the ventral and
dorsal bladder wall, and the uterus with satisfactory safety parameters. The temperature was
maintained within the desired range with reasonable accuracy (1°C within the target range),
precision, temperature variation, and heating uniformity for up to 30 minutes. Satisfactory safety
parameters were measured by contrast-enhanced MRI, macroscopic tissue observations, and by
histological analysis.
For the large field HT characterization with the diameter of 58 mm, MRgHIFU-induced largevolume HT is feasible in both deep (i.e., 6-cm) and superficial (i.e., 2-cm) targets with
satisfactory (<1°C within the target range) temperature characteristics. Target tissue histology
showed some localized tissue damage within the HT volume. No thermal-related skin or
subcutaneous tissue damage was observed. We also demonstrated the potential of using feedback
control planes to tailor the spatially delivered thermal dose to clinical targets.
For the retrospective study, we found that most late-stage cervical cancer patients were targetable
by MRgHIFU-induced HT in at least one orientation/angle assuming minimal intervention. No
xvi

rotation, or a rotation of less than 5°, had the highest chance of anterior targetability, while a
rotation of 25°–30° had the highest chance of posterior targetability. Patients’ characteristics and
anatomical geometric factors could be used to predict the anterior or posterior targetability and
the targeting cross-sectional diameter.
Here the results have demonstrated that this technique has the capability to safely heat an array
of different pelvic target geometries with mild/reversible tissue damage (with Ø=18 mm), to
achieve satisfactory temperature for both deep and superficial (with Ø=58 mm) with heating
distributions modifiable by user-definable parameters, as well as to target most late stage cervical
cancer primaries with no/minimal potential intervention. These results therefore support
proceeding into clinical trials of HT delivered by MRgHIFU for late-stage cervical cancer
patients receiving RT.

xvii

Chapter 1: Ultrasound-induced
hyperthermia for radiosensitization
1.1 Introduction
Hyperthermia therapy (HT) refers to the procedure of raising tissue temperatures to 40–45°C for
various lengths of time (up to 60 min) [13–15]. HT is different from thermal ablation. Thermal
ablation rapidly heats cancerous tissue to temperatures >60°C, which are sufficient for
coagulative necrosis [16]. In contrast, HT is not intended to produce substantial cell death
directly. There have been efforts to treat tumors with HT alone over the years; however, HT is
most often used in combination with other therapeutic modalities including chemotherapy and
radiation therapy (RT). HT has been successfully used as a sensitizer for chemotherapy in the
treatment of various solid tumors [15,17–20]. Several reviews have summarized the current
understanding of HT synergistic effects with chemotherapy and outcomes from various clinical
studies [21–23]. This chapter focuses on discussing the combination of HT with RT for cancer
treatment.
HT is one of the most effective radiation sensitizers [24]. Treating cancer with heat dates
back to pre-Christian times, with reports found on Egyptian papyrus and writings from
Hippocrates [25,26]. At the beginning of the 20th century, William Coley observed that induction
of fever by injecting patients with killed bacteria led to tumor regression [27]. Clinical studies
from the 1990s until now have demonstrated that HT could interact synergistically with ionizing
RT to improve tumor control and survival rate, as summarized in several reviews [23,24,28,29].
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By the end of the last century, there was a dampening in the enthusiasm for HT in clinical
practice mainly due to a lack of proper heating and temperature monitoring techniques [30].
Since the beginning of this century, there has been a resurgence of interest in HT because of the
development of reliable HT applicators and adequate dosimetry using non-invasive magnetic
resonance (MR) thermometry. MR thermometry is a noninvasive temperature monitoring
technique based on MR parameters that are sensitive to temperature changes [31–34]. As of
2014, there were 109 clinical trials involving HT listed at ClinicalTrials.gov [35], and more
recent trials have been summarized by [29]. The positive outcomes of numerous trials strongly
support the rationale of using HT to improve the outcomes of RT in the clinic.
The evolution of ultrasound HT techniques up to the 20th century has been summarized in a
review by Diederich and Hynynen [10]. This chapter presents advances in ultrasound HT devices
to date, evaluates clinical studies on ultrasound HT radiosensitization, and concludes with a
discussion of remaining challenges and future directions. Specifically, by the discussion in this
chapter, we elaborate the reason for selecting ultrasound for inducing HT and justify the reasons
for choosing the pelvic geometry as a potential suitable candidate for receiving the HT. It was
written by performing an extensive bibliographic search associated with ultrasound-mediated HT
and RT in PubMed using the following keywords: radiotherapy, hyperthermia, ultrasound
hyperthermia, high-intensity focused ultrasound, and ultrasound. The references from selected
studies were manually examined to identify relevant reports and summarized in this review.
Clinical studies published after 1990 were considered only when those studies explicitly mention
that informed consent was received from each patient and the study protocol was approved by
the local ethics committee or institutional review board. This criterion was not used for clinical
2

studies published before 1990, given that explicit mention of conformance to human study rules
was not required in published works in those early years.

1.2 Mechanisms of HT-induced radiosensitization
The exact mechanisms for HT-induced radiosensitization were slowly revealed. As briefly
described below, existing understanding of the underlying rationale of heat-induced
radiosensitization includes HT impairment of deoxyribonucleic acid (DNA) repair caused by RT,
HT induced changes in the tumor microenvironment, and HT stimulation of immune response
[36,37]. More detailed discussions of the mechanisms are available in several reviews [38,39].
Early studies concerning the mechanisms of HT-induced radiosensitization focused on the
cellular consequences of combined treatments on DNA damage and its repair [40,41]. HT alone
was found to neither lead to DNA damage by itself nor to increase the DNA damage induced by
RT [42]. Most studies concluded that the inhibition of the repair of RT-induced DNA damage by
HT accounted for the synergistic interaction of HT and RT [43,44]. More recent studies have
found that HT inhibits homologous recombination [45–47] and leads to the shunting of early
DNA double-strand break repair to nonhomologous-end rejoining, which is more error-prone
[48]. In other words, it has a higher possibility to encounter an error in the DNA repair process
comparing with homologous end rejoining, which is essentially error-free. HT was recently
found to inhibit many other types of DNA double-strand break repair [49], which suggested the
possibility of using synthetic lethality, a type of genetic combination where the co-occurrence of
two genetic events results in organismal or cellular death [50], to escalate the effectiveness of
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such inhibition [51]. The latter approach has been reported to be successful using poly (ADPribose) polymerase inhibitors [47].
The tumor microenvironment plays an essential role in both tumor progression, metastasis, and
therapeutic response [52,53] and alterations in the tumor microenvironment are a hallmark of
cancer [54]. In the tumor microenvironment, persistent hypoxia formed due to a lack of oxygen
diffusion in the highly abnormal tumor microvasculature and the failure of rectifying the oxygen
insufficiency. Hypoxia leads to a lack of oxidation of DNA free radicals by O2, thus causing the
failure to induce DNA breaks, which is one of the main mechanisms of ionizing radiation
affecting the tumor cells [55]. Additionally, tumor hypoxia has been proved to drive the tumor to
a more malignant phenotype and stimulating the tumor invasion and metastasis [56]. HT can
rectify the hypoxia at both tissue and cellular levels [57]. At the tissue level, HT has been shown
to increase blood flow and enhance tissue oxygenation, all of which improve the response of
tissues to RT, as reviewed by Vaupel and Kelleher 2010 [57]. Increased blood flow also changes
the pH in the tumor, which in turn sensitizes the tumor to HT [reviewed in [37])]. These effects
have been found in several clinical studies [58–60]. At the cellular level, HT has a greater effect
on hypoxic cells than on aerated cells regarding cytotoxicity [61,62] through the induction of
mitochondrial damage and oxidative stress [63].
There is compelling evidence that HT can lead to activation of the immune system [64]. HT
induces heat shock proteins [65], some of which can activate both the innate and adaptive
immune systems [66,67]. Inhibitors of the most abundant heat shock protein 90 (hsp90) lead to
radiosensitization, and a subset of soft-tissue sarcomas that express elevated levels of hsp90 was
associated with poor prognosis, arguing for the use of such inhibitors in the clinic [68]. Another
4

important effect of hypoxia that has been elucidated recently is the suppression of the anti-tumor
effector cells and the enhancement of the escape of the tumor from immune surveillance [69].
Several studies have shown that such immune suppression can be reversed by HT [69]. RT has
also been shown to affect the host immune system both locally and systematically [70]. RT
promotes the release of cytokines that recruit antigen presenting cells into the tumor
microenvironment, leading to the activation of the cytotoxic T-cell function. The interaction of
these immunological consequences of RT with HT has been reviewed in the context of using
high-intensity focused ultrasound (HIFU) heating for radiosensitization [71].
In addition, there are other critical mechanisms related to HT-induced radiosensitization,
including tumor thermotolerance and vascular thermotolerance, both of which should also be
taken into considerations when designing clinical trials. Tumor thermotolerance refers to that one
HT session may cause a temporal heat resistance in the tumor cells against subsequent HT
(Overgaard and Nielsen 1983)[72]. The vascular thermotolerance means that two HT sessions
with an interval of within 48 hours can substantially increase the blood flow compared with a
single HT [73,74]. The vascular thermotolerance is of great significance because they can
potentially be utilized to improve tumor oxygenation for up to 2 days after the application of one
HT session. Both of these two mechanisms have an impact on the designing of clinical studies
because an optimal time interval between sequential HT sessions can be found, below which
adding more HT sessions may improve tumor oxygenation for the radiosensitization; while
above which additional HT may have little beneficial effects on RT response. Multiple HT in a
row is still advantageous for clinical hyperthermia when they are separated by a few days
because thermotolerance decays back to baseline thermosensitivity after a few days [75]. It was
5

recommended that HT treatment should be given only twice per week to remove effects of
thermotolerance [25].

1.3 HT techniques
HT techniques typically fall into three categories: whole-body, local, and regional [26]. Wholebody HT is typically used to treat metastatic disease by heating the entire body of patients using
physical modalities, such as heated air, heated water, infrared chamber, heated blankets, and
extracorporeal blood-warming [76,77]. Local HT is generally used to treat solid, localized
disease at or near the surface of the skin or natural body orifices [21,23]. Regional HT is
generally used for diseases in deeper tissues [78]. One approach to deep-seated tumor heating
has been applying technologies used for external local heating at regional levels. Another
approach has been inserting specially designed sterile probes through body cavities for
intracavitary heating. The heating techniques are often characterized as superficial or deep, or as
external and internal [79]. The route of application various for different methods. Superficial
heating is normally achieved using devices outside the body. Non-invasive deep tissue heating
uses extracorporeal devices to delivery energy deep into the body without any surgery.
Intracavitary HT is achieved using miniature heat sources situated within the lumen or body
cavities. Physical means for induction of local/regional HT include hot water, radiant heat
(visible and infrared), capacitive/inductive radiofrequency, microwaves, ultrasound, and
magnetic field heating of nanoparticles [77,80–82]. All these techniques are derived from three
basic physical mechanisms for delivering heat energy to the body [79]: (1) Thermal conduction
of heat (heat flows from higher to lower temperature), such as using hot water and infrared
chamber; (2) Resistive or dielectric losses from an applied electromagnetic field, such as
6

radiofrequency waves and microwaves; (3) Mechanical losses due to molecular collisions from
an ultrasound pressure wave. The clinically applicable devices for inducing the HT have been
summarized in previous publications [80,83].

Local/regional HT in the clinic is delivered mainly by microwaves (100 MHz to 3 GHz
electromagnetic wave), radiofrequency waves (500 kHz to 15 27 MHz electromagnetic waves),
or ultrasound (300 kHz to 10 MHz mechanical waves). Other techniques are either little-used or
in the developmental stage, such as magnetic nanoparticle heating [84]. Low-frequency
electromagnetic waves with the wavelength vary from about 4 cm to 200 cm in “practical”
frequency ranges (such as microwaves and radiofrequency waves) can penetrate deep into the
body (1–15 cm as typical aperture-to-tumor distance) but are difficult to focus. Focusing can be
achieved at higher frequencies for microwaves and radiofrequency waves; however, absorption
at higher frequencies prevents adequate tissue penetration. As a result, electromagnetic wavesbased techniques are mostly limited to treating superficial tumors or regional heating of deep
sites [10]. Ultrasound, which is a mechanical wave, provides an alternative technology for
generating heat through mechanical friction, which has the unique advantages of having
adequate tissue penetration at wavelengths that permit beam shaping and focusing. The
penetration depth of the ultrasound can be adjusted from less than 1 cm up to about 20 cm [85],
which allows ultrasound to treat both superficial and deep regions. The disadvantages of
ultrasound include high bone absorption and unable to penetrate through tissues that contain air
(e.g., respiratory tract and gastrointestinal tract).
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In parallel to the development of HT techniques, the development of strategies to detect
temperature changes induced by HT is also critical. Thermometry has been a rate-limiting
challenge for the more widespread clinical adoption of HT [29]. Early methods of thermometry
require insertion of thermometers into the tumors, which are invasive, cumbersome, and only
provide information at a few points [23,30]. In the recent few years, there is an expanding
interest in integrating HT with MR thermometry. Thermometry techniques used in HT are
summarized in a later section. The integration of ultrasound HT with MR thermometry has been
implemented in commercially available MR-guided high-intensity focused ultrasound
(MRgHIFU) systems. MR thermometry provides real-time, noninvasive, volumetric temperature
measurements. Feedback control algorithms based on MR thermometry have been implemented
for on-line controlling of the HIFU output. MRgHIFU has the great potential to overcome the
long-standing challenge in HT: localized and homogeneous heating of the tumor within an exact
temperature range for a precise period of time.

1.4 Thermal dosimetry
With the development of HT for the treatment of cancer in conjunction with RT, thermal
dosimetry is of great importance. CEM43, which represents cumulative equivalent minutes at a
temperature of 43°C is currently recognized as the most commonly used thermal dosimetry
parameter [86]. CEM43 is a normalized parameter to convert various time-temperature
exposures to equivalent exposure time in minutes at a reference temperature, 43°C. There are
limitations of CEM43 as it was originally designed to predict tumor cell death based on the direct
cell kill of HT alone, which is generally not the main therapeutic action of HT in synergy with
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RT [81,87]. Nevertheless, there is a fair body of evidence that CEM43 works reasonably well as
a measure for thermal dose [25,88,89]. Other thermal dose parameters have also been used, such
as T90, T50, and T10, which stand for the temperature exceeded by 90%, 50%, and 10% of the
intra-tumor measured points, respectively. These parameters lack integrated information over
time. Parameters that combine CEM43 and Tx (i.e., T90, T50, and T10) were also used, such as
CEM43T90 which calculates an equivalent treatment time with T90 equal to 43°C [15].

The quality assurance (QA) or quality assessment of heating, which aims to assure the clinical
HT being satisfactorily delivered to all patients in a given protocol, has evolved in the past three
decades. The earliest QA requirements for hyperthermia were published in a 1984 paper that
suggested applying HT until the maximum temperature measured by a set of sensors reaches
about 40°C, then reducing the power to permit thermal equilibrium [90]. The challenges in early
days of HT QA were reported by the Radiation Therapy Oncology Group (RTOG) [90]. These
challenges included less optimal heating in larger lesions (>3 cm) and the limited ability of
invasive thermometry to accurately characterize the temperature distribution in the tumor [91].
Recently provided QA guidance for clinical studies specified that the general objective is to
avoid temperatures exceeding 43°C in normal tissue and heat HT targeted tissue to 44°C for 60
min [92]. Recent research used temperatures in the range of 39–43°C to achieve the concomitant
oncological therapeutic effect and at the same time minimize the cytotoxicity to normal tissues
[25,93]. The latest QA guideline published in 2017 [94] specified that the minimum thermal dose
requirement for superficial HT of tumors extending from skin to cutaneous tissue layers is to
reach T90 of 40°C for 1 hour and T50 exceeding 41°C throughout the target volume with the
maximal normal tissue temperature of 43–45°C.
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1.5 Image guidance techniques
Recently, there was an expanding interest in integrating HT with temperature imaging
techniques. Several non-invasive, real-time temperature imaging techniques have been
developed based on MR [95], ultrasound [96], photoacoustic [97], and X-ray computed
tomography [98]. MR thermometry is the only clinically-available modality for non-invasive,
real-time, volumetric, and quantitative temperature measurement [95]. A detailed review of
various thermometry techniques can be found in a recent report by Lewis et al. [96]. Here we
briefly summarize the progress in MR thermometry for HT guidance.

With the advent of MR thermometry about two decades ago, many MR thermometry methods
have been developed. The most commonly used method is based on the temperature sensitive
proton resonance frequency shift [33]. The rationale of this method is that the magnetic field at
each voxel shows excellent linearity and sensitivity with the temperature-induced changes in
proton-electron screening in the temperature range of hyperthermia if neglecting the magnetic
volume susceptibility [99,100]. Thus, by measuring phase changes at each voxel, the relative
temperature can be derived from the electron screening of proton in the application of nonadipose tissue [101–103]. The most prevalent challenge for the proton resonance frequency shiftbased MR thermometry is motion-induced phase artifacts. This motion includes physiological
motion (e.g., respiratory, cardiac, and digestive-related motion) and bulk tissue motion.

Extensive studies were performed to evaluate the performance of MR thermometry. A group at
Duke University performed earlier work on assessing the potential of MR thermometry in
hyperthermic oncology and found the uncertainties of MR thermometry ranging from 0.3°C to
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1.4°C (1 standard deviation) within a 40 s scan time for monitoring HT induced by a diffusing
laser fiber inserted into ex vivo porcine liver [104]. Carter et al. [105] demonstrated the
feasibility of performing MR thermometry during HT of patients with sarcoma in the lower
extremity. Gellermann et al. [106] performed MR thermometry in patients with high-risk soft
tissue sarcomas of the lower extremities and pelvis during regional HT and found a significant
correlation between pathohistological response (defined as a necrosis rate>90%) and
standardized thermal parameters such as CEM43T90. Craciunescu et al. [107] compared MR
thermometry with invasive temperature measurements in patients with extremity sarcomas
during HT by a radiofrequency applicator and found an excellent correlation between
noninvasive MR thermometry and invasive measurement. Lam et al. [108] evaluated the
performance of MR thermometry for monitoring MRgHIFU ablation treatment (duration up to 2
min) of patients with bone metastases in the upper body and pelvis. They found the average
temperature variation for the MR thermometry was higher in the upper body as compared to the
pelvis.

The integration of ultrasound HT with MR thermometry has been implemented in commercially
available MRgHIFU systems. MR thermometry provides real-time, noninvasive, volumetric
temperature measurements. Feedback control algorithms based on MR thermometry have been
implemented for on-line controlling of the HIFU output [109,110]. Recently, our group
evaluated the performance of MR thermometry in healthy volunteers at different anatomic sites
(chest wall, bladder wall, and leg muscles) for long scan times (30 min and 60 min, V. V. N.
Kothapalli et al. 2018). We found that only the leg muscles had mean precision and accuracy
<1°C as the leg muscles had the lowest motion-induced artifacts in MR thermometry when
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compared with the chest wall and bladder wall. Reliable MR thermometry is achievable for
relatively stabilized tumors such as sarcoma in extremity and recurrent rectal carcinoma [1], but
moving organs in the upper abdomen are still challenging. Further development of temperaturesensitive MR sequence is strongly needed to compensate motion artifacts, as well as other
challenges, such as tissue heterogeneities, temperature-dependent tissue changes, and
perfusion[112].

1.6 Ultrasound HT technology
According to the design of ultrasound transducers, we can divide the evolution of ultrasound HT
devices into four generations (Figure 1.1): (1) The 1st generation: single, unfocused, piston
transducers in conjunction with temperature measurements using a single thermocouple (Figure
1.1 (A)); (2) The 2nd generation: arrays of separately controllable stationary or static transducer
arrays in combination with multiple thermometers for temperature monitoring (Figure 1.1 (B));
(3) The 3rd generation: mechanical scanning of ultrasound beams (Figure 1.1 (C)); (4) The 4th
generation: focused ultrasound transducers that integrate mechanical scanning and electronic
beam steering, combined with noninvasive, real-time, volumetric MR thermometry (Figure 1.1
(D)). The ultrasound HT technology can also be categorized based on the location of the
applicators into external, intratumoral, and intra-cavitary techniques. In the following, we
describe several selected ultrasound HT devices as examples to demonstrate the advantages and
limitations associated with ultrasound technology used for HT. These examples are not meant to
be inclusive as many devices have been developed throughout the history. Note that ultrasound
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thermal ablation systems share some common features as the ultrasound HT devices; however, in
this chapter, we focuse on the HT devices.
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Figure 1. 1: Representative images are showing the evolution of the ultrasound hyperthermia
therapy (HT) radiosensitization devices.
Figure caption: (A) The 1st generation: a single element unfocused piezoelectric ultrasound
transducer used to generate the ultrasound waves. The temperature of the circulating water was
adjusted to control skin temperature by thermal diffusion [113]. (B) The 2nd generation: Multielement unfocused applicator (Sonotherm 1000) can be operated at 1 MHz for heating deeper
regions (3–6 cm) or the third harmonic of 3.4 MHz for more superficial sites (2–3 cm). (C) The
3rd generation: A scanning double-faced V-shaped reflector reflected the ultrasound waves
coming from ultrasound arrays at the side ends of the applicator head [114] in parallel with the
photon/electron beam to the treatment volume. (D) The 4th generation: magnetic resonanceguided high-intensity focused ultrasound (MRgHIFU) HT system, originally designed for
thermal ablation, has been optimized for ultrasound HT under real-time, noninvasive, volumetric
MR thermometry guidance.
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The 1st generation clinical ultrasound HT device used a single element unfocused piezoelectric
ultrasound transducer of 1–3 MHz in frequency [113], as displayed in Figure 1.1 (A) from a
report by Marmor and Hahn [113]. The transducer was covered by a flexible membrane of Mylar
or latex and directly placed on the skin over the tumor. The skin was cooled by circulating cold
water through the transducer housing. The temperature was measured by a thermocouple inserted
in the center of the superficial tumor. A large number of similar ultrasound HT systems were
manufactured. Those systems were simple to construct and operate. The energy deposition
pattern was well collimated and relatively uniform power output could be obtained over the
whole surface of the transducer. The main advantage of the 1st generation systems was the simple
design and manufacturing. The major limitation was the lack of spatial and temporal control of
the heating.
The 2nd generation devices were developed in the 1980s, which used separately controllable
stationary or static transducer arrays in combination with multiple thermometers for temperature
monitoring. Compared with the 1st generation systems, the 2nd generation devices had the main
advantage of better spatial and temporal control over the energy deposition. An example of this
system is Sonotherm 1000 (Figure 1.1 (B)), a commercial system designed with either a 4- or 16element ultrasound array [115–117]. This system was approved by the United State Food and
Drug Administration (FDA) in 1989. It is the first, and the only FDA approved ultrasound HT
device, and it is still in use nowadays in the clinic. This applicator can be operated at 1 MHz for
heating deeper regions (3–6 cm) or the third harmonic of 3.4 MHz for more superficial sites (2–3
cm). The power level of each element can be individually controlled during treatment to modify
the temperature distribution in response to heterogeneous and dynamic tissue-heating properties,
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as well as patient discomfort. Normally, 2–16 needle thermocouples are inserted into the tissue to
monitor temperature and provide feedback control for each transducer element’s output [118–
121]. The limitations of the Sonotherm system include that the applicators are heavy and bulky
and setting up the system is time-consuming [122]. A clinical study obtained temperature data
from 31 patients who underwent a total of 147 HT sessions with the Sonotherm system and
found its ability to achieve 42°C minimum tumor temperature for 60 min is limited [122]. The
proportion of treatment with a space-time-average temperature  42°C was only 19% in this
patient group.
Different from the first two generation devices which consist of static or stationary
ultrasound transducers, the 3rd generation systems were characterized by the addition of
mechanical scanning of the ultrasound beams [123–127]. The mechanical scanning was achieved
through two different strategies: (1) mechanically scan an acoustic reflector while keeping the
ultrasound transducer stationary and (2) mechanically scan the ultrasound transducer itself. The
first strategy was evident in the scanning ultrasound reflector-linear array system (SURLAS)
developed in the 1990s by Moros et al. at the Washington University in St. Louis (Figure 1.1(C))
[124–126]. The SURLAS system was configured with a linear ultrasound array (frequency
ranging between 1.0–5.0 MHz) positioned at the side of the applicators outside the RT field. The
ultrasound energy was directed from the arrays toward a scanning acoustic reflector that
redirected the ultrasound energy into the target volume. This system enabled the acoustic waves
and the RT beams to enter the targeted volume from the same direction simultaneously.
Temperature elevations inside the targeted volume were dependent on the array size, operating
frequency, reflector scanning motion, thermal properties of tissue, and blood perfusion. A dual16

array system utilizing parallel-opposed linear ultrasound arrays with different frequencies and a
double-faced (V-shaped) scanning reflector was later proposed for improving the penetration
depth control by varying the excitation magnitude of one array relative to the other [126].
Software was developed to run the SURLAS system and coordinate the output power of the
therapy applicator to achieve a proper and safer operation, [123]. The software can divide the
applicator’s treatment window into 64 sectors with a dimension of 2 cm for each sector and
control the power of each sector independently to adjust the power deposition in three
dimensions. Simultaneously, the software could log the monitored temperature from the
thermocouples and terminate the treatment in case of a malfunction in any part of the system or a
violation of a safety criterion [123]. SURLAS was unique in that it allowed simultaneous
delivery of HT and RT, but it carried the limitation that temperature fluctuations were observed,
which was caused by the cyclical motion of the scanning reflector.
The second strategy was evident in the scanned focused ultrasound system (SFUS), which
mechanically moves the transducer to improve temperature uniformity throughout the tumor
volumes [127]. Typical SFUS systems included four to six spherically focused transducers, and
they were aligned to form a common focal zone of a few millimeters in diameter. The focal zone
was mechanically scanned within the tumor following circular or octagonal patterns [10]. SFUS
achieved a high degree of spatial control of power deposition patterns by controlling the
operating frequency and applied power levels as a function of location to account for variations
of tumor thickness. This high degree of spatial control of power deposition offered a solution to
compensate for temperature variations due to tumor irregularities, perfusion heterogeneity, and
the presence of blood vessels [128]. Thermocouples with small diameters (e.g., 25 to 125
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microns) were used for temperature measurements and feedback control [128]. The SFUS
system was used in multiple clinical trials for the treatment of brain tumors after craniotomy was
performed [129], as well as tumors in breast, superficial sites, and within the pelvis [130]. SFUS
formed the basis for the development of the 4th generation ultrasound HT devices, MRgHIFU, as
discussed below.
The 4th generation of ultrasound HT radiosensitization devices started to emerge in the 1990s.
These devices comprised of HIFU phased array transducers integrated with MR imaging,
commonly known as MRgHIFU. MRgHIFU devices were originally designed and currently used
in the clinic primarily for thermal ablation treatments. HIFU has the ability to rapidly heat up the
target tissue to an ablative temperature in a very precise manner while sparing the surrounding
normal tissue. MR thermometry can monitor the temperature in real time non-invasively. About
30 ongoing clinical trials on MR-guided FUS were summarized in a recent publication [131],
most of which aim for ablation or thermal surgery. These devices can also be modified to
incorporate HT capabilities [132,133]. Profound’s (formerly Philips’) MRgHIFU system has
incorporated HT into its Sonalleve® system (Figure 1.1 (D)). As far as we know, this is the only
MRgHIFU system that has been commercially available for HT applications. The system is
equipped with a 256-channel phased-array transducer (radius of curvature of 70 mm, focal length
of 140 mm, frequency of 0.8 MHz and 1.2 MHz). The transducer is housed inside the patient
table and connected with an electromechanical positioning system to deliver spatially and
temporally controlled heating. This system can generate heating cells with different sizes: 18
mm, 32 mm, 44 mm, and 58 mm [12]. MR imaging is used for treatment localization, real-time
temperature mapping and feedback control of the HIFU treatment, and post-treatment evaluation
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of the treated tissue. A binary feedback control algorithm based on MR thermometry has been
implemented to turn on/off the HIFU output to achieve homogenous and precise volumetric
heating. The system also features a direct skin cooling (DISC) device consisting of a water
cooling reservoir which is mounted on top of the patient tabletop above the acoustic window of
the HIFU transducer and directly in contact with the patients’ skin. The temperature of the water
cooling reservoir is regulated at constant room temperature (20°C), such that the temperature is
well tolerated on bare skin [134]. Preclinical studies using pigs have shown the feasibility and
safety of the MRgHIFU HT, and clinical trials are currently ongoing [1]. With the advent of
MRgHIFU HT technology, ultrasound HT is entering a new era with unprecedented flexibility
and precision in volumetric temperature control, although further research is warranted to
develop and evaluate this technique.
Currently, it has been demonstrated in preclinical studies that MRgHIFU HT allows focal
heating of tissue to well-defined temperatures under MR image guidance. MRgHIFU HT has
been successfully used in HT-triggered local drug delivery in combination with temperaturesensitive nanoparticles loaded with chemotherapy agents to enhance the local delivery of the
chemotherapeutic into liver tumor, pancreatic tumors, and glioblastoma in preclinical studies
[135–139]. MRgHIFU has been used in a clinical study for HT of 10 patients with inoperable
recurrent rectal adenocarcinoma, and it was completed delivered in three patients. In all three
patients who completed the treatment, MRgHIFU-induced HT was safely delivered. Our group at
the Washington University in St. Louis has been working on obtaining an investigational device
exemption from the FDA for starting the first clinical trial combining RT with MRgHIFU HT in
the United States. As an emerging clinical application of MRgHIFU HT for radio-sensitization,
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there is the need to summarize the literature on the clinical studies of ultrasound-induced HT and
guide the development of this emerging field.

1.7 Clinical studies of ultrasound-induced HT
Over the past few decades, clinical studies have shown that the use of ultrasound HT is an
effective adjuvant to RT for improving tumor control and response rates. Therapies combining
ultrasound HT with RT have shown efficacy in the treatment of different types of tumors. Here
we summarize clinical studies in the treatment of head and neck, breast cancer, prostate cancer,
cancer in the pelvis, and central nervous system malignancies. More than half of the studies
included more than one type of cancer. We organized the clinical studies based on the disease
type that had the largest patient population. Table 1.1 summarized clinical studies included in
this paper regarding the treatment site, RT dose, HT device (generation 1-4 is shorten to G1-G4),
HT temperature, HT duration (D), HT session (S) numbers, treatment efficacy, and treatment
toxicity. The clinical outcomes considered were: (1) Complete response (CR), defined as
complete disappearance of the treated tumor; and (2) Partial response (PR), defined as greater
than or equal to 50% reduction in tumor volume.
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Table 1. 1 Clinical studies evaluating adjuvant ultrasound hyperthermia therapy combined with radiation therapy
HT2
Author
Year
Woeber
1960

Xia
2001

Emami
1992

Myerson
1999

The site (# of
patients or
lesions)

RT1 dose
(Gy)

Basal cell
cancer (26 pts),
squamous cell
carcinoma (20
pts), malign
melanomas (2
pts).
Head & Neck
(15pts), breast
(9pts), lung (8
pts), esophagus
(6 pts),
colorectal (6
pts), soft tissue
(5 pts),
extremity (3
pts), other (2
pts)
Head and neck
(40 lesions),
chest wall (52
lesions), axilla
(7 lesions),
abdomen (2
lesions), pelvis
(7 lesions),
extremities (4
lesions), back (4
lesions), other
(2 lesions)
Head and neck
(21 pts), chest
wall (15 pts),
other trunk sites
(7
pts),

30–40
(4–6 Gy/fr,
7-8 fr)

G13

Immediately
pre-RT

NA

40–70
(1.8–2.0
Gy/fr,
5 fr/wk)

G2

Post-RT,
within 30min
after RT

6–115
(4Gy/fr,
2fr/wk, 4–
5wks)

G1 & G2

Post
within
60min

28–32
(2–4Gy/fr,
4fr/wk)

G2

Simultaneou
s

Device

Sequence

RT,
30-

Treatment
efficacy

Treatment
Toxicity

NA; 7-8

RT+HT:
33% decrease
of RT dose
compared
with RT alone

Peculiar
burning
pain in regions
where bone lying
closely underneath

60

2; 6–10

RT+HT:
CR4:32.6%;
PR5: 46.2%;
No
effect:21.1%

Hot sensation, pain,
and
blistering
showed in most
cases.

CEM436 ≥15min
achieved in 78%
cases

NA

1 or 2; 1–18

RT+1 HT/wk:
CR: 54.7%;
Tumor
control: 42%
RT+ 2 HT/ wk:
CR: 57.8%;
Tumor
control: 40%
No sig. diff.

Severe soft tissue
necrosis (18%).

36% cases have
CEM417>60min.

45

1; 4–8

RT + HT:
CR: 51%
(1yr); PR:
17% (1yr).

Slow healing soft
tissue
ulcers
required a median
of 7 months to heal
(21%).

Temperature
(°C)

Duratio
n
(min)
30–60

T(center)>42.5 °C
for > 20 min in
55.4% cases.
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Session/wk
; Session #

Dunlop
1986

Bornstein
1993

extremity
(4
pts).
Adenocarcinom
a at the breast
(18 pts),
adenocarcinom
a at lung (1 pts),
adenocarcinom
a at stomach (1
pts), squamous
carcinoma at
lung (1 pts),
squamous
carcinoma at
head and neck
(2 pts),
melanoma (4
pts), Kaposi’s
sarcoma (1 pts)
Breast (29 pts;
39 lesions)

Jones et
al. 2005

Breast (70 pts);
head and neck
(14 pts);
melanoma (11
pts); other (25
pts)

Marmor
and Hahn
1980

Multiple
superficial
metastatic sites
(15 pts)

25–30
(2.5–
3Gy/fr,
10fr)

G1

Post-RT,
within
1520min or 4h
later

CEM43 ≥20min
achieved in 58
cases

NA

NA; 1–4

RT only:
CR: 35%.
HT only:
CR:
11%(p<0.05)
RT+ HT:
CR: 86%( p
<0.05)

Termination during
treatment due to
pain and discomfort
(9.09%); superficial
blistering or burns
arose
around
puncture sites

12–66 avg:
37;
(2–4Gy/fr,
1–4fr/wk)

G2

Pre-RT,
within 0.5-1h

Average
Ttumor=41.2±1.7°
C

53.9±7.9

1; 4–6

HT+RT+
chemotherapy
: CR: 53%
(10months)

30–66 Gy
for
previouslyirradiated
lesions;
60–70 Gy
for
unirradiate
d lesions
(1.8–
2.0Gy/fr,
5fr/wk)
32–60
(2–4Gy/fr)

Microwav
e

Post-RT

Achieve thermal
dose
of
10
CEM43 T90

1–2
hours

1 or 2; not
reported

HT+RT: CR:
66.1%.
RT
alone:
42.3%.
No
overall
survival
benefit
was
seen.

Persistent
ulceration
of
previously
irradiated
areas
(67%);
ulceration
need surgical repair
(38%).
Catheter
complications (pain,
infections,
hemorrhages)
(11%);
thermal
burns
(25%
of
grade I; 16% of
grade II; 5% of
grade III).

G1

Pre-RT for
15min
and
post-RT for
30min

TSkin controlled
below
43°C.
Target
T
of
tumor: 43°C.

45

NA

RT only: CR:
25%; PR: 25%
RT + HT: CR:
100%
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Increased
cutaneous reaction
to RT (13.3%);
desquamated
reaction (6.7%).

Kapp
1990

Head and neck,
thorax, pelvis,
extremities. (70
pts in total,
without specify
number of each
disease)

21.6–66
(1.8–3.5
Gy/fr, 2–5
fr/wk)

G1 & G3

Post
within
45min

Kapp
1992

Superficial
thorax (122
lesions), head
and neck (47
lesions),
extremities (27
lesions), deep
head and neck
(6 lesions),
eccentric thorax
(2 lesions),
eccentric
abdomen,
superficial
pelvis (10
lesions),
eccentric pelvis
(14 lesions),
deep pelvis (25
lesions),
eccentric
extremity (1
lesions), deep
extremity (1
lesions).
Chest wall (57
pts)

5.4–82.0

G1 & G3

Post
RT,
within 0.5-1h

46-50
(1.8–
2Gy/fr)

G2

Simultaneou
s

Varma
2012

RT,
30-

Intratumoral
40.2±1.2°C

45

1 or 2; 2 or 6

Average
Ttumor=42.0±1.3°
C

45

1–2; 1-14

All
monitored
thermometry
more than ≥41°
C for 0.5h

60

1 or 2; 4 or 8

23

T:

RT + 2 HT
sessions: CR:
52%;
PR:
7%(3wks)
RT + 6 HT
sessions: CR:
51%;
PR:
9&(3wks) No
sig. diff.
Maximum
tumor
temperature
and number
of treatments
per field can
predicate the
development
of
complications
in RT + HT.

Skin
depigmentation
(24%);
subcutaneous
indurations/fibrosis
(16%);
tumor
ulceration (9.1%);
normal
tissue
ulceration (2.4%).
Tumor ulcerations,
infections,
indurations and
fibrosis, edema,
persistent pain and
late erythematous
skin reactions,
superficial (13.6%);
deeply located
(11.8%)

RT + 4 HT
sessions:
disease
recurrence
rate:
30%
(4yrs);
RT + 8 HT
sessions: No
sig. diff.

Moist
desquamation in
the chest wall
(43.86%); Grade2
morbidity (47.37%);
Grade3 morbidity
(14.04%);
sensation
abnormalities

OS9: 73%
(5yrs); Causespecific
survival rate:
79 % (5 yrs);
Median
survival:
36months;
Biochemical
no evidence
of disease:
35% (5 yrs).
RT and HT are
well-tolerated
and
can
consistently
heat prostate
gland.

Algan
2000

Prostate (23 pts)

50–68
(1.8–
2.0Gy/fr,
5fr/wk)

G1
(TRUSH)

Simultaneou
s

Ttumor>42.5°C for
at least 30 min

NA

1; 1–2

Fosmire
1993

Prostate (14 pts)

67–70
(1.8–
2.0Gy/fr,
5fr/wk)

G1
(TRUSH)

Simultaneou
s

CEM
42.510>30min in
36% cases.

30

1; 1–2

Hurwitz
2002

Prostate (30 pts)

66.6±5%
(1.8–
2.0Gy/fr)

G1
(TRUSH)

Simultaneou
s

Mean
CEM43
7.3min.

T90
is

39-80

1;2

Rectal toxicity
of RT and HT
correlates
with maximum
allowable
rectal wall
temperature.

Hurwitz
2005

Prostate (37 pts)

66.6±5%
(1.8–
2.0Gy/fr)

G1
(TRUSH)

Simultaneou
s

Mean
CEM43
8.4min.

T90
is

39–80

1; 2

Grade
2
proctitis was
greater
for
patients with
Tmax
in
rectal>40°C
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(29.82%);
telangiectasia
(17.54%);
scaliness/roughnes
s (3.50%)
Perineal
discomfort, urinary
related, or more
frequent bowel
movements and
diarrhea are the
most common
acute side effects.
The duration of HT
trended toward
significance for OS
(P=0.06).
Mild hematuria
(22.73%);
moderate
hematuria (9.09%);
treatment limited
secondary to
position intolerance
and/or pain
(9.09%).
Grade 2
Gastrointestinal
(GI) toxicity
(35.71%); the rate
of acute grade 2
proctitis correlates
with maximum
allowable rectal
wall T. No grade 2
GI toxicity
observed.
Acute grade 2
proctitis was
greater for patients
with an allowable
rectal wall

Hurwitz
2011

Prostate (37 pts)

66.6±5%
(1.8–
2.0Gy/fr)

G1
(TRUSH)

Simultaneou
s

Mean
CEM43
8.4min.

Diederich
2011

Cervix (4 pts),
prostate (3 pts)

NA

G1
(Catheter)

Simultaneou
s

Harari
1991

Pelvis (22 pts),
chest wall or
breast (14 pts),
neck (8 pts),
axilla (7 pts)

10–76.4
(1.5–4
Gy/fr)

G3

Guthkelc
h
1991

Brain (11 pts)

12–65 (5
fr/wk, the
fraction
dose
depend on
clinical
situations)

Corry
1982a

Melanoma (11
lesions),
adenocarcinom
a in lung, cervix,
ovary, or breast
(7 lesions),
sarcoma (2
lesions),
squamous cell

24–40 (4
Gy/fr,
3fr/wk)

39–80

1; 2

Ttumor=40-45°C
for 1h.

60

1; 1–2

Pre-RT, 1030min

Intratumoral
Tmin≥42.5°C for
0.5 h

30

1; 1–4

G1

Pre-RT

Average
Ttumor
max=43.0±1.0°C

15-60

1; 2–4

G1

Immediately
prior to RT

Intra-tumor
T=43±0.5°C

60

3;
≥6
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T90
is

than patients
with
Tmax
limited
to
40°C.
OS: 100% (2
yrs); 97.2% (4
yrs); 93.5 %
(5-7 yrs).
Target
temperature
achieved
without
adverse
events
or
toxicity
observed.
RT + HT: CR:
22%;
PR:
40%; dramatic
local
pain
reduction:
42%; disease
free up to 1 yr
in 83% of the
CR.

temperature of over
40.8°C.

RT+HT: 12-65
Gy.
HT:
42.5°C at the
boundary, 1560
min/session,
once
per
week.
RT only:
PR +
chemotherapy
: 30%
RT+HT:
CR: 62%;
PR + CR:
100%

Multiple infections
(6%); Large areas
of
treatmentinduced necrosis of
tumor
in
all
autopsied patients
(33.3%).

Not reported.

No adverse events
or
toxicity
associated
with
hyperthermia.

Transient
pain
during HT (75%);
superficial
skin
burns
(10%);
persistent
skin
blisters or burns
(2.8%)

Minimal with one
case with sequelae.

Corry
1982b

carcinoma (1
lesions).
Melanoma (10
pts), sarcoma (7
pts), squamous
cell carcinoma
in head and
neck and lung
(5 pts),
adenocarcinom
a in lung,
breast, and
renal (6 pts).

Not
reported

G1

Post
RT,
time interval
is
not
reported

Tmax: 43~44°C in
21.43% cases;
45~47°C in 25%
cases; 48~50 °C
in 48% cases.

60

>6

1.

HT: hyperthermia therapy.

2.

RT: radiation therapy.

3.

G: the generation of the ultrasound hyperthermia device

4.

CR: Complete response, defined as complete disappearance of the treated tumor.

5.

PR: Partial response, defined as greater than or equal to 50% reduction in tumor volume.

6.

CEM43: Cumulative equivalent minutes reached 43°C.

7.

CEM41: Cumulative equivalent minutes reached 41°C.

8.

TRUSH: Transrectal ultrasound hyperthermia.

9.

HT: CR: 10%;
PR: 50%
RT + HT: CR +
PR: 81%
HT only: CR +
PR: 41%

Treatment limiting
pain relieved within
minutes
of
the
cessation of therapy
(20%);
skin
blistering (13%).

OS: Overall survival, defined as the length of time from the start of treatment for a disease that patients diagnosed with the disease
are still alive.
10.

CEM42.5: Cumulative equivalent minutes reached 42.5°C.
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1.6.1 Head and neck cancers
Ultrasound-mediated HT combined with RT has been explored for the treatment of superficial
sites located in the head and neck. Previous studies evaluated the efficacy, safety, and thermal
parameters correlated with the treatment outcome and concluded that ultrasound-mediated HT
combined with RT was well-tolerated with minimal cytotoxicity and increased long-term benefit
compared to RT alone.
The therapeutic efficacy of combined ultrasound-mediated HT and RT for head and neck cancer
treatment has been consistently demonstrated in multiple trials. Woeber [140] reported that
combined treatment of X-ray therapy and ultrasound HT of superficial tumors obtained the same
therapeutic results (no principle differences in the reaction of the tissue or the subsequent healing
process) as that achieved by the classical X-ray therapy with one third less radiation dose.
However, this earlier trial is limited in that no thermometry was used to measure thermal
treatment parameters.
Thermal parameters related to tumor response were also analyzed. A more recent trial confirmed
the correlation between adequate thermal dose and complete tumor response using a non-focused
ultrasound array system, Sonotherm 1000 [119]. It found that intra-tumoral cumulative
equivalent minutes of over 42.5°C could be an important thermal parameter for predicting tumor
response. Kapp et al. [144] conducted a prospective randomized trial that compared the tumor
response after two versus six total HT sessions as adjuncts to RT and showed no statistically
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significant differences in tumor response between the two versus six HT populations (p=0.89).
When used as an adjunct to RT, neither the number of HT sessions performed per week nor the
number of sessions in total were found to influence the treatment outcome, which could be
associated with thermotolerance.

1.6.2 Breast and chest wall cancers
We found several studies that analyzed the correlation between thermal parameters and
CR rate for breast cancer treatments with RT combined with HT (RT+HT). One study compared
the efficacy of the combination of RT and HT, RT alone, and HT alone in a phase I/II study
[121] and showed that adequate HT (CEM43 >20min for more than one session) combined with
RT reached a higher CR rate of 86% compared with RT alone (35%, p<0.001) or RT with
inadequate HT (35%, p<0.001). HT was performed post RT, either “immediately” (15–20 min)
or 4 h later, usually twice per week with successive heat sessions separated by at least three days.
Dunlop et al. [121] demonstrated that tumors receiving RT and effective HT had higher complete
response rate than those receiving RT with inadequate HT (p<0.001), indicating that sufficient
heating is critical to the success of the RT+HT. However, a phase I/II clinical trial reported a
conflicting conclusion that increases or decreases in CR rate were not associated with any
examined treatment factors, including interval between initial diagnosis and first failure, prior
radiation, prior chemotherapy, prior hormonal therapy, treatment site, current radiation dose, HT
technique, number of HT, and chemotherapy agents [142]. However, this conclusion was limited
by the small number of patients (29 patients) included in this study. In a prospective randomized
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clinical trial with 122 patients enrolled, Jones et al. [155] used cumulative equivalent minutes at
43°C exceeded by 90% of monitored points within the tumor (CEM43 T90) as a measure of
thermal dose and found a thermal dose more than 10 minutes of CEM43T90 conferred a
significant local control benefit (measured by the duration of achieved local control) in patients
with superficial tumors (including chest wall cancer) receiving RT[155]. Although HT was given
using microwaves instead of ultrasound, this landmark paper highlighted the significance of
rigorous thermal dose prescription and administration. As for the minimal number of HT
sessions required for local control without complications, a phase III clinical study [13] showed
no significant difference in CR between HT fractionation of once per week and twice per week.
These results agreed with the results reported by Kapp et al. [144], both of which demonstrated
that the number of HT sessions per week caused no difference in the CR rate.
Studies were also performed to identify parameters predictive for complications of treatment,
such as maximum tumor temperature, cumulative thermal dose, and the number of HT sessions.
Reported safety issues associated with HT included superficial burns at the location of
thermocouple insertion, pain during HT, increased cutaneous reactions to RT in the heated area,
and desquamation reactions (Marmor and Hahn 1980). A phase I clinical trial (Kapp et al. 1992)
enrolled 124 patients and performed 249 HT sessions. The range of the maximum temperature
for all treatments was 38.3–54.1°C. The average percentage of temperature within the tumor
higher than 43.5°C was 43.5±25.0%. It found statistically significant correlations between the
development of complications and multiple parameters, including: (1) the average of the Tmax in
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tumors; (2) the average percentage of recorded tumor temperature higher than 43.5°C (47.6%
and 34.1% in the cases with and without complications, respectively, p=0.0071); and (3) the
average number of HT courses (3.79 of the cases with complications and 3.03 of the cases
without complications, p=0.038). This study also found the correlation between the maximum
temperature achieved in tumors with the rate of complication in both acute and chronic toxicity.
For complications which can heal within one month, the Tmax≤42.5°C correlated to a low rate of
complication of blistering (9.1%) and 42.6°C≤ Tmax≤43.9°C correlated to an increased frequency
of blistering (53.6%). For chronic complications, this study showed that burns requiring one
month to heal did not appear when Tmax<44°C but developed in 55.6% of the tumors when
Tmax≥44°C. In another respective study [142], the likelihood of complications and the total
radiation dose was reported to have a statistically significant association. Another stage II-III
clinical trial [146] performed 4–8 sessions of simultaneous thermoradiotherapy and studied the
relationship between toxicities and treatment factors. They demonstrated that there was no
relationship between above 2-grade morbidity and either total thermal dose or a total number of
HT sessions (4 or 8), but there was a trend that the addition of HT to RT led to a greater late
chest-wall morbidity compared with the RT alone.

1.6.3 Prostate Cancer
Prostate cancer was mostly treated with transrectal ultrasound HT in combination with RT. The
effectiveness of RT+HT has already been demonstrated by the improvement of the disease-free
survival rate [147–151]. A phase II clinical study compared the survival rate of RT+HT
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combined with androgen suppression therapy (AST) and AST alone in patients with prostate
cancer [151]. The results showed that the 2-year disease-free survival rate (84%) improved
significantly by RT+HT compared with the survival rate (64%) of similar patients on the 4month AST. However, another phase I/II study administered RT concurrently with HT to a
temperature of 42.5°C for 30 minutes for the treatment of patients with locally advanced prostate
carcinoma [147]. It found that there was no significant improvement in treatment outcome by
RT+HT when compared with other studies reported in the literature evaluating external beam RT
with or without androgen suppression.
As for the evaluation of complications, it was consistently found that RT+HT were well-tolerated
with limited gastrointestinal toxicity in both short and long terms. In patients with trans-perineal
thermometer catheter placements, mild hematuria occurred in 5/22 of the patients, while
moderate hematuria occurred in 2/22 of the patients [148]. As for the evaluation of
gastrointestinal toxicity, two studies have been performed [149,150]. A phase II study applied
RT ± AST with 2 HT sessions to assess the rectal toxicity of HT+RT in treating prostate cancer.
Results showed that the multi-modality treatment-induced gastrointestinal toxicities were limited
to Grade 2 [150]. Rectal toxicity correlated with average rectal wall Tmax, and average prostate
Tmax. Later, the same team verified that both short- and long-term gastrointestinal toxicity were
limited to grade 2. Acute grade 2 proctitis was correlated with a rectal wall temperature of over
40°C. Late gastrointestinal and genitourinary toxicity was not associated with the allowable
rectal wall temperature. No late grade 3 or greater toxicities occurred [150].
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1.6.4 Cancers of the pelvis
Cancer in the pelvis could be treated with both intracavitary and external ultrasound HT
devices. Intracavitary HT could be applied with high-dose-rate brachytherapy implants during
RT in the treatment of cervical cancer. These catheter-based ultrasound devices provide a
method to deliver 3D conformal heating integrated with high-dose-rate brachytherapy. Several
publications have characterized the theoretical heating patterns to improve implantation
strategies for these devices [156,157], but only one study performed HT using intracavitary
catheter-based ultrasound applicator [152]. In that study, 100% of treatments achieved a goal of
>60 min heating duration. No adverse events or toxicities in surrounding regions were observed.
This study demonstrated the endo-cervical ultrasound applicator could provide conformal and
selective therapy, deliver efficacious temperatures and thermal dose (CEM43 calculated based on
thermocouple measurements) to targeted volume, and reduce bladder and rectum exposure.
As for the external application of ultrasound for treating pelvis tumor, Harari [153] reported that
RT combined with HT led to CR in 22% of the treated tumors, partial response in 40% of the
treated tumors, dramatic local pain reduction in 42% of the treated tumors, with 83% of the
complete responders remaining disease free for up to 12 months.
In the annual meeting of the Society of Thermal Medicine in 2018, an on-going phase-I clinical
trial of MRgHIFU HT as an adjuvant to RT and chemotherapy was reported (Chu et al. 2018).
Of the ten patients enrolled with inoperable recurrent rectal adenocarcinoma, three patients who
completed all HT sessions had no unintended tissue damages. The mean temperature of the three
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patients who completed all three HT sessions were 41.2°C, 42.3°C, and 41.8°C with CEM43 of
3.3, 41.3, and 17.7, respectively. Additional studies are still needed to evaluate the efficacy of the
MRgHIFU HT.

1.6.5 Central nervous system malignancies
A small phase I clinical study reported by Guthkelch et al. demonstrated the feasibility of
ultrasound-mediated HT combined with RT for the treatment of primary malignant tumors of the
brain (Guthkelch et al. 1991). Fifteen patients with a histological diagnosis of primary malignant
tumors of a cerebral hemisphere received RT+HT repeatedly. A single-element focused
ultrasound transducer was used to perform HT after a craniotomy, which avoided the attenuation
of the ultrasound beam by the skull. The intra-tumoral temperature was measured by inserting
thermal sensors, and the target temperature of 42.5°C was achieved at the tumor boundary by
more than one point. Results showed that brain tumor HT was feasible and therapeutic
temperatures (≥42.5 °C) were achieved in approximately 50% of the measured points without
unexpected toxicity (Guthkelch et al. 1991).

1.6.6 Melanoma
Two clinical studies published in 1982 revealed the increased efficacy when applying RT+HT
compared to either modality alone. In one study [159], the superficial tumors were heated to
43.5±0.5°C for one hour immediately before irradiation resulting in an overall response rate of
100% in RT+HT group compared with 30% in RT group and 50% in HT group. The other study
[154] found escalation of temperature was remarkably correlated with both the increased
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response rate from 53% (43–44°C) to 83% (48–50°C) and the increased duration of response
(from 29 to 250 days for the same temperature increase).

1.8 Challenges and future directions
The ultrasound-mediated HT technology has been developed from stationary one size fits all
planar transducers to site-specific conformal arrays generated by mechanical and electrical
scanning of phased arrays. Thermal monitoring has evolved from recording at sparse, fixed
locations using invasive thermal sensors to real-time, volumetric, noninvasive temperature
monitoring using MRI. The real-time characterization of temperature changes in 3D provides
feedback control of the ultrasound heating in 3D, bringing the possibility of achieving
homogeneous heating of the tumor to an exact temperature range. Promising clinical results have
been reported since the 1960s, which indicate that ultrasound HT has favorable effects as a
radiation sensitizer in the treatment of cancer.
A better understanding of the ultrasound radiosensitization mechanisms is needed, although the
mechanism for HT radiosensitization in general, regardless of the heating technology, has been
studied for several decades. More work is needed to understand the potential unique mechanisms
of ultrasound HT for radiosensitization. For example, although numerous studies have provided
convincing evidence on the benefits of ultrasound HT combined with RT, we still need to better
understand the synergistic interactions between ultrasound HT and RT. The mechanisms behind
treatment enhancement effects induced by different ultrasound HT and RT sequence, time
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interval, thermal dose, and radiation dose are critical for establishing effective treatment
protocols.
Besides understanding the mechanisms, ultrasound HT technology development remains to be
the main challenge. Clinical HT trials have shown that most tumors are inadequately heated, and
cold spots exist even in the most favorable cases [160–162]. Although a minimum temperature
of 41°C was claimed to be clinically feasible and tolerable for superficial tumors [141], the
temperature measured is not based on volumetric thermometry. Thus, a major effort must be
made to measure the temperature throughout the tumor and to increase the fraction of target
tissue heated to therapeutic temperatures [10]. Before the recent introduction of MRgHIFU for
HT, the clinical applications of ultrasound HT was limited by several technique challenges, such
as the lack of real-time, noninvasive temperature measurement technology and difficulties in
controlling the temperature in deep tumors [28]. One preclinical study in pigs has demonstrated
the safety and feasibility of using MRgHIFU HT in the porcine leg muscles under real-time
noninvasive temperature monitoring [12]. The MRgHIFU technique offers more control over the
power deposition pattern, translating into better temperature distributions. Thus, one would
expect that the clinical benefit of HT would also increase with this technique. Future efforts are
needed toward improving the MRgHIFU HT technology, such as developing robust MR
thermometry techniques and improving HIFU HT technique for fast and homogeneous heating.
With the continued advancement of the MRgHIFU technology, extensive efforts are needed to
push this new ultrasound HT technology toward regular clinical implementation.
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The prognostic variables of HT in combination with RT need to be evaluated. Thermal dose
parameters, such as CEM43 have been used as a predictor for treatment efficacy. Such thermal
doses are originally defined based on the cytotoxicity effect of HT to cells, which has ignored
other critical effects caused by HT and its synergy with RT [163]. However, clinical studies did
report a significant correlation between the thermal dose such as CEM43 and treatment effect
[17,155,161,164–174]. The MR thermometry technique will function as a propelling factor for
the measurement of volumetric thermal dose. Extensive effort is still needed to develop the
volumetric thermal dosimetry method as prognostic variables for HT.
In summary, we elaborated the reasons for selecting ultrasound for inducing HT. We also
demonstrated that, geometrically, pelvic targets are potentially suitable candidates to receive HT.
This was shown by reviewing previous clinical studies that showed ultrasound induced HT was
able to be administered to cancer located in the pelvis (i.e. cervical cancer). To successfully
apply MRgHIFU HT to cervical cancer, the next step is to illustrate the feasibility and safety of
applying MRgHIFU induced HT to pelvic geometrical targets with different parameters (i.e.
heating diameters, depth, etc.). In the following chapters, we have performed a comprehensive
evaluation of the potential feasibility of MRgHIFU induced HT for cervical cancer.
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Chapter 2: Feasibility and safety assessment
of magnetic resonance-guided high-intensity
focused ultrasound (MRgHIFU)-mediated
hyperthermia in pelvic targets evaluated
using an in vivo porcine model
2.1 Introduction
The last chapter reviewed how ultrasound induced HT could be applied to pelvic targets in
clinical studies. In this chapter, in order to demonstrate the feasibility and assess the safety
parameters of MRgHIFU induced HT to pelvic cancers, such as cervical cancer, we performed
MRgHIFU HT using an array of clinically mimicking porcine pelvic geometries (i.e. muscles in
proximity to the bladder and uterus) as alternative targets that share some similarities with those
in the human pelvis.

In pelvic cancers, the addition of HT to RT can increase complete response rates (CRRs), partial
response rates (PRRs), and improve overall survival [175–177]. For example, a prospective,
randomized, multicenter trial reported increased CRRs of 26% (p=0.003), 22% (p=0.01), and 6%
(p>0.05) in the treatment of cervical cancer (n=114), bladder cancer (n=101), and rectal cancer
(n=143) [6], respectively, when using HT+RT compared to RT alone. Such results showed the
addition of HT to RT resulted in a significant enhancement of treatment efficacy. Other studies
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showing pelvic cancer treatment sites that could benefit from adding HT to an RT treatment
regimen include bladder cancer [6,178,179], rectal and colon cancer [177,180], uterine cancers
(including both uterine cervix and uterine corpus) [4,181–183] and prostate cancer [151].

MRgHIFU can potentially be used to administer non-invasive, actively monitored, volumetric
HT treatments using MR thermometry and feedback control [109]. However, performing HT to
pelvic targets within a heterogeneous space containing moving organs, moving fluids, and a
variety of tissues may be technically challenging due to the motion, the inhomogeneity in
thermal property of tissues in the pelvic space, the required narrow temperature range, and/or the
extended duration of HT. Previous studies have demonstrated that a commercial, table-mounted
MRgHIFU system (Sonalleve® V2, Profound Medical Inc., Mississauga, ON, Canada) has the
ability to uniformly heat deep thigh muscle tissue and the muscle near the rectum in an in vivo
porcine model[1,12]. However, these published studies focused only on extremities with limited
motion (e.g. thigh muscle) or very specific geometries (e.g. muscle near the lower
gastrointestinal tract), neither of which is fully representative of the spectrum of geometrical
challenges that might be present in pelvic MRgHIFU treatment. Furthermore, the lack of
histological analysis in previous studies limits the scope of the safety evaluations of HT induced
by MRgHIFU techniques. As such, these studies were unable to provide evidence of any damage
– or lack thereof – that HT may induce at the cellular level.
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The purpose of this chapter is to evaluate the feasibility and safety parameters of using
MRgHIFU to deliver HT to an array of different tissue geometries in the pelvis. These
geometries were selected to represent a broader range of prospective HT treatment sites
compared to previous studies. As such, this study aims to build on previously published work to
enhance opportunities for the use of MRgHIFU-mediated HT in treating a wider array of pelvic
malignancies than is done in current studies and/or practices. To achieve this, a set of
representative pelvic targets were heated in an in vivo porcine model. Here, “representative” is
meant to reflect both the geometry of target locations and organs-at-risk (OARs) adjacent to
treatment targets in or near the beam path that may be encountered in a variety of pelvic
MRgHIFU HT treatments, as well as some challenges to successful therapy, such as organ
motion during treatment (examples include peristalsis and bladder filling, among others). The
accuracy, precision, temporal variation, heating uniformity, thermal dose, and heating time for
each target were analyzed and compared in order to evaluate the feasibility of MRgHIFUmediated HT in various pelvic geometries. Imaging evaluation, gross pathology, and histological
analysis were performed as a measurement of the safety profile of MRgHIFU-induced HT.

2.2 Materials and methods
2.2.1 Targets Site Selection
Three targets were selected as representative treatment sites for pelvic HT therapy: the muscle
adjacent to the ventral wall of the urinary bladder (MVB), the muscle adjacent to the dorsal wall
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of the urinary bladder (MDB), and the uterus. These sites were selected to mimic treatment
geometries in terms of positions of the target relative to nearby OARs as well as prospective
HIFU beam paths for an array of treatment sites including, but not limited to, those found in
genitourinary cancers (e.g. bladder, ovarian, cervical, prostate etc.), gastrointestinal cancers (e.g.
anal, colorectal, etc.), and pelvic sarcomas. The selection of treatment sites was intended to be
diverse while being within experimental constraints imposed by the size, weight, age and pelvic
geometry of the pig model, as well as the limitations of the current configuration of the
MRgHIFU system such as the maximum focal depth of 8 cm.

Each of these targets presents a unique set of conditions to consider. The MVB is a thin,
relatively superficial muscle layer situated between adipose tissue and the urinary bladder, while
the MDB, also a thin muscle layer, is deeper and requires traversing the bladder to reach it. As
the urinary bladder is a fluid-filled organ with variable volume, there is potential for MR
thermometry artifacts caused by the urine filling and organ motion, requiring additional
considerations when planning accurate thermal treatment [184]. The uterus presents a different
tissue type than the muscle layers, one that not only may be in or near a number of HT targets in
women, but also tissues whose rich blood flow could potentially convect heat more easily
compared to muscle layers adjacent to the urinary bladder.
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2.2.2 Animal protocol
MRgHIFU induced HT was performed to the MVB, MDB, and uterus in six pigs (57.58±11.17
kg). Pigs either received one (N=1), two (N=3), or three (N=2) HT sessions on a given day. For
multiple treatments on the same pig, a different location was selected for each treatment such
that repeated heating to the same location was avoided. For multiple HT treatments on the same
animal, the time interval between each HT session ranged from 17 to 67 minutes with a median
of 24 minutes. Animal experiments were carried out with approval from the Institutional Animal
Care and Use Committee and the Division of Comparative Medicine at Washington University
School of Medicine in St. Louis. Before every experiment (or prior to the intubation) the animal
was pre-sedated with an intramuscular injection of ketamine/xylazine cocktails including
ketamine (2 mg/kg), xylazine (2 mg/kg), and telazol (4 mg/kg). Each animal was then intubated
and ventilated. General anesthesia was maintained using isoflurane at a concentration of 1~5%,
with forced ventilation generally at a tidal volume of 10 mL/kg. In order to ensure acoustic
propagation through the skin, the lower abdomen, the groin strain, and the regions in proximity
were carefully shaved with any remaining hair removed using depilatory cream (Nair, Church &
Dwight Co., Princeton, NJ, US). A bardex lubricath foley catheter (SureStep™ Foley Tray
System, Bard, Inc., Murray Hill, NJ) was used to drain the bladder prior to any MDB-targeting
HT session when the MDB was deeper than the 8-cm Sonalleve® treatment depth limit and the
bladder was in the beam path, making the MDB accessible. The bladder was not actively drained
during any treatment session.
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2.2.3 Experimental Design
The Sonalleve® V2 system was used for ultrasound exposures[111,185]. In HT treatment mode,
the system is comprised of a patient table locked into the bore of an MRI scanner (Ingenia 1.5T,
Philips, Best, the Netherlands). The table contains a HIFU transducer immersed in an oil bath.
The system is equipped with a 256-channel phase-array transducer with a radius of curvature of
70 mm. At a frequency of 1 MHz and pressure of -6 dB, the length and width of the focal point
are 14.65 mm and 1.90 mm, respectively. The acoustic window on the patient table is sealed with
a thin Mylar membrane and contains a 2-channel RF receive coil.

The anesthetized pigs were placed in a prone position on the MRgHIFU table. A 3-channel
pelvic RF receive coil was secured over the targeted anatomy. To acoustically couple the
animals’ skin with the ultrasound transducer, gel pads (Parker Laboratories Inc., Fairfield, NJ,
USA) shaved into a reciprocal shape with the morphology of the animals’ skin were used when
necessary. A 2:1 homogenous mixture of ultrasound gel (Aquasonic, Parker Laboratories Inc.,
Fairfield, NJ, USA) and degassed water was slowly placed between the animal’s skin, the
acoustic window, and the gel pad to create a relatively homogeneous acoustic path and minimize
the potential for skin burns due to air bubbles in the beam path.

HT treatment planning was done using T2-weighted MRI [12,111] with the following
parameters: echo time = 130 ms, repetition time = 1300 ms, number of signal averages= 1,
spatial resolution (in-plane pixel size) = 1.12×1.19×2.5 mm3, and flip angle = 90°. MRgHIFU29

mediated HT was monitored with MRI thermometry using the proton resonance frequency shift
(PRFS) method [1,111,186]. For the temperature monitoring by MR thermometry, a dynamic,
RF-spoiled, segmented, fast-field-echo echo-planar imaging (FFE-EPI) sequence was utilized to
obtain magnitude and phase images to produce temperature maps. The FFE-EPI images used the
following parameters: echo time = 19 ms, repetition time =36 ms, flip angle =20°, number of
signal averages =1, EPI factor =11, voxel size=2.5×2.5×7 mm3, and temporal resolution =3.7 s.
Six FFE-EPI planes (5 coronal, 1 sagittal) are used by the Sonalleve® system for temperature
monitoring, as illustrated in Figure 2.1 (A). In Figure 2.1 (A), the red dashed line represents the
“target” slice (the centermost portion of the focal region), and the other lines show the other
monitoring planes: one slice each 7-mm distal and proximal to the target slice, a sagittal slice
along the beam path perpendicular to the target slice, one near field slice located at the gel pad or
the subcutaneous muscle layer, and one far field placed beyond the focal plane. Figure 2.1 (B)
presented the location of the transducer, ultrasound beam path, and temperature monitoring slices
overlaying on the coronal MR images.
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Figure 2. 1 (A). Illustration of the experimental setup showing the animal’s position, MR
thermometry slices, locations of MR coils, gel pad, and treatment organs. (B). Coronal slice of
the MR images overlays with the schematic illustration of the beam path and the transducer in a
HT session in the treatment of the uterus as an example.
Figure Caption: Stars indicate the three target areas: MVB (muscle adjacent to the ventral
bladder wall), MDB (muscle adjacent to the dorsal bladder wall), and uterus.
In advance of performing HT in each pig, the MR thermometry sequence was run on an
MRgHIFU commercially-available quality assurance phantom (Philips, Vantaa, Finland) for 510 min with the purpose to maintain the magnet hardware to a thermal-stable condition [187].
All HT treatments were administered using a target region (cell) of 18-mm cross-sectional
diameter - the smallest HT treatment cell size available for the Sonalleve® system. This cell size
of 18-mm was the only one used in this study as the tissue targets in the pigs were small (pig size
was limited by size and weight constraints of what we could accommodate with our equipment
and experimental setup) as well as the desire to limit heating to other non-target nearby
structures in the pig pelvis. For all sonications, continuous ultrasound wave with a frequency of
1.0 MHz and acoustic power of 100 W were utilized. The output spatial-peak intensity of the
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system was 4321.34 W/cm2, calculated based on a validated method [188]. The average derated
maximum intensity in situ was 3572.78 W/cm2, estimated based on the tissue types in the beam
path and the depth of the targets of all HT targets [189]. The acoustic power of 100 W was
selected based on its use in a previous publication [12], as well as our intent to employ it in a
subsequent clinical trial. The target temperature at the centermost slice was set at 42°C with a
sonication duration of 30 minutes (note: one HT session only lasted for 28 min due to MRI
system failure). The target temperature and duration were chosen to represent clinical HT
objectives.

HT was controlled by a temperature feedback algorithm developed by Tillander et al.
[12]. Briefly, the HT cells contain a predefined set of foci on concentric circles with diameters of
4, 8, 12, and 16-mm in the plane perpendicular to the beam path. The heating at each foci is
controlled by adjusting the sonication power. The feedback algorithm also incorporates a
maximum threshold temperature to prevent temperature overshoot. The threshold temperature
was set to 44°C at the near field slice in this study. During heating, if any points in the target
plane show a temperature above the target temperature (here, 42°C), or if any pixel in the beam
path cross-section in the near field exceeded the maximum temperature threshold (here, 44°C),
the sonication power was to drop to zero until the points fall back under the respective threshold;
the heating then resumes at 100W power. The near field slice was chosen for the maximum
temperature check due to its proximity to the target (thus being representative of nearby nontarget tissue). The use of the 44°C threshold was a safety measure allowing for reasonably strict
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temperature control. It was motivated by the fact that temperatures ≥45°C have been shown to
cause thermal damage within minutes during HT treatments [190] and Chu et al. [1] found that
when using a maximum temperature threshold of 45°C with the Sonalleve®, thermal-induced
muscle coagulation occurred.

The temperature drift, due to either magnetic field drift, RF phase changes, or susceptibility, was
corrected by the Sonalleve® system through well-established methods described by Bing et al.
[187], which employs a second order drift correction algorithm. In the Bing et al. [187] study, a
temperature consistency compared to expected levels of 0.57°±0.58°C and 0.54°±0.42°C was
reported in the heated and unheated region, respectively. To validate the functionality of this drift
correction, our group performed a volunteer study using the Sonalleve® [111], in which
temperatures were monitored in unheated subjects. In human leg muscles over the course of 60
minutes, measured body temperature changed by 0.49°±0.03°C.

2.2.4 Analysis of HT feasibility
Thirteen HT sessions were conducted in vivo in the MVB (7 sessions), the MDB (3 sessions),
and the uterus (3 sessions) in 6 different pigs. Temperature maps were processed using methods
described by Kothapalli et al. [111]. Data from all 13 sessions were analyzed using the
temperatures acquired by MR thermometry. The accuracy of the MR temperature mapping has
been assessed by comparison between fiberoptic temperature sensors and the Sonalleve®reported temperatures and deemed reasonable for clinical use (i.e. being within 1°C of each
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other) [12]. These results were verified on the system used in this study using a similar
technique (data not shown). For the acquired FFE-EPI images processed offline, IDL 6.1 (ITT
Visual Information Solutions, Boulder, CO, USA) was utilized, which implemented the magnetic
field drift-correction algorithm described by Bing et al. [187]. Temperature distributions within
the target region-of-interest, or tROI, (with an 18-mm diameter) in the centermost slice were
evaluated and a number of factors tabulated: spatial mean temperature (Tavg), the maximum
temperature of all the pixels within the tROI (Tmax), the minimum temperature of all the pixels
within the tROI (Tmin), the temperature that only 10% of the pixels reached (T10), the temperature
that 90% of the pixels reached (T90), and the spatial standard deviation of all the pixels within the
tROI (σT). Each parameter was first tabulated in a given “dynamic”, i.e., one of the temperature
maps acquired every 3.7 s, then averaged across all dynamics. For example, if Tavg,d is the
average tROI temperature in a given dynamic, then Tavg is the average of all Tavg,d values for a
specific dataset. Tavg values were also calculated for the cross-section of the near field slice along
the beam path for safety monitoring purposes. A standardized thermal parameter, cumulative
equivalent minutes at 43°C of T90 (CEM43T90), that was found to be correlated to local benefit
when HT was combined with RT in human patients [155], was also calculated.

Four parameters were then used to quantify and assess the temperature in the tROI: temperature
mapping accuracy, precision, temporal variation, and heating uniformity. The accuracy was
quantified as the difference between Tavg and the desired temperature of 42°C. The precision, a
measure of spatial temperature variability across the tROI, was assessed by σT. The temporal
34

variation in a given dataset was calculated as the standard deviation of the Tavg,d values across all
dynamics. The heating uniformity was calculated by the temporal average of the largest
difference between the Tavg,d and either the T10,d or T90,d. These temperature metrics were
selected due to their previous use in the literature [1,111] to allow for benchmarking of our data
against other studies. Analyses were performed using GraphPad Prism (Version 8.0.1, La Jolla,
CA, USA). The Mann-Whitney U test was used to determine whether there was a significant
statistical difference (𝑝<0.05) between different target sites.

For patient and treatment management purposes it is important to assess both how
quickly the temperature reaches the target therapeutic range after the initiation of sonication and
how rapidly the temperature falls out of this temperature range after the sonication ceases. Thus,
in order to compare the efficiency of the heating deposition or dissipation in the different target
pelvic organs, the time required for the Tavg in the tROI to reach ≥41°C after the start of
sonication and cool down to ≤40°C after the termination of sonication was also recorded. As
more heat dissipation was expected when targeting relatively deeper organs, the one-tailed
Mann-Whitney U test was used to assess significant statistical differences (𝑝<0.05) between the
times needed for heat deposition or dissipation between different organs.

2.2.5 HT safety parameter measurement
Safety parameters of the HT treatments were measured by assessing thermal damage through
three different techniques: contrast-enhanced MRI, gross pathology, and haematoxylin and eosin
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(H&E) stain histological analysis. Negative controls for the HT were benchmarked using
untreated tissue from similar structures as the target. In order to provide observable references
during necropsy to triangulate the locations of the HT treatment targets, as well as provide a
permanent tissue damage site for comparative evaluation of HT targets, ultrasound ablations to
the skin layer, subcutaneous tissue, the skeletal muscle, or the uterus were performed after the
conclusion of HT. These ablation lesions were used as “positive controls” for heating and
damage assessment because they provided benchmarks for comparison of HT targets from the
aspects of both temperature profile and histopathological changes. These positive controls, along
with the unheated negative control tissues would allow for the clearest comparative illustration
of the relative state of the HT target tissue against the two treatment extremes (permanent,
destructive heat damage vs. no heating). The parameters of the ablation sonication were: 200-W
power, 1.2-MHz frequency, 24-s duration, and 8-mm diameter cell in the target coronal plane.

For the contrast-enhanced MRI assessment of potential thermal damage, T1-weighted 3D high
resolution isotropic volume excitation (THRIVE) MRIs [12] were acquired before and after the
injection of gadobenate dimeglumine (MultiHance; Bracco Imaging, Milan, Italy) about 1-2
minutes after the completion of the ultrasound ablation. In these images, thermal coagulation
appeared as non-perfused areas. After completion of MRI, the animals were euthanized, and
macroscopic dissection was performed close to the HT and ablation targets. The anatomical
structure characters, the location of the ablated lesions, along with the MR images, were used as
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landmarks to identify the locations of the HT targets. Gross pathological analysis at the HT target
site was performed.

After euthanasia, tissues (1) within the HT targets, (2) within ablation targets (for use as positive
controls), (3) within ultrasound beam path, and (4) far from the treatment locations (for use as
non-heated negative controls) were identified and collected for the H&E analysis. The skin and
muscle ablation lesions were used, along with imaging, as landmarks to locate the HT lesions
during necropsy. Tissue types collected for HT-targets included ventral and dorsal bladder tissue
adjacent to MVB and MDB (for safety evaluation of MVB and MDB), uterus, and ventral
abdominal wall musculature overlay with the urinary bladder. Tissues collected as positive
controls included the ablated muscle, uterus, and skin/subcutaneous tissue. Tissue types collected
within the ultrasound beam path included skin, subcutaneous fat, muscle proximal to the HT
targets (i.e. representative of the near field), and muscle and colon tissue distal to the HT targets
(i.e. representative of the far field). Tissues collected as negative controls included the skin,
subcutaneous fat, uterus, bladder tissue, muscle tissue, and colon/rectum tissue outside the beam
path and far from the sonication targets. Tissues collected for histopathology were fixed in 10%
neutral buffered formalin. After fixation, the tissues were trimmed, processed according to
standard procedures, paraffin-embedded, and sectioned at 5-micron thickness. The sections were
stained with hematoxylin and eosin (H&E) for standard histopathologic evaluation. For each
lesion, 2–3 sections were examined. Tissue processing, staining, and histopathologic
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examination were performed by the Division of Comparative Medicine Animal Diagnostic
Laboratory.

2.3 Results
2.3.1 HT feasibility evaluation
Representative examples of HT treatment and delivery process for each target site (MVB, MDB,
and uterus) are shown in Figure 2.2. tROIs are shown on the planning MRIs in Figure 2.2 (A).
Figure 2.2 (B) shows the voxel-by-voxel Tavg maps in the target slice. Figure 2.2 (C) shows
temperature as a function of time for Tavg, Tmax, and Tmin corresponding to the treatment in Figure
2.2 (B). Note the stability of the temperature parameters throughout the entire 30-minute HT
session in Figure 2.2 (C); this stability was also evident in all other analyzed treatments. A
summary of the temporal-average evaluation statistics in the tROI for all HT sessions (Tavg, Tmax,
Tmin, T10, T90, σT, and CEM43T90) is presented in Table 2.1, as well as Tavg within the beam
cross-section in the near field slice. Tavg in the target slice was 41.6±0.4°C, 41.6±0.3°C, and
41.4±0.2°C for MVB, MDB, and uterus, respectively, i.e., within 1.0°C of the desired
temperature (Table 2.1). In the near field, the Tavg was 38.1±0.9°C, 37.3±0.4°C, 37.5±0.4°C for
MVB, MDB, and uterus, respectively (Table 2.1). Tmax, T90, T10 of the near field were also
presented in Table 2.1. For the thermal ablation used for the positive control of the study, after
ablation for 24s, the maximum achieved temperature had an average of 95.22°C ±25.43°C
(range: 69.1°C to 154.9°C).
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Figure 2. 2 (A) Illustration of the target region-of-interest selection indicated by the red circle on
the axial MRIs (target slice) for three different treatment locations. (B) The representative
average temperature map of the axial plane (target slice) of the three pelvic targets. (C) The
representative average temperature (Tavg), maximum temperature (Tmax), and minimum
temperature (Tmin) during the 30-minute HT session and the 5-minute cooling periods.
Figure caption: From left to right: muscle adjacent to the ventral wall of the urinary bladder
(MVB), muscle adjacent to the dorsal wall of the urinary bladder (MDB), and the uterus.
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Table 2. 1 Temperature statistics in the target region-of-interest (tROI) within the target slice and
the beam cross-section in the near field in six animals
Treatment Site
Location

Target Slice

Near Field

Statistic
MVB

MDB

Uterus

Depth (mm)

19.4 ± 4.3

34.2 ± 41.6

45.1 ± 5.5

Tavg

41.6 ± 0.4

41.6 ± 0.3

41.4 ± 0.2

Tmax

44.9 ± 0.7

45.2 ± 0.2

44.1 ± 0.5

Tmin

38.4 ± 0.7

37.7 ± 0.9

38.1 ± 0.9

T10

43.7 ± 0.6

43.8 ± 0.1

43.1 ± 0.4

T90

39.6 ± 0.5

39.5 ± 0.7

39.6 ± 0.5

σT

1.5 ± 0.3

1.7 ± 0.3

1.4 ± 0.2

CEM43T90 (min)

0.6 ± 0.3

0.6 ± 0.4

0.5 ± 0.3

Tavg

38.1 ± 0.9

37.3 ± 0.4

37.5 ± 0.4

Tmax

40.8 ± 1.3

39.4 ± 0.9

39.8 ± 0.4

T10

39.4 ± 1.0

38.2 ± 0.5

38.7 ± 0.5

T90

36.8 ± 1.2

36.3 ± 0.4

36.3 ± 0.8

Table caption: Statistical metrics are defined in the text. All metrics are reported in °C unless
otherwise indicated.
Figure 2.3 shows the calculated temperature accuracy (A), precision (B), temporal variation (C),
and heating uniformity (D) within the target. Across all cases, an average accuracy of
0.51±0.32°C, a precision of 1.55±0.30°C, a temporal variation of 0.80±0.16°C, and a heating
uniformity of 2.01±0.42°C was achieved. Figure 2.3 also shows the breakdown of these
parameters by treatment sites for the MVB, MDB, and the uterus. No statistically significant
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differences were found in accuracy, precision, temporal variation, or heating uniformity when
comparing different treatment sites.

Figure 2. 3 Temperature metrics for the three pelvic target region-of-interests in °C. (A)
Temperature accuracy. (B) Temperature precision. (C) Temporal variation. (D) Heating
uniformity.
The calculated CEM43T90 among different treatment sites is presented in Table 2.1. An average
of 0.59±0.31min CEM43T90 was achieved across all cases. A comparison between the achieved
CEM43T90 among three different organs is presented in Figure 2.4(A). The average CEM43T90
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values were 0.6±0.3 min, 0.6±0.4 min, and 0.5±0.3 min to the MVB, the MDB, and the uterus,
respectively. No statistically significant differences were observed between the three groups.

Figure 2. 4 (A) The CEM43T90 calculated based on the temperature in each voxel within the
target region-of-interest (tROI). (B) Time (s) for the average temperature of the tROI to reach
41°C after the start of the sonication. (C) Time (s) for the average temperature of the tROI to
decrease to 40°C after the termination of the sonication.
The durations needed for the average temperature within the tROI to increase to ≥41°C and
decrease to ≤40°C (outside the HT range) are shown in Figure 2.4 (B) and Figure 2.4 (C),
respectively. The Tavg,d reached ≥41°C after the start of the sonication in 32.8±12.6 s, 77.6±38.9
s, and 50.6±11.8 s for the MVB, MDB, and uterus, respectively, with an overall average time of
47.3±26.5 s. Compared to targeting the MVB, the time needed for Tavg.d to increase to ≥41°C is
statistically significantly longer when targeting the deeper MDB and uterus targets (p=0.05,
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Figure 2.4(B)). The average time for the Tavg,d to cool down to ≤40°C was 76.7±76.5 s,
69.1±52.3 s, and 39.5±42.8 s for MVB, MDB, and uterus, respectively, with an overall average
of 66.4±62.7 s.

2.3.2 HT safety parameter assessment
No abnormally perfused tissue in the HT target region was observed on the post-treatment
contrast-enhanced MRIs when compared to the pre-treatment images (Figure 2.5 A–B). This is
starkly different than the ablated regions, seen as hyper-intense signals in the MRIs at the sites of
the ablative lesions performed after HT sessions (Figure 2.5 C). Similarly, for the gross
pathology, no macroscopic lesion was observed at any location that received HT treatment or in
the beam path. By contrast, several hemorrhagic regions showing severe edema were observed at
the locations that received ablation (e.g. skin and subcutaneous tissue, muscle, and uterus), as
shown in Figure 2.5 (D).
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Figure 2.5 (A) The contrast-enhanced MRI before any intervention. (B) The contrast enhanced
MRI at the completion of the hyperthermia therapy (HT). (C) The contrast enhanced MRI right
after ablation. (D) The gross pathology of the uterus after the completion of HT and ablation.
The yellow arrows indicate the location of the HT target. The blue arrow indicates the ablation
lesions (thermal damage).
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Table 2.2 presents a classification of the histopathological findings based on the target locations
in proximity to 13 targets receiving 30-minute HT. Nine targets showed reversible changes
expected of mild heat therapy as compared to the control, while four targets showed no notable
lesions. None showed any permanent damage. Among the reversible changes, a minimal to mild
congestion in the wall of the skeletal muscle adjacent to the urinary bladder wall or uterus was
the most frequent phenomenon, occurring in five treatment sessions (Figure 2.6 B). The second
most common histological phenomenon, seen in four sessions, was an accumulation of white
blood cells composed of mononuclear cells with fewer neutrophils and eosinophils, or a minimal
perivascular inflammation in the interstitium of the muscularis of the urinary bladder or the
uterus. In two HT targets, there were mild multifocal hemorrhages in the lamina propria or the
interstitium of the muscularis of the urinary bladder wall or the uterus. These were presumed
artifactual as they were also detected in the control tissue.
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Table 2. 2 Categorization of the post-HT histological analysis based on target locations
# Sessions show corresponding histological changes
Location

No significant
lesion

Reversible (nonpermanent) changes

Permanent
damage

Ventral Bladder Wall

1

6

0

Dorsal Bladder Wall

2

1

0

Uterus

1

2

0

Ventral abdominal wall musculature
overlay with HT targets in the urinary
bladder

4

1

0

Note: The numbers indicate the number of sessions (out of 10) which showed the corresponding
histological changes in different anatomical locations.
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Figure 2. 6 Representative H&E images of analyzed tissues.
Figure caption: Columns left-to-right are tissues which received HT and/or were within
ultrasound beam path, controls, and ablation targets. Rows show samples from different tissue
sites: (A) muscle adjacent to the ventral wall of the urinary bladder (MVB), (B), uterus, and (C)
skin and subcutaneous tissue.
Five samples of ventral abdominal wall musculature overlay with the HT targets in the urinary
bladder (when heating MVB) were also analyzed, as shown in Table 2.2. Four showed no
notable lesions and one lesion showed a mild separation of myofibers at the cutting edge,
suggested an artifact of tissue processing/sectioning. No notable HT-related lesions were
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detected for the skin and the subcutaneous fat layer along the ultrasound beam path, or for the
colon and/or rectum tissue immediately distal to the target area. Ablation lesions as positive
controls were characterized by an array of permanent damage types, including degeneration and
necrosis of muscle fibers including hypereosinophilic, homogeneous, swollen fibers with nuclear
pyknosis and fiber fragmentation in the skeletal muscle (Figure 2.6 A), variable swelling and
homogeneity of fibers and variable nuclear pyknosis in the subcutaneous tissue (Figure 2.6 C). In
uterus tissue, separation of the basal layer of the epithelium from the underlying lamina propria
in the uterus was also possible, as were severe edema, hemorrhage, and congestion (Figure 2.6
B). These results suggest that 30-min HT treatments are able to be successfully performed
without creating any detectable irreversible damage in the target tissue, the skin and
subcutaneous tissue in the beam path, or the adjacent healthy tissue beyond the target.

2.4 Discussions
The results of our study demonstrate that MRgHIFU can feasibly deliver HT to a variety of
pelvic target geometries in vivo in a porcine model with satisfactory safety characterization. For
each of our HT targets, the average temperature accuracy was <0.8°C with an overall average
accuracy within 0.5°C of the desired 42°C target temperature. This agrees well with published
guidelines requiring the temperature to be maintained within 1°C of the target temperature
[107,111,187]. The average temperature variation was <1°C for all three sites demonstrating that
the average temperature was fairly stable throughout the 30-minute treatment. Both the precision
and uniformity measurements show that most voxels in the HT target remained within the
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hyperthermic temperature range throughout treatment. The lack of observed statistically
significant differences in any temperature parameter between sites shows the stability of the
therapeutic approach. These results thus display the feasibility of pelvic MRgHIFU HT
treatments when using the 18-mm cell size. This could potentially be used to treat small clinical
targets in a single treatment or larger targets by clustering multiple 18-mm cell treatments. The
safety parameters of the MRgHIFU HT approach are shown to be satisfactory through the fact
that the contrast-enhanced image assessments, gross pathology, and histopathology showed
either no damage or minimal, reversible tissue damage at the HT target sites and tissues in the
beam path.

Overall, the assessment results agree well with previous studies that analyzed only specific
homogeneous target geometries [1,12], although in certain cases there were some differences.
For example, Chu et al. measured a temporal variation of 0.3±0.2°C in HT sessions of the pig leg
muscle [1], somewhat lower than our result. We also had some outliers, such as one MVB
heating session that had an accuracy of 1.2°C. While this could be due to statistical variation,
there are a couple of other potential explanations. First, unlike the previous studies in which
large areas of homogenous muscle were targeted, our target sites occupied smaller volumes
abutting other tissues and organs (e.g., bladder or rectum), despite the fact that we used the same
18-mm diameter for tROI as in these other studies. Different types of tissues within the tROI
with varying thermal properties could impact the measured thermometry parameters and give
rise to some of the observed differences. This impact could be exacerbated by the fairly course
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spatial resolution (2.5 × 2.5 × 7 mm3) of the temperature monitoring. More tissue heterogeneity,
both throughout the volume and per voxel, could give rise to higher measured thermometry
parameters compared to previous studies with more homogenous targets.

Furthermore, motion from breathing, bladder filling, and/or digestive peristalsis can create MRI
thermometry artifacts that may result in higher temporal variability in the tROI [2,12,33,108],
especially given that the excursion times for these tissues is on the same order of magnitude as
the temporal resolution of the MR thermometry images (3.7 s). In comparison to prior studies,
although the temporal resolution was the same, the HT targets herein were in closer proximity to
sources of artefactual motion (bladder filling, rectum peristalsis, etc.), potentially influencing
MRI thermometry. Finally, another difference with previous studies [1,12] was the target
temperature and threshold of the maximum temperature set in the near field. Chu et al. [1] used a
target temperature of 42.5°C and a threshold of 43°C, while we had a target temperature of 42°C
and used a slightly higher threshold (44°C). Our selection of target temperature was to be in line
with our desired clinical applications in human patients following the conclusion of this study.
The higher threshold selection (and thus broader target-to-threshold range) was to allow the
system more flexibility to manage with the higher tissue heterogeneity in our targets as well as
noise/artifacts due to greater proximity to sources of potential motion. These differences in
target temperature and threshold selection could contribute to some of the differences seen in the
temperature statistics.
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CEM43T90, a metric of thermal dose was calculated for each treatment, and has been shown to
be clinically meaningful,. For example, increased CEM43T90 was reported to associate with a
better local relapse-free survival in patients with cervical carcinoma [191], locally advanced
cervical cancer [165], and locally advanced breast cancer [192]. The overall average CEM43T90
of 0.6 min reported herein is lower than the minimum thermal dose requirements proposed in
recent guidelines for superficial hyperthermia of tumors [94], and lower than results described
from study by Chu et al. [1]. Clinically, higher CEM43T90 might be achieved by increasing the
target temperature and/or total treatment time, both of which can be adjusted using a clinical
MRgHIFU system capable of HT, such as the Sonalleve®. This is shown in the Chu et al. study
where they used a target temperature of 42.5ºC and treated for 44-60 minutes. The absence of
observed statistically significant differences between treatment sites in this study speaks to the
stability and reproducibility of the MRgHIFU HT technique analyzed here.

It is important to gauge the time for Tavg to increase to ≥41°C (i.e., within 1°C of the target
temperature) after the start of the sonication and the time for the average temperature to decrease
to ≤40°C (i.e., fall below the hyperthermic range) after the termination of the sonication. Longer
durations for the temperature build up in vivo lengthen the overall treatment time. While times on
the order of a few minutes may have minimal impact, substantially longer treatments increase the
chance for discomfort (due to having to hold the same position for a protracted period of time)
and/or motion which can lead to temperature monitoring artifacts and/or loss of good patienttransducer coupling. Assessing the ramp-up times is thus important to gauge if they might be
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problematic; excessively long treatment times might even require some additional intervention
(such as sedation) to ensure successful treatment. Here, the ramp-up time for the Tavg to increase
to ≥41°C was statistically significantly shorter in the shallow MVB targets compared to the
deeper uterus. However, these differences were not deemed clinically significant because all
measured times were ~two minutes maximum; reasonably short for patients to maintain still with
good transducer contact.

Assessment of cool-down times following HT is potentially important as long cool-down
durations could have implications for patient management. If a treatment regimen requires
multiple HT targets in a single session, or if treatment is interrupted, it would be useful to
understand how long temperatures in the heated tissues take to return from the hyperthermic
region to ensure accurate and safe MR-guided HT when treatment is resumed and minimize the
chance for nearby healthy tissues to be overheated. Protracted cool down times could result in
longer times for the patient during to wait between HT applications and/or spur the use of
intervention such as flushing of organs like the bladder with cool water and/or ice packs placed
on the skin to allow for a more efficient continuation of treatment. Such interventions might also
be needed to aid in patient comfort/relief due to the heating process, especially with a longer cool
down time. The relatively short cool down times (3-4 minutes or less) noticed in this study
across all treatment sites implies that minimal management may be needed when using the 18mm cell. Further investigation is needed using larger treatment cells with (presumably) longer
associated cooling down periods to determine if more active interventions might be warranted.
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In this study, no abnormally-perfused area was detected on contrast-enhanced MRI or under
gross observation at the HT target site, in agreement with two previous studies that performed
HT in porcine leg model [1,12]. The use of ablation sites was a novel approach in this study to
provide a system for localization of the HT targets as well as positive controls, both of which are
absent from the previous studies. The hyper-intensive lesion shown in the contrast enhanced
MRI were consistent with results from a prior publication [193], and matched the severe
hemorrhage and fluid filled cavities observed in the macroscopic and histological results. Some
studies found post-ablation targets to be seen as non-perfused areas in the MR images, as
opposed to the hyper-intense regions seen here [194–196]. However, the power of 200W and the
sonication duration of 20s that we employed were much lower than the power of 305-402 W
[194–196] and sonication duration of 90s-3864s [194–196] used in those studies, implying that
the immediate effect on the tissue could be different. Furthermore, the ablative target of normal
uterus here is generally more vascularized than uterus fibroid targets of these studies [195]. This
implies that hemorrhage and/or fluid filled cavities are a more likely outcome for our ablation
targets compared to uterine fibroids. Ultimately, the differences seen in the observable,
permanent damage of the ablation sites in this study compared to the HT targets and unheated
tissues, reinforce the utility of the MRgHIFU induced HT treatment.

Histopathologic examination showed no remarkable lesions in the HT target tissues, in the
overlaying skin, or the subcutaneous tissue along the beam path. Instead, minimal to mild
congestion was observed in some of these targets. Our findings are consistent with other reports
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that HT exposure may cause vascular congestion, dilation, and potentially hemorrhage [197–
199]. In two HT targets, there was mild, multifocal hemorrhages in the wall of the urinary
bladder and the uterus. However, several mild hemorrhages were also noted in the corresponding
control samples. Thus, these findings were likely related to tissue collection. The second most
common histological feature was an accumulation of white blood cells in the interstitium of the
muscularis of the bladder or the uterus tissue. Such phenomena agree with previous reports that
HT is able to initiate an immune response of both the innate and adaptive immune systems
through the release of extracellular heat shock proteins (HSP) [200–205]. This transient damage,
characteristic of HT-level heat exposure, was different from the irreversible damage lesions seen
in the histopathology of the ablated tissue samples.

A few limitations in the current study deserve mention. First, this study did not analyze a
comprehensive set of pelvic clinical targets and/or geometries and only used female pigs. Pig
size and allowed weight on the tabletop limited the accessible targets, especially when coupled
with the maximum HT target depth of 8 cm in the current implementation of the Sonalleve®
clinical MRgHIFU system. The pigs would have had to be older or larger to accommodate malespecific organs (e.g., prostate) of targetable size (depth in these instances would also have raised
targetability concerns). However, a review of our clinical cases (not shown) implies that the
geometries analyzed herein have applicability to other pelvic targets (e.g. cervix, prostate,
colorectal, pelvic sarcomas, among others). Second, we did not do anything to manage motion
related MRI thermometry artifacts due to, e.g., respiration, peristalsis, and bladder filling, other
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than securing the pigs tightly to the HIFU tabletop with the vendor-provided MRI pelvis coil and
using sand bags to limit the extent of the respiratory excursion. This was thus reasonably
representative of treating a patient with minimal intervention. Minimizing intervention is
desirable as it can limit risk to the patient and potentially enhance comfort which in turn helps
patients maintain good coupling to the transducer. The one caveat to this was that the pigs were
anesthetized, so the breathing motion was more regular than it might be in a conscious human
subject. Concerns about artifacts due to peristalsis could be managed with interventions such as
inserting a saline-filled rectal balloon as was done by Chu et al.[1]. Ultimately, in this study,
peristaltic motion resulted in some minor artifacts in the far field, but, in general, did not inhibit
HT, although the lack of intervention could have contributed to the somewhat improved thermal
parameters seen in the Chu et al. study.

A single set of settings of the Sonalleve® system was used in this study to ensure consistency
between each of the HT sessions used in this study. The treatment cell size, sonication power,
heating time, target temperature, and near field temperature threshold used for feedback are all
user-adjustable parameters. Parameters were selected (i.e., 42ºC target temperature, 100W
power, etc.) to reflect what our group intends to employ in a subsequent clinical trial, except for
the use of the 18-mm diameter treatment cell (the smallest available on the Sonalleve® system).
This was motivated by target size limitations within the pigs; given the size/age of pigs we could
reasonably treat, the tissue targets were too small to accommodate larger cell sizes. Clinical and
experimental targets may differ in geometry (size, shape, and depth, etc.) and desired heating
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characteristics (target temperature, heating time, etc.). Thus the preferred operating parameters
will need to be determined on a study-by-study (or case-by-case) basis. An investigation into
techniques to optimize the operating parameters of the system is outside the scope of this
analysis, although the consistency of our results across different sites and depths argues for some
degree of treatment robustness to operating parameter selection. Further study is needed to
investigate the impact of using the larger cell sizes if they are deemed to be clinically relevant for
the desired targets. Some limited work has been done on the feasibility of larger cell sizes in
homogenous in vivo targets [1,12].

It is also important to note that the pig model used herein does not perfectly correlate with
human tumor targets. For example, the 6-8 mm thickness of abdominal subcutaneous fat in the
pigs is likely thinner than in most human patients, and the distribution of fat between tissue
layers may be different between pigs and humans. This may present issues in human treatments,
especially as the MR thermometry method used herein does not model temperature change well
in adipose tissue, although neither the subcutaneous fat nor the intra-tissue fat layers caused
significant challenges in the porcine model used in this study. Furthermore, the targets here are
likely smaller than human tumor targets of interest. In order to cover larger targets, treatments
would need to be comprised of larger cell sizes and/or the use of multiple clustered hyperthermia
cells sequentially delivered within the same treatment session or spread across multiple treatment
sessions. The depth and/or limited access due to bone/air proximity of portions of targets, among
other aspects, may pose further issues in treating human patients. Ultimately, future work in
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both clinical trials and device development is likely needed to elucidate and/or address all of
these challenges.

Nevertheless, the results of this study support proceeding into human clinical trials. The variety
of target geometries, along with the accuracy and consistency of the achieved dose distributions
speak strongly to the potential of MRgHIFU as a tool for applying HT to an array of pelvic
targets. This work corroborates that the described MRgHIFU technique would be a feasible and
viable approach for HT treatments of human pelvic malignancies with acceptable safety
parameters. However, additional work would be needed to optimize application techniques on a
site-specific basis.

2.5 Conclusions
In this study, we demonstrated the feasibility of using MRgHIFU HT to heat a set of clinically
mimicking pelvic targets including the muscle adjacent to the ventral and dorsal bladder wall,
and the uterus with satisfactory safety parameters. The temperature was maintained within the
desired range with reasonable accuracy, precision, temperature variation, and heating uniformity
for up to 30 minutes. Safety parameters of this HT treatment modality were measured for all
targets by contrast-enhanced MRI, macroscopic tissue observations, and by histological analysis.
The results support the assertion that the technique is feasible for use in treating an array of
pelvic malignancies in human patients.
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Chapter 3: Characterization of magnetic
resonance-guided high-intensity focused
ultrasound (MRgHIFU)-induced largevolume hyperthermia in deep and superficial
targets in a porcine model
3.1 Introduction
Chapter 2 demonstrated the feasibility of MRgHIFU HT for heating a set of clinically relevant
pelvic targets with the smallest usable heating diameter (Ø=18 mm). Previous work from other
institutions [1,12] also showed successful implementations of in vivo MRgHIFU-HT where
depths of the tROI ranged from 35 mm to 80 mm when using a tROI Ø ≤44-mm with an
acceptable safety profile. So far, no successful implementation of HT for large-volumes (here,
defined by tROI Ø=58-mm) or superficial targets (i.e., <25-mm from the skin) in vivo with
satisfactory temperature statistics has been reported. However, due to the extended heating
duration typical of HT therapies, using multiple separate heating events to cover a large tumor is
either efficient or desirable from a clinical-treatment perspective. In addition, target dimensions
for RT+HT can be larger than 44-mm and are located at both deep and superficial locations, for
pelvic cancers as well as other sites, such as sarcoma and skin cancer. As we mentioned in
chapter 1, in treatment of skin cancer or sarcoma treatments, the combination of RT and HT
(RT+HT) resulted in a significantly increased response rate compared with RT alone
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[13,58,119,121,140,141,153–155,159,206–209]. Thus, it is also necessary to evaluate the
feasibility of utilizing a larger heating size (i.e. Ø=58 mm) to heat the porcine targets in different
depths, and characterize the temperature field and tissue profiles of MRgHIFU induced largevolume (Ø=58 mm) HT for both deep and superficial targets in vivo to facilitate clinical
translation to a broader array of clinical targets, both in the pelvis and elsewhere.

In this chapter, we aim to characterize the temperature distribution and tissue profile of largevolume HT in both deep and superficial locations by applying a series of large-volume HT
treatment cells to both superficial and deep targets in vivo with different user-definable
parameters. Temperature statistics within the tROI and temperature distributions were
characterized. Three-dimensional measurements of the thermal dose distributions were
benchmarked against a commercial phantom. Finally, contrast-enhanced MR images,
macroscopic examination, and histopathological analysis were performed for tissue damage
characterization.

3.2 Materials and Methods
3.2.1 Animal Overview
All animal procedures were reviewed and approved by the Institutional Animal Care and Use
Committee at Washington University in St. Louis following the National Institute of Health
Guidelines for animal research. This study used eight female pigs (107.6±4.3 day-of-treatmentage, 119.6±5.9 lbs.). Pigs either received one (N=1), two (N=4), three (N=2), or four (N=1) HT
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sessions on a given day. For pigs that received multiple HT sessions, we applied each HT session
to different areas of the hind leg muscles to avoid reapplying HT to the same area of the muscle.

3.2.2 Description of MRgHIFU system
The Sonalleve® V2 system [111,185,210] is comprised of a patient tabletop that can be locked
into an MRI scanner bore (Ingenia 1.5T, Philips, Best, the Netherlands). The tabletop
accommodates a 2-channel RF receive coil and a 256-channel phased-array HIFU transducer.
Another 3-channel pelvic RF receive coil were embedded in the pelvic surface-coil. The
transducer is immersed in an oil bath inside the tabletop, and access to the target is provided
through an acoustically transparent Mylar membrane. The transducer can operate within a
frequency range of 0.85-1.45 MHz.

3.2.3 Temperature feedback control
A temperature feedback control algorithm introduced by Tillander et al.[12] was employed to
control the HT sonication by integrating electronic beam steering and mechanical movement of
the transducer [12,211]. In short, HT was primarily regulated by the tROI temperature in the
target plane. The aim was to raise the temperature to a pre-defined target temperature and to
homogenously maintain the temperature in each voxel within the tROI [210]. The 58-mm
diameter circular tROI was divided into seven “subcells” (each with Ø=16-mm) arranged on a
hexagonal grid [12]. For heating within each subcell, only electronic steering was employed. The
method of electronic beam steering, number of points within a subcell, and sonication point order
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has been described by Köhler [211] and Tillander et al. [12]. The transducer is mechanically
translated between different subcells. The HT algorithm first increases the average temperature
of the middle subcell to the target temperature, and then moves to one of the “coldest”
surrounding subcells. The sonication temporarily pauses if none of the subcells had an average
temperature lower than the target temperature. The HT feedback algorithm also contains a
maximum-threshold-temperature for preventing temperature overshoot in one or more userdefined and positioned plane(s), which are here collectively labeled as “threshold-plane”. If any
voxel in the beampath cross-section within the threshold-plane exceeds a user-defined maximum
temperature threshold, the sonication power would be set to zero until all voxels of interest cool
to temperatures under the maximum threshold.

3.2.4 Experimental procedure
1. Animal preparation: The pig was anesthetized with an intramuscular injection of
ketamine (2 mg/kg), xylazine (2 mg/kg), and telazol (4 mg/kg) in the cervical muscles,
intubated and ventilated. General anesthesia was maintained using isoflurane at a
concentration of 1–5%, and a tidal volume of 10 mL/kg. The blood oxygen saturation and
pulse rate were monitored by a fiber-optic pulse oximeter (Nonin 7500FO, Plymouth,
MN). The pigs’ body temperature was monitored rectally.

2. Animal placement: To acoustically couple the animals’ skin with the Mylar membrane
and adjust the position of the targets into an accessible range, a 1.5-cm or 4.0-cm gel pad
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(Profound Medical Inc., Mississauga, ON, Canada) and modified mixture of ultrasound
gel (Aquasonic, Parker Laboratories Inc., Fairfield, NJ, USA) and degassed water in a 3–
4:1 ratio were utilized. Clippers were used to remove the hair from the hind leg, rump,
and adjacent regions and any remaining hair was removed using depilatory cream (Nair,
Church & Dwight Co., Princeton, NJ, USA). After laying the animal on the tabletop in a
lateral position, the pelvic coil was secured over the target anatomy. Sandbags were used
to further stabilize and support the animal on the HIFU table (Figure 3.1(A)).
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Figure 3. 1 (A&C) Schematic illustration of the experimental setup in an example
superficial (A) and deep (C) HT session viewed in the transverse plane, with the animal
placed on the HIFU tabletop in the left decubitus position (not to scale). (B&D)
transverse view of T2-weighted MRI overlaid with a schematic illustration of the
beampath and the transducer in an example superficial (B) and deep (D) HT session.
Figure caption: Orientation: AP = anterior-posterior, LR = left-right, and FH = foot-head.
The target slice is denoted in red, and the near field and far field are denoted in orange.
3. Treatment planning: A T2-weighted MRI [12,111,210] was acquired to image the hind
leg muscle for treatment planning: echo time =130 ms, repetition time =1300 ms, flip
angle =90°, number of signal averages =1, field-of-view =250×259 mm2, acquisition
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matrix =250×217, spatial resolution (voxel size) =1.12×1.19×2.5 mm3, scan time =190 s.
We maintained a safety margin of ≥10 mm [31,212,213] between the HIFU beampath
and any bone.

4. Temperature monitoring: The proton resonance frequency shift (PRFS) method was used
for temperature mapping [1,12,111,210] using field of view =400×400 mm2, voxel size
=2.5×2.5×7 mm3, temporal resolution =3.7 s. Briefly, a dynamic, RF-spoiled, fast-fieldecho echo-planar imaging (FFE-EPI) sequence was utilized to obtain magnitude and
phase images. Six FFE-EPI planes (five coronal, one sagittal relative to the transducer, as
shown in Figure 3.1) were used for temperature monitoring. Coronal slices include: a
“target” slice, placed at the target depth; two slices, one each 7-mm distal and proximal to
the “target” slice, respectively; and user-positioned “near field” and “far field” planes
proximal and distal to the target slice relative to the transducer, respectively. The sagittal
slice was along the ultrasound beampath perpendicular to the target slice.

5. The depths of the target slices were separated into two groups: (1) Superficial HT
targeted depths of approximately 20-mm from skin surface (average=18.8±1.8 mm,
N=11) (Figures 3.1(A, B)); (2) Deep HT targeted depths of approximately 60-mm from
the skin surface (average=62.2±2.3 mm, N=8) (Figure 3.1(C, D)). For superficial HT, the
near-field-only (N=4), the far-field-only (N=3), or both the near- and far- fields (N=4)
were selected as the threshold-plane. In deep HT, the near-field-only (N=4), or both near64

and far-field (N=4) were selected as the threshold-plane. Since we detected some skin
damage when using the far-field only as the threshold-plane for superficial targets, we did
not apply the far-field-only as the threshold-plane for deep HT, although later analysis
revealed those changes were not related to the heating. In all sessions, attempts were
made to keep the distance between the near-field and tROI, and the distance between the
far-field and tROI as consistent as possible. Of note, some adjustments (generally <1.0cm) were made on a case-by-case basis to avoid placement of the tROI/near-field/farfield on a blood vessel or nerve as well as to address practical access limitations of the
system. The distance between the near field and tROI was 54.55±4.95 mm and
11.80±3.75 mm for deep and superficial HT, respectively. The distance between the far
field and the tROI was 32.60±4.41 mm and 28.73±11.62 mm in deep and superficial HT,
respectively.

6. HT treatment: Prior to HT treatment in each animal, the MR thermometry sequence was
performed for 10–15 min to bring the magnet hardware to a thermal steady-state [187].
HT treatment then proceeded with the following parameters for all sonications: acoustic
power 100 W; treatment duration 30 min; target temperature 42°C; maximum threshold
temperature 44°C (applied to threshold-plane). A frequency of 1.0 MHz was used,
producing an ellipsoidal focal point with length and width of 14.65 mm and 1.90 mm,
respectively [210]. All sonications employed continuous ultrasound waves.
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7. Post-sonication scanning: After HT completion, two T1-weighted 3D high resolution
isotropic volume excitation (THRIVE) sequences were acquired before and after the
injection of gadobenate dimeglumine (MultiHance; Bracco Imaging, Milan, Italy) at a
dose of 0.2 mL/kg [210]. Potential thermal damage was presented as abnormallyperfused areas. To avoid the temperature rise or the thermal damages from a completed
HT session affecting a subsequent HT session, we took the following steps. First, we
waited for the temperature to decrease to below 39°C before starting planning of the
subsequent HT session. Second, five out of the eight pigs received two HT sessions or
less. In four of these pigs, we heated both legs to avoid the overlapping of heated tissue in
the second HT session. Third, for the three pigs who received ≥3 HT sessions, we
changed the pigs’ positions/orientations to target a separate portion of the same leg or the
other leg in a consecutive HT session, so that there was enough cooling down time. Due
to a relatively smaller heated volume in superficial HT, when a pig received ≥3 HT
sessions, the third or fourth HT sessions were performed on superficial targets so that the
decreased heated volume could help to minimize any heating overlap in the previously
heated deep-seated regions.

8. Animal euthanasia: After the MRI exam, pentobarbital (150 mg/kg) was administered
intravenously for euthanasia.
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3.2.5 tROI temperature quantification
The acquired FFE-EPI images were processed after the experiment using a previously-described
method [111,210]. The reliability of the MR thermometry of Sonalleve® system has been
verified by a comparison between the temperature measured by fiberoptic sensors and the
Sonalleve® reported temperature. Only through a discrepancy of those two measurements by
less than 1°C, was the system deemed reliable for clinical use [40]. This accuracy has also been
similarly validated in our system. Therefore, the temperature reported by Sonalleve® system was
used for the temperature analysis in this study. Temperature statistics within the tROI were
evaluated and a number of factors tabulated [210]. Briefly, the spatial average temperature (Tavg),
the maximum temperature of all the voxels within the tROI (Tmax), the minimum temperature of
all the voxels within the tROI (Tmin), the temperature that only highest tenth percentile of voxels
reached (T10), the temperature that only the lowest tenth percentile of voxels reached (T90), and
the spatial standard deviation of all voxels within the tROI (σT) were all evaluated. Each metric
was first calculated in each “dynamic”, i.e., one of the temperature maps acquired every 3.7 s,
and the metrics were then averaged across all dynamics. Additionally, the maximum value of
Tmax,d in tROI of each session was calculated, as well as the Tavg, Tmax, and T10 values in the crosssection within the beampath of the near field slice. Cumulative equivalent minutes at 43°C of T90
(CEM43T90), a thermal dose predictor of clinical efficacy for RT+HT in cancer patients in
several clinical trials [155,167,168,191,214–221], was also analyzed. We chose to evaluate the
CEM43T90 since it characterizes the lower end (T90) of the temperature distribution over
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extended time which was reported to have the most relevance for the tumor response
[168,214,219,220]. Additionally, cumulative equivalent minutes at 43°C of Tavg (CEM43Tavg) at
the tROI were also characterized in order to benchmark the achieved thermal dose with previous
studies for the muscle tissue damage [190,222–225].

The following four parameters were calculated for evaluation of the system performance
[1,12,210]: temperature accuracy, precision, temporal variation, and heating uniformity.
Temperature accuracy was calculated by subtracting the desired temperature of 42°C from the
achieved Tavg. Precision was quantified by σT, an estimate of the spatial temperature variance of
each voxel across the tROI. Temporal variation was gauged by the standard deviation of the
Tavg,d across all dynamics. Heating uniformity was assessed by the temporal average of the
largest difference between the Tavg,d and either the T10,d or T90,d, to evaluate the degree of spatial
temperature homogeneity. We chose to quantify the above-mentioned parameters due to the fact
that they have been calculated in our previous study [210] and others’ work [1,12], thus allowing
benchmarking of our results against the existing data. For clinical management purposes, it was
also crucial to evaluate how quickly the temperature increases to within 1°C of the target
temperature (here, 42°C), as this is generally considered a reasonable benchmark for successful
heating with these MRgHIFU systems. Thus, the duration required for the Tavg,d in the 58-mm
tROI (not any subcell in the tROI) to reach ≥41°C after the start of sonication was also recorded.
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Two-tailed Mann-Whitney U tests were used to assess significant statistical differences (p<0.05)
among different heating conditions for the tROI temperature metrics and/or the time for the
temperature to increase.

3.2.6 Three-dimensional temperature characterization
The volume and shape of temperature distributions within the tROI were evaluated using the
time-in-range (TIR) concept in both the sagittal and the coronal slices. Briefly, the TIR values of
10 min/20 min/25 min (TIR10/TIR20/TIR25) were calculated and presented as maps of voxels
that stay within 40–45°C for 10-min/20-min/25-min during the whole 30-min sonication. The
dimensions of TIR maps along the ultrasound beampath were analyzed in the sagittal plane. The
dimensions of the TIR maps perpendicular to the ultrasound beampath were analyzed in the
target plane along both horizontal and vertical axes to characterize the beam profiles at the target
depth.

We benchmarked the size and shape of the HT heating distributions against those seen in a
commercial HIFU cylindrical gel phantom filled with a proprietary hydrogel (Profound Medical
Inc., Mississauga, ON, Canada) using the same sonication parameters as in vivo. The inclusion of
HT in the phantom served as a model with few external heating artifacts (i.e. animals’
cardiovascular, respiratory, and digestive motions) to help validate any potential changes in
temperature distributions caused only by the different positions of the threshold-plane. All TIR
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maps of HT sessions both in vivo and in phantom were processed in MATLAB (R2018a,
MathWorks, Natick, MA, USA).

The one-tailed Mann-Whitney U test was used to assess significant statistical differences
(p<0.05) in penetration depth since the depths of the TIR dimensions were expected to be more
superficial when the threshold-plane for temperature regulation included the far-field compared
to when it excluded the far-field. The two-tailed Mann-Whitney U test was used to assess
significant statistical differences (p<0.05) for comparison of the TIR dimensions along the
horizontal and the vertical axes. GraphPad Prism (Version 8.3.1, La Jolla, CA, USA) was used
for all statistical analyses in this study.

3.2.7 Tissue damage characterization
Tissue damage caused by HT was assessed by contrast-enhanced MRI, gross pathology, and
histopathology using hematoxylin and eosin (H&E) staining. After euthanasia, the locations of
HT targets were identified using anatomical landmarks (greater trochanter of the femur and tibial
tuberosity) to identify the hip, knee, and orientation of the femur as reference. A gross
examination of the skin surface overlaid on the treatment area was done and then each lesion was
collected for histopathological analysis.

The pathological samples were taken by referring the distances (measured in the MR images)
from the tROI to palpable and recognizable anatomical landmarks (greater trochanter of the
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femur and tibial tuberosity) and its location relative to the femur during gross dissection. During
the dissection, we located the center of the tROI by finding the point that has the same distances
to the above mentioned bony landmarks and its geometrical location relative to the femur as seen
in the MR images. This method resulted in a collected tissue section (25×20 mm) smaller than
the heated volume, so this study did not quantify the geometrical boundaries of the tissue
damage. The following tissues were collected: (1) muscles within the heated volume (including
the center of the tROI and tissues 20-mm distal to the HT targets relative to the transducer); (2)
tissues within ultrasound beampath, including skin and subcutaneous fat (i.e., representative of
the near field); and (3) muscles from the non-heated contralateral leg (as negative controls).
Tissues were processed as previously described [210].

3.3 Results
3.3.1 tROI temperature characterization
An illustration of the HT and off-line processing is shown in Figure 3.2, including the tROI
denoted by the red dashed circle overlaid on a representative axial MRI target slice (Figure 3.2
A), the corresponding Tavg map of the target slice (Figure 3.2 B), and the TIR10/TIR20/TIR25
maps in this target slice (Figure 3.2 C). For this treatment, Figure 3.2 D presents the temporal
Tavg,d/Tmax,d/Tmin,d of all voxels within the tROI during the 30-min HT session and 15-min
cooling period. The spatial homogeneity (Figure 3.2 B) and temporal stability (Figure 3.2 D)
evident in this case were seen in all other HT sessions. The temporal-average metrics in the tROI
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for all HT sessions (Tavg, Tmax, Tmin, T10, T90, σT, CEM43T90 and time for Tavg to reach 41°C) are
shown in Table 3.1, along with the Tavg, Tmax, and T10 in the cross-section of the near-field.
Across all HT sessions, the Tavg in the tROI were 41.7±0.4°C and 41.6±0.5°C for deep and
superficial HT, respectively. The maximum Tmax in tROI averaged 51.3±2.2°C and 49.4±2.1°C
for deep and superficial HT, respectively. Tavg, T10, and Tmax in the near-field cross-section were
39.1±0.7°C, 42.0±0.8°C, and 44.8±1.2°C across all deep HT sessions, and 40.2±1.0°C,
42.1±1.0°C, and 45.4±3.7°C across all superficial HT sessions. The average CEM43T90 and
CEM43Tavg was 0.9±0.7 min and 12.7±6.1 min, respectively. Among all HT sessions, Tavg
reached 41°C at 247.8±66.5 s.
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Table 3. 1 Temperature statistics in the target region-of-interest (tROI) within the target slice
and the beam cross-section in the near field (NF).
Deep tROI
Loca
tion

Threshold-plane

tROI

NF

Superficial tROI

NF only

NF & FF

NF only

FF only

NF & FF

depth (mm)

64.5±5.8

59.9±2.1

20.9±4.2

18.3±3.1

17.4±1.1

Tavg

42.0±0.2

41.4±0.4

42.1±0.3

41.2±0.3

41.1±0.4

Tmax

46.6±1.2

46.1±0.5

45.8±0.2

45.1±0.4

44.5±0.4

Tmin

37.6±0.7

37.5±0.3

38.6±0.6

38.0±0.2

38.4±0.3

T10

43.6±0.3

43.1±0.5

43.5±0.2

42.7±0.4

42.3±0.4

T90

40.2±0.1

39.8±0.2

40.6±0.4

39.6±0.2

39.9±0.3

σT

1.3±0.1

1.3±0.1

1.1±0.1

1.2±0.1

1.0±0.1

Maximal Tmax

51.8±2.7

50.8±1.7

49.1±3.3

48.7±0.6

48.4±0.6

CEM43T90 (min)

1.2±0.4

0.4±0.3

1.7±0.9

0.3±0.1

0.6±0.3

CEM43Tavg (min)
Time of Tavg,d to
get 41°C (s)

19.5±7.2

10.6±2.9

16.7±3.7

8.8±1.7

7.0±1.5

216.6±69.3

286.0±110.2

216.3±7.9

259.7±56.7

263.2±48.5

Tavg

38.7±0.3

39.4±0.9

40.4±1.3

39.8±0.7

40.4±1.0

T10

42.5±0.8

41.5±0.5

42.2±1.1

42.2±1.2

42.1±1.2

Tmax

45.6±0.9

44.0±1.0

46.7±6.2

44.6±1.2

44.7±1.8

location

All metrics are in °C unless otherwise indicated.
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Figure 3. 2 Workflow of the HT to thigh muscle and off-line temperature processing.
Figure caption: (A) Illustration of the target region-of-interest (tROI) selection indicated by the
red dashed circle on the axial MRI (target slice). (B) For the treatment in (A), a representative
average temperature map of the target slice with the tROI outlined in red dashed circle is shown.
(The high temperature region in the upper left portion is an artifact) (C) Time-in-range map
(TIR) map of 10-min, 20-min, and 25-min of the target slice for the 30-min HT for this
treatment. (D) The representative average temperature (Tavg), maximum temperature (Tmax), and
minimum temperature (Tmin) of all voxels within the tROI during the 30-min HT session and 5min cooling period.
Figure 3.3 shows the metrics within the tROI in different locations in the threshold-plane in both
deep and superficial HT, including the accuracy (A), temporal variation (B), precision (C),
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heating uniformity (D), CEM43T90 (E), CEM43Tavg (F), and the time needed for the Tavg,d to
reach 41°C (G). Across all HT sessions, accuracy was -0.4±0.5°C, precision was 1.2±0.2°C,
temporal variation was 0.6±0.2°C, and heating uniformity was 1.5±0.2°C. For deep HT, the
CEM43T90 was significantly lower when the threshold-plane included both the near- and farfields, compared to the threshold-plane applied for the near-field only (Figure 3.3 E). For
superficial HT, the CEM43Tavg was significantly lower when the threshold-plane included both
the near- and far-field, compared to the threshold-plane applied for the near-field only (Figure
3.3 F).
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Figure 3.3 Temperature metrics for both deep HT (blue triangles) and superficial HT (red dots)
in thigh muscle. Plane(s) included in the threshold-plane are shown on the abscissa: near-field
only (NF), far-field only (FF), or both near- and far-fields (Both).
Figure caption: (A) Difference between Tavg and desired temperature of 42°C. (B) Temporal
variation. (C) Temperature precision. (D) Temperature uniformity. (E) The CEM43T90 (min)
calculated based on the T90 for the 30-min in each voxel within the target region-of-interest
(tROI). (F) The CEM43Tavg (min) for the 30 min calculated based on the Tavg in each voxel
within the target region-of-interest (tROI). (G) Time (s) for the average temperature of the tROI
to reach 41°C after the start of the sonication. All results are presented in form of mean (central
black line) ± standard deviation (black range bars). The statistically significant differences
(p<0.05) are indicated by asterisk (*).

3.3.2 Three-dimensional temperature characterization
Table 3.2 presents the average dimensions of the TIR10/TIR20/TIR25 along the sagittal axis, the
horizontal axis, and the vertical axis in both porcine thigh muscle and phantom. Across all 19
sessions in the thigh muscle, the widths of TIR10, TIR20, and TIR25 within the treatment plane
averaged 73.7±13.2 mm, 61.1±7.5 mm, and 53.3±6.9 mm, respectively. Due to its high
conformality to the target cell size (58 mm), TIR20 was selected as a representative metric for
describing the heating dimensions. Figures 3.4 A&B and Figures 3.4 C&D show representative
examples of HT performed in the phantom and pig thigh muscle in vivo, respectively. The red
dashed lines indicate the locations of the target slice, and the orange dashed lines represent the
locations of the threshold-plane. The threshold-plane was in the near-field only in Figures 3.4
A&C, while it was both the near- and far-fields in Figures 3.4 B&D. Visually, the TIR maps
appear to be more superficial in Figures 3.4 B&D compared to Figures 3.4 A&C. This is evident
in both the porcine thigh muscle (Figure 3.4 A&B) and phantom (Figure 3.4 C&D).
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Table 3. 2 The dimensions of the time-in-range (TIR)-10/20/25 min in three dimensions
Target
location

Analyzed axis of
TIR

HT target
location

Thresho
ld-plane
location

Thigh

Sagittal axis

Deep

NF

TIR10 (mm)
126.3±22.9

TIR20 (mm)
105.0±14.7

TIR25 (mm)
83.1±18.5

FF

116.5±12.0

85.8±12.7

60.8±16.8

NF

106.5±3.1

87.5±2.9

80.8±9.1

FF

86.0±9.6

65.0±2.5

52.5±11.5

Both

96.3±8.5

73.9±20.8

47.5±21.3

NF

80.0±7.4

66.3±4.8

56.9±3.2

FF

85.8±18.0

66.3±7.5

55.3±9.6

NF

72.6±7.0

64.5±4.2

58.3±4.7

FF

59.2±9.5

50.0±2.5

45.3±2.5

Both

65.6±9.7

57.6±6.0

55.3±6.4

NF

81.3±8.8

62.8±5.3

51.9±4.3

FF

85.0±15.7

63.3±4.7

51.0±9.3

NF

69.4±2.4

62.5±2.9

58.8±1.4

FF

59.2±2.9

52.7±2.5

44.2±5.2

Both
NF

71.9±12.3
145.6±12.3

60.6±7.2
130.3±5.3

46.9±15.3
121.5±8.7

Both

140.8±12.3

133.3±5.2

109.2±5.2

NF

114.5±10.9

102.0±3.2

96.4±4.7

FF

99.4±6.6

94.4±7.2

83.3±3.4

Both

102.0±9.8

87.0±1.4

79.4±3.1

NF

76.3±3.2

70.6±3.8

64.4±3.8

Both

78.5±1.3

70.0±2.5

62.7±2.5

NF

78.8±1.4

73.1±1.3

72.5±2.0

FF

74.5±2.3

69.4±2.4

66.3±1.4

Both

80.1±1.8

73.1±4.3

68.1±3.8

NF

76.3±3.2

71.5±3.1

68.1±3.8

Both

79.2±5.2

74.2±3.8

65.0±2.5

NF

72.5±2.0

68.8±2.5

65.6±2.4

FF

65.6±2.4

60.6±1.3

57.5±2.0

Both

66.3±1.4

61.9±1.3

57.5±2.0

Muscle
Superficial

Frontal axis

Deep
Superficial

Vertical axis

Deep
Superficial

Phantom

Sagittal axis

Deep
Superficial

Frontal axis

Deep
Superficial

Vertical axis

Deep
Superficial

Table caption: Time-in-range (TIR) values of 10-min/20-min/25-min (TIR10/TIR20/TIR25) were
presented as maps of voxels that stay within 40–45°C for 10-min/20-min/25-min during the whole
30-min sonication. Here the TIR was measured in the sagittal axis (along LR orientation shown in
Figure 3.1), the frontal axis (along the AP axis in Figure 3.1), and the vertical axis (along the HF
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axis in Figure 3.1) in both the porcine thigh muscle and the commercial phantom. Orientation: AP
= anterior-posterior, LR = left-right, and FH = foot-head.

Figure 3. 4 Representative time-in-range (TIR)-10/20/25min maps overlaid on the Tavg maps
acquired from MR thermometry in the sagittal plane for superficial targets in both phantom
(A&B) and porcine thigh (C&D).
Figure caption: The target slice is denoted by the red dashed line and the near- and/or far-fields
denoted by orange dashed lines. The threshold-plane included only the near-field in (A, C), while
the threshold-plane included both the near- and far-field in (B, D). Orientation: AP = anteriorposterior, LR = left-right, and FH = foot-head.
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An analysis of TIR20 dimensions for different locations of threshold-plane is shown in Figure
3.5. In superficial HT in vivo, a 22.5-mm difference (sagittal; Figure 3.5 A) and a 10.2-mm
difference (vertical; Figure 3.5 E) in TIR20 dimensions were observed when the threshold-plane
included only the far-field (Figure 3.5 E) or both fields (Figure 3.5 A) compared to when the
threshold-plane included only the near-field (p<0.05). Such differences were also observed in the
phantom; the TIR20 dimensions along the sagittal and vertical axes were significantly decreased
(p<0.05) when far-field or both fields were included in the threshold-plane compared to when the
near-field alone was included (Figure 3.5 B&F). For deep HT, no statistically significant
difference was found in TIR20 dimensions either in the thigh muscle or in the phantom. Similar
results were also observed in the dimensions of TIR10 (Figure 3.6) and TIR25 (Figure 3.7) when
the threshold-plane was applied to only the near-field compared to when the threshold-plane was
applied to the far-field only or both fields.
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Figure 3. 5 Dimensions of time-in-range (TIR)-20 min on the sagittal axis, frontal horizontal
axis, and vertical axis in both phantom and porcine thigh muscle, respectively.
Figure caption: All results are presented in the form of mean (central black line) ± standard
deviation (black range bars). The results of deep HT are denoted by blue triangles and the results
of superficial HT are denoted by red dots. The plane included in the threshold-plane is shown on
the abscissa: near-field only (NF), far-field only (FF), or both near- and far-fields (Both).
Statistically significant differences (p<0.05) are indicated by an asterisk (*).
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Figure 3. 6 Dimensions of time-in-range (TIR)-10min on the sagittal axis, frontal horizontal axis,
and vertical axis in both the phantom and porcine thigh muscle, respectively.
Figure caption: All results are presented in the form of mean (central black line) ± standard
deviation (black range bars). The results of deep HT are denoted by blue triangles and the results
of superficial HT are denoted by red dots. The plane included in the threshold-plane is shown on
the abscissa: near-field only (NF), far-field only (FF), or both near- and far-fields (Both).
Statistically significant differences (p<0.05) are indicated by an asterisk (*).
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Figure 3. 7 Dimensions of time-in-range (TIR)-25min on the sagittal axis, frontal horizontal axis,
and vertical axis in both phantom and porcine thigh muscle, respectively.
Figure caption: All results are presented in the form of mean (central black line) ± standard
deviation (black range bars). The results of deep HT are denoted by blue triangles and the results
of superficial HT are denoted by red dots. The plane included in the threshold-plane is shown on
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the abscissa: near-field only (NF), far-field only (FF), or both near- and far-fields (Both).
Statistically significant differences (p<0.05) are indicated by an asterisk (*).

3.3.3 Characterization of tissue damage
Post sonication, contrast-enhanced MRI showed abnormally-perfused, hyper-intense regions
within the tROIs in ten out of nineteen sessions (Figure 3.8). The nature of the post-HT MRI
changes in the heated volume (both in the tROI and 2-cm distal to the tROI) was very subtle and
only presented in sub-volumes in the heated area (as represented in Figure 3.8 B&D) in some
cases. Although some image quantification techniques were attempted, they were not able to
capture these changes. Therefore, whether there was post-HT MRI enhancement in T1 MR
images was evaluated based on observer-scoring. No abnormally-perfused area was observed in
the contrast-enhanced MRI for subcutaneous tissues or skin that overlaid the tROI. In gross
analysis, no abnormalities were observed on the skin surface for any HT session.
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Figure 3. 8 (A, C) A representative T1-weighted 3D high resolution isotropic volume excitation
(THRIVE) MRI in the coronal view before HT. (B, D) Contrast-enhanced MRI in the coronal
view in the same plane as (A, C) at the completion of HT, respectively.
Figure caption: The yellow circle represents the cross-section of the beam path, and the red
arrow shows hyper-intense regions detected in the cross-section of the beam path, indicating
potential tissue damage.
For the histopathological analysis, heated muscle tissues from sixteen HT sessions were
examined and classified based on the target depth and the location of the threshold-plane, as
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summarized in Table 3.3. Tissues from the other three sessions were destroyed before they could
be collected for analysis. Overall, the pathological changes in the muscle tissues within the
heated volume (including tissues at the center of the tROI at the heating depth and 20-mm distal
to heating depth) could be classified into three categories. First, acute myofiber degeneration and
necrosis, characterized by swelling and hypereosinophilia of myofibers, with variable
vacuolation, fragmentation, contraction band necrosis, loss of cross-striations, or nuclear
pyknosis or loss, as shown in Figure 3.9 A&B, were detected in ten sessions (62.5%, as shown in
Table 3.3). Second, mild to moderate edema, characterized as mild separation of myofibers, was
captured in two sessions (as shown in Table 3.3 and Figure 3.9 C&D), both of which were
accompanied by the acute myofiber degeneration and necrosis as we described previously. Third,
no significant lesions compared to the negative control tissues were detected in the rest of the
sections, as shown in Figure 3.9 E&F. For the skin and subcutaneous tissue, in all HT sessions,
compared with the control tissue, we did not detect any acute changes related to experimental
procedure, as shown in Figure 3.9 (G&H).
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Table 3. 3 Categorization of the post-HT histological analysis

tROI depth

Deep
Deep
Superficial
Superficial
Superficial

Thresholdplane

# Analyzed
session

NF
Both
NF
FF
Both
Sum

1
4
4
3
4
16

# sessions
Muscle tissue within the heated volume
Acute myofiber
Mild to moderate
degeneration/necrosis
edema
1
0
4
2*
2
0
0
0
3
0
10
2

Table caption: The number of lesions were classified based on the target depth, threshold-plane
slice, and different tissue types. The numbers indicate the number of sessions that present a
corresponding damage. *These two sessions that show mild to moderate edema were all
accompanied by myofiber degeneration/necrosis.

87

Figure 3. 9 Representative H&E images of the collected tissues related to HT exposure.
Figure caption: (A, B) Muscle tissues in the heated volume showed acute myofiber degeneration
and necrosis. (C, D) Muscle tissues in the heated area presented mild to moderate edema. (E, F)
Muscle tissues presented no significant lesions. (G, H) Skin and subcutaneous tissues in the HT
session showed no significant lesions related to HT.
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3.4 Discussions
This study was the first to characterize temperature statistics and tissue damage of large-volume
MRgHIFU-mediated HT in both superficial and deep targets in vivo. The satisfactory
temperature profile within the tROI indicates its potential clinical utility. Most HT sessions
showed irreversible tissue damage within the heated (target) volume. The skin and subcutaneous
tissues presented no significant damage. Overall, these results demonstrate that large-volume
MRgHIFU HT could be clinically feasible and safe with some precautions. Furthermore, the
characterization of the heating distributions imply that applying the threshold-plane to different
locations/orientations might provide another potential way of shaping temperature distributions.

Generally speaking, temperature statistics obtained from the tROI agree with published studies
[1,12,210]. The difference between the achieved and the desired temperature averaged -0.4°C,
and agrees with the requirement in published guidelines of less than 1°C [107,111,187].
Precision averaged 1.2°C and uniformity averaged 1.5°C, both showing that the tROI
temperature remained within the hyperthermic range. Temperature uniformity was consistent
with the previous studies at 1.4°C [1].

Some subtle differences were seen when comparing the results to those of previous studies. For
example, the higher (worse) precision here compared to previous studies (0.3°C [1] and 0.8°C
[12]) was expected due to the larger cell size [1,12], more subcells [1], and/or a lower MRI field
strength used in our study [1]. The use of mechanical motion and electronic beam steering to
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manage seven subcells for the 58-mm target compared to electronic steering only for the 18-mm
cell likely lead to an increase in the standard deviation of temperature in the tROI, and thus
worse precision. Nonetheless, any differences between this and previous studies may not have
clinical significance. The absence of statistically significant differences in temperature metrics
between different HT heating conditions (in Figure 3.3) implies the robust and reliable
performance of large field HT heating with the MRgHIFU system for both deep and superficial
targets.

The CEM43T90 averaged 0.9 min in our study. This is slightly lower than a published clinical
guideline of CEM43T90≥1 min for superficial HT [94]. However, a different randomized trial
[155] by Jones et al. deemed superficial tumors treatable if a CEM43T90 ≥ 0.5min over a one
hour HT. Eighteen out of 19 sessions in our study would pass Jones’s threshold. The concept of
CEM43T90 has been widely used as a treatment goal in many studies [155,167,191,215–218,221]
and is one of the quality indicators in guidelines [94,226]. It has been reported to be correlated
with positive outcomes: significantly higher complete response [155,191], longer or improved
local control [167,216], and longer disease-free survival [191,218] in the treatment of various
types of cancer. Therefore, its relationship with the clinical outcome has been mostly revealed.
For example, CEM43T90≥1 min was shown to be correlated with longer local survival in cervical
cancer [191]. In our study, a relatively higher CEM43T90 (1.2 min in our case) was considered
more preferable to a lower one (i.e. 0.4 min). In this way, the characterization of CEM43T90
benchmark of this work with previous studies and can potentially help us to determine a
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clinically-relevant and achievable thermal dose in our subsequent clinical trial. Additionally, as
an incorporation of time and temperature, heating duration and target temperature might have a
stronger impact for the CEM43T90/CEM43Tavg than the selection of threshold-plane(s).
However, part of the goal of the study was to investigate the impact of the threshold-plane on
temperature distribution. Thus we presented CEM43T90/CEM43Tavg as an illustration of the
impact of the selection of the threshold-plane on the thermal dose. A relatively higher
CEM43T90/CEM43Tavg could be obtained by the modification of T90/Tavg, the number of HT
fractions, and/or the durations of each fraction, all of which were potentially adjustable. On
another note, the selection of the threshold-plane may influence the thermal dose (including
CEM43T90 and CEM43Tavg) in some cases. For deep HT, CEM43T90 became significantly lower
when the threshold-plane included both fields (0.4±0.3 min) compared to the near-field alone
(1.2±0.4 min, Figure 3.3 E). For superficial HT, CEM43Tavg was significantly lower when both
near- and far- fields were included in the threshold-plane (16.7±3.7 min) compared to including
the near-field alone (7.0±1.5 min, Figure 3.3 F). The explanation for this might be that when
including the far-field plane into the threshold-plane, sonication will be disabled more frequently
due to the Tmax in the far-field reaching the cut-off temperature, thus providing a lower overall
energy delivered to the tROI. The significance of the lower CEM43T90/CEM43Tavg is that it
demonstrated using two temperature threshold planes instead of one might decrease the delivered
thermal dose (CEM43T90/CEM43Tavg) in the target level. A lengthened heating duration or a
relatively higher target temperature (i.e. 42.5°C) might be needed to achieve a preferable
CEM43T90 (i.e. 1.2±0.4 min) if CEM43T90/CEM43Tavg were used as the treatment objective,
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then when using two threshold planes for temperature regulation. However, despite a statistical
significance, the difference seen in this study might not have clinical significance, potentially
due to the relatively smaller sample size and possible anatomical differences between animals
and humans. Ultimately, this study highlights that thermal dose may be dependent on several
different factors for MRgHIFU systems although clinically-relevant CEM43T90 values may be
reasonably achievable for both deep and superficial MRgHIFU HT.

The time to reach the therapeutic HT temperature range is an important practical consideration.
Protracted “warm up” times could add considerably to treatment time (i.e. >15-20 min), resulting
in more patient discomfort, motion artifacts or baseline drift in the MR thermometry, and
challenges in maintaining good patient-to-transducer coupling. Severe instances could warrant
interventions such as mild or moderate sedation. Our results show that the overall time needed
for Tavg to reach 41°C was around 4 min, with the longest time of approximately 7 min (Table
3.1 and Figure 3.3F). These reasonably short times imply that minimal patient interventions may
be needed when treating patients with large field MRgHIFU-mediated HT.

For superficial HT, both in hind leg muscle and in phantom, the dimensions of the
TIR10/TIR20/TIR25 along sagittal, horizontal, or vertical axes were found to be significantly
shorter (Figures 3.5, 3.6, and 3.7) when the far-field or both fields are included in thresholdplane, compared to only applying the threshold-plane to the near-field. This finding informs a
potential strategy to adjust the penetration or shape of the heated region by manipulating the
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locations of the threshold-plane. In cancer treatment, the shape, size, and/or location of the tumor
could be variable, depending on its properties (i.e. tumor type, stage, previous treatment, degree
of malignancy, invasiveness, route of metastasis, etc.) and its surrounding anatomy. Due to these
differences, ideal implementation of HT would have the ability to modulate the heated volume to
be conformal to the tumor lesion, while avoiding heating of the normal surrounding areas. Since
the tumor volume could vary from patient to patient, the intended heated volume needs to be
discussed on a case-by-case or a tumor-by-tumor basis, based on the specific property of each
tumor as described above. General speaking, using only near field as the threshold-plane might
be optimal for the heating of a large tumor extended from the superficial subcutaneous tissue to
the deep-seated region (with a depth of approximately up to 80 mm). Using both near- and farfield as the threshold planes might be optimal for the protection of the more deep-seated normal
tissue for heating a more superficial tumor. Multiple heating events could be used to cover the
whole target volume for extremely large tumors, Manipulation of both the position and threshold
values for the threshold-plane might provide the ability to shape the thermal dose distribution,
achieving more conformal HT to desired targets and/or avoiding the heating of nearby sensitive
tissue structures.

This study found acute myofiber degeneration/necrosis within the heated volume in ten out of
sixteen HT sessions. This result differs from our previous work [210], where no permanent tissue
damage was found in pelvic targets treated with 18-mm-diameter HT. However, that previous
study had a lower average Tmax of 44.7°C and an average of the maximum temperature of each
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HT session of 48.7°C compared to this study (averaged Tmax of 45.7°C and averaged maximum
temperature in each HT session of 50.2°C), that may explain the observed tissue damage. As for
the thermal dose-damages relationship, our CEM43Tavg averaged 12.7±6.1 min in our study,
which is slightly lower than the reported thermal damage threshold in normal muscle tissue
[190,222]. It was previously reported that CEM43 between 41 and 80 min cause acute but minor
damage to muscle, while significant and chronic damage (i.e. hemorrhage and necrosis) resulted
from a thermal dose of CEM43 higher than 80 min[190]. Ichinoseki-Sekine et al. [222] reported
a CEM43 of 26 min using microwave did not cause thermal damage, as evaluated by blood
creatine kinase levels and tissue histology. Several studies have detected muscle damage with a
higher thermal dose. At higher thermal dose level, Zderiz et al. reported a CEM43 of 283 min
caused thermal damage to muscle immediately after the heating; and Mahoney et al.[223]
reported that a higher CEM43 (between 650 and 1.9×1010 min) caused tissue necrosis in the
rabbit thigh. Compared to these two studies, our results showed tissue necrosis or degeneration at
a relatively lower thermal dose level (CEM43Tavg of 5.8 min –29.7 min). The reason for the
difference might be due to different treatment systems, different temperature measurement
methods, and/or a different targeting temperature, among many other factors. Ultimately, it
would be desirable to correlate thermal dose with tissue damage, but this relationship might be
more comparable when using the same heating modality/system, targeting similar heating
dimension, with the same temperature measurement modality, and heating the same type of
tissue. To our knowledge, this is the first study that evaluated the large-volume (with a diameter
of 58 mm) HT using the MRgHIFU system. In addition, more advanced technology
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incorporating a higher spatial/temporal resolution of the MR thermometry, more temperature
monitoring planes, and/or better heating control algorithm, might be needed. Additionally, the
mild to moderate edema, as seen in two sessions, were all accompanied by myofiber
degeneration/necrosis, so we considered it as an accompanying lesion which might not have
always been captured in the examined section. Future study is needed to more fully characterize
the damage when using large fields, its severity, and potential selective effects on tumor tissue.
In terms of clinical utilization, permanent damage in tumor tissues were deemed desirable for
cancer therapy, since the necrotic cell death by HT was reported to be able to release tumor
antigens in complexes, taken up by dendritic cells, and induce specific anti-tumor immunity
[29,64,71,227]. These results imply that large-volume MRgHIFU-mediated HT could be
clinically implemented with some precautions, such as placement of the target volume largely
within the tumor volume.

For the skin and subcutaneous tissues, we did not detect any changes either in contrast-enhanced
MRI, gross observation, or histopathological analysis compared to the negative control tissue of
each pig. These results imply that the damage to the skin and/or subcutaneous tissue might not be
a concern for the HT therapy with target depths utilized in our study. Nevertheless, future work
is needed to assess any potential skin damages at other targeting depths or delivered thermal
dose, and explore any other potential alternative image-based strategies to assess skin damage in
MRgHIFU therapies.
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Several limitations need to be mentioned. First, this study only provided histopathology analysis
of the tissues within and 2-cm beyond the tROI and the skin and subcutaneous tissues without
providing quantified geometrical boundaries of the irreversible/reversible damage. This was due
to limitations on the volume and geometries of tissues examined in the histological analysis, as
H&E staining of the entire large heated volume was not practical. Nonetheless, we believe that
this study provides critical information for those wanting to perform such treatments, and these
results may serve as a basis for further research. Second, we did not explore the full scope of the
six adjustable parameters (acoustic power, HT duration, frequency, HT cell size, target
temperature, and different target threshold temperature) provided by the system, or assess the
effects of different geometrical arrangements of the different MR planes (distances of the nearfield and/or far-field planes from the tROI). Since this study aimed to compare heating effects
caused only by the location of the threshold-plane, all other factors were kept the same.
However, these six parameters could potentially affect the heating performance. For example,
theoretically, for deep HT, the acoustic power might need to be increased to compensate for the
intensity lost due to the increased depth. This adjustment was not considered in this study, as the
aim here was to characterize the temperature distribution and tissue damage with all the
parameters maintained the same, and our previous published work [210] and another study[12]
suggest 100W is a reasonable power level to use in this work. Regarding the selection of target
temperature, in clinical practice, the target temperature might vary when HT is used for different
applications, such as RT, chemotherapy, chemo-RT, or for the delivery of thermo-sensitive
agents. For RT+HT, published target goal temperature included 41.0°C [146], 42.0°C [144],
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42.5°C [147,153], 43.0°C [143,159,228]; for chemotherapy, the objective temperatures included
42.0°C [208,229,230] or the range of 41°C–43°C [20,231]; for chemotherapy + RT + HT, one
study has the target temperature of 42.5°C–43°C (T90) [232]. However, for HT assisted localized
drug delivery, the target temperature could be slightly lower (i.e. higher than 40°C [110,233]),
since the blood flow and oxygenation start to rise at a lower temperature (i.e. 39°C), reach the
maximum and decrease again after the temperature become higher than the thermal threshold of
stasis [163]. Also, the target temperature is related to the composition of the lipid layer
[233,234], with the main purpose of allowing the maximal release of therapeutic agents into the
target area. Investigation of the impact of the parameter space on the performance of the
MRgHIFU system is outside the scope of this study, although an area for future research.

Third, this study only analyzed the effect of large field HT on porcine muscle and other nearby
tissues, and does not provide specific guidance for HT in different tissue types. Different organs
and/or disease types might show different responses. Further investigations are needed to assess
each organ/tissue of interest in a case-by-case basis.

Fourth, we demonstrated a proof-of-concept in changing the shape of the temperature
distribution by manipulating the threshold-plane. To fully understand this strategy and move
toward clinical implementation, additional studies are needed to better characterize the
temperature/dose distribution and optimize the methodology for conforming thermal dose
distributions to desired targets/regions. Some technological limitations of the MRgHIFU system
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also need to be mentioned. The values of the threshold temperature could not be set to be
different in the near-field and the far-field, preventing the ability to use different near- and fieldfar field temperature thresholds to control the thermal dose distributions. Also, the accessible
depth of the MRgHIFU system in HT is 8-cm, limiting the application of MRgHIFU HT in
deeper-seated tumors.

Furthermore, the average temperature map shown in Figure 3.2 B presented some heterogeneity
within the tROI that mimicked the shape of the subcell. This might be due to the feedback-based
temperature control algorithm which only directly heated the tROI by targeting seven subcells
subsequently, while the heating to the space outside the subcells were through heating diffusion.
Therefore, as a result, the subcells within the tROI seem to have a relatively higher average
temperature. However, the result is generally in line with previous work, which spoke for the
satisfactory temperature profile obtained from this work as we benchmarked the temperature
uniformity with previous studies [1,12,210], despite some subtle difference that might be due to
the larger tROI size and/or lower MRI field strength.

Last but not least, this study did not observe any significant correlation (data not shown) between
the existence of the observed contrast-enhanced MRI changes and the thermal damages shown in
the histopathology, Tmax, or any quantified thermal dose. There are several potential reasons for
this. First, the contrast enhanced MR images immediately after the HT session (within 10
minutes) might not be sensitive enough to manifest all the histological changes. Second, the
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collection of the section (in the 2.5×2.0cm tissue cassette) at the heated volume did not cover all
the corresponding heated area, so it is possible that the sectioned tissue did not capture the subvolume changes present in the MR images. Third, the relatively coarsely-sampled pixel size
(2.5mm ×2.5mm ×7mm) or temporal resolution (3.7 s) of the MR thermometry of the system
may impair the ability to correlate the MR thermometry measurement with tissue damage. Future
studies are needed to investigate techniques to correlate thermal damage with contrast enhanced
MRI and/or temperature measurements.

Nonetheless, this study demonstrates that large-volume MRgHIFU-mediated HT may be feasible
for both superficial and deep targets, implying that such devices may be able to treat a broader
range of targets and disease sites. Furthermore, the potential ability to achieve spatial
temperature control by adjusting the position of threshold-plane might provide a new way of
improving the ability to conform the heated volume to the tumor shape and/or modulating the
heating pattern to increase the thermal dose to desired target sub-volumes while
decreasing/avoiding thermal dose to neighboring healthy tissues. This strategy might allow
conforming spatial thermal dose delivery to complement the delivered RT and/or chemotherapy
dose distribution when HT is combined with RT and/or chemotherapy. This work could open
new horizons in the control and precision of HT as an adjuvant therapy to RT and/or
chemotherapy although additional work is needed to actualize/optimize this strategy.
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3.5 Conclusions
MRgHIFU-induced large-volume HT is feasible in both deep (i.e., 6-cm) and superficial (i.e., 2cm) targets with satisfactory temperature characteristics. Target tissue histology showed some
localized tissue damage within the HT volume. No thermal-related skin or subcutaneous tissue
damage was observed, implying a satisfactory safety profile of MRgHIFU HT of the skin tissues.
The results of this study also demonstrated the potential of using feedback control planes to tailor
the spatially delivered thermal dose to clinical targets. This study lays the foundation for the
future development of spatially controlled HT.
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Chapter 4 Targetability of cervical cancer by
magnetic resonance-guided high-intensity
focused ultrasound (MRgHIFU)-mediated
hyperthermia (HT) for patients receiving
radiation therapy
4.1 Introduction
In the last two chapters, we demonstrated that MRgHIFU is able to heat an array of different
geometries of pelvic targets (Ø=18 mm), as well as to achieve a satisfactory temperature
distribution at both deep and superficial targets with the largest usable heating diameter (Ø=58
mm). However, the previous two chapters did not evaluate the targetability of MRgHIFU
induced HT to cancer in the human pelvis (i.e. cervical cancer). In this chapter, we
retrospectively assess the targetability of MRgHIFU induced HT in cervical cancer, the optimal
patients’ position(s) for a higher targetability, and the potential anatomical/demographical factors
that are related to a higher probability of targetability which could be used for patient screening.

Cervical cancer is the fourth most prevalent cancer of women worldwide after breast, lung, and
colorectal cancer [235,236]. Patients with locally advanced cervical cancer (FIGO stage IB2–
IVA [237]) have worse survival and higher rates of recurrence compared to early stage (IA–IB1)
[238]. The 5-year survival is 89.1%, 41.5%, and 22.0% for stages IB1, IIIB and IVA,
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respectively [238]. While the first-line treatment is typically chemotherapy in combination with
RT to the primary cancer and metastatic lymph nodes [239], a study of 238 cervical cancer
patients receiving chemo-RT found that 38% experienced a recurrence within three months, as
detected by positron emission tomography (PET) [240]. Additionally, chemo-RT is associated
with a negative impact on the quality-of-life [241–244]. For example, one clinical study reported
bowel dysfunction (49%), sexual dysfunction (55%), and sense of femininity loss and/or divorce
(42%) in cervical cancer patients (N=98) receiving chemo-RT [244]. Innovative treatment
modalities could potentially improve the response rate, survival, and/or quality-of-life.

The addition of HT to RT of locally advanced cervical cancer substantially improves local
control and overall survival without affecting treatment-related grade 3–4 toxicity, according to a
meta-analysis [176] from the Cochrane Database of six phase III/IV clinical trials [3–9].
MRgHIFU induced HT has been shown to be feasible and safe in living animals [1,12,210] and
is being evaluated in ongoing clinical trials for rectal cancer [158] and pediatric sarcoma [245].
However, the accessibility of targets by MRgHIFU depends on a clear ultrasound beam-path
without bone and/or air-containing structures due to the potential for acoustic mismatches and/or
energy absorption-related heating injury of adjacent normal tissues (at the interfaces of air/bone
and tissue). Therefore, a careful examination of the target anatomy is required to assess the safe
and effective targetability by HT.
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While there have been some limited studies that analyzed the targetability of MRgHIFU-induced
thermal ablation [212,213,246–248] and/or HT [213,249]. None of these studies investigated,
factors that could potentially influence targetability (i.e. demographics, anatomical factors, or
patient setups). In terms of analyzing targetability for thermal ablation, previous studies have
been performed on a number of sites, including pediatric sarcoma [213], osteoid osteoma, bone
metastases [246], recurrent gynecological tumors [247], and abdominal neuroblastoma [248].
The data is even more limited for cervical cancer with only two case reports [250,251] and a
virtual planning study (n=6 in recurrent lesions) [247] demonstrating feasible targeting by
thermal ablation. For HT, targetability has only been assessed in pediatric sarcoma [213] and
osteomyelitis [249] and no analysis of the targetability of MRgHIFU-induced HT in primary
cervical cancer or metastatic lymph node(s) has yet been performed.

Thus, the objectives of this study were to: (1) evaluate the percentage of primary lesions and
metastatic lymph node(s) in late-stage cervical cancer (stage IIIB–IVA) patients that can be
targeted by a MRgHIFU device; (2) assess optimal patient positioning for the highest
targetability rate; and (3) analyze any statistical correlation between the patients’ anatomical
geometries/demographics and targetability. To achieve these aims, we retrospectively reviewed
treatment imaging from stage IIIB-IVA cervical cancer patients receiving RT (external beam
radiation therapy (EBRT) or high dose rate brachytherapy (HDR brachytherapy)) at our
institution over a 9-year period. We determined the targetability of each patient using
commercial MRgHIFU planning software with ultrasound beam-path targeting from both
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anteriorly (patients in prone position) and posteriorly (patients in supine position) at different
angles relative to the transducer. An array of anatomic and demographic parameters for each
patient were tabulated and their association with targetability was evaluated.

4.2 Methods
4.2.1 Ethical approval
The study protocol was approved by the Institutional Review Board at the Washington
University School of Medicine. All patient-identifying information was kept confidential. Patient
anonymity was preserved, and the principles of the Declaration of Helsinki were followed. All
procedures followed the guidelines set forth by the Health Insurance Portability and
Accountability Act Privacy rule.

4.2.2 Patient selection
This study selected patients with a pathological diagnosis of late stage cervical cancer (stage
IIIB–IVA) who received EBRT, HDR brachytherapy, or the combination of these two modalities
at the Siteman Cancer Center at Barnes Jewish Hospital in Saint Louis from January 01, 2010 to
April 1, 2019. From a database of 118 consecutive patients, 39 were excluded due to a lack of
PET-CT images and/or recognizable tumor lesions. The remaining 79 patients were analyzed.
Demographic parameters including patients’ age, weight, height, BMI, tumor stage, and RT
modalities/dosages were recorded.
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4.2.3 Image examination and processing
For each patient, co-registered PET-CT images in the Eclipse treatment planning system (Varian
Medical Systems, Palo Alto, CA) were reviewed. In the FDG-PET images, “metabolic tumor
volumes” from both the primary tumor lesion (MTV) and any metastatic lymph node(s) (MTVLN, if present) were contoured by selecting the regions equal to or greater than a standardized
uptake value (SUV) of 40% of the peak tumor intensity (the standard value for quantifying tumor
volume on PET-CT) [252,253] as shown Figure 4.1 (A, C, E, F). The MTV/MTV-LN represents
the metabolically active tumor region(s), and is an independent prognostic factor for disease-free
survival in cervical cancer patients [254]. They were also used as the target tumor lesions in this
study. All delineated MTVs and MTV-LNs were drawn and approved by experienced radiation
oncologists and utilized for the treatment planning of RT.

On each PET-CT image series, four bony pelvic landmarks were identified and marked: the left
ischial spine (LIS), the right ischial spine (RIS), the pubic symphysis (PS), and the coccyx, as
shown in Figure 4.1 (B, C, D). Next, a number of anatomical measurements were tabulated
(Figure 4.1 (A, C)): the largest dimension of MTV in the head-foot axis (MHF), the largest
dimension of the MTV in the right-left axis (MRL), the largest dimension of MTV in the
anterior-posterior axis (MAP), the anterior (ventral) depth of the MTV (DMA), the posterior
(dorsal) depth of the MTV posteriorly (DMP), the thickness of the anterior subcutaneous fat
layer at the level of the MTV (AF), the thickness of the posterior subcutaneous fat layer at the
level of the MTV (PF), and the distance of the body from the anterior to the posterior skin
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surface (DAP). Other metrics shown in Figure 4.1 (B, D) include: the distance from the MTV to
the coccyx (MC), the distance from the MTV to the pubic symphysis (MPS), the distance from
the left ischial spine to the coccyx (LISC), the distance from the right ischial spine to the coccyx
(RISC), the average of the LISC and RISC (ISCavg), and the distance from the right ischial spine
to the left ischial spine (DIS). For patients having MTV-LN(s), the depth of the MTV-LN (DLN) and its closest distance to bony structure (DB-LN) were evaluated, as shown in Figure 4.1
(E, F).
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Figure 4. 1 The schematic illustration of pelvic bony landmarks on a representative PET-CT
imaging and the anatomical measurements.
Figure caption: (A) Axial view that presents the largest cross-section of MTV, MHF, MRL,
DMA, DMP, AF, PF, and DAP. (B) Axial view that presents RIS, LIS, coccyx, LISC, RISC, and
DIS. (C) Sagittal view that presents the coccyx, PS, MTV, bladder, MC, MPS, and MAP. (D) 3dimensional reconstruction of bony structures of CT images that illustrates the LIS, RIS, coccyx,
PS, DIS, RISC, and LISC. (E) Coronal view demonstrates MTV and MTV-LN. (F) Axial view
illustrates the MTV-LN, D-LN, and DB-LN.
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The distances between specific pelvic landmarks, as well as the distances between the tumor
targets and some of the landmarks were measured. These distances were selected because they
were amenable to measurement by use of CT or MR imaging (and/or palpated intraoperatively)
[255]. Furthermore, they could be potentially useful for predicting targetability, as these
landmarks are relatively adjacent to the MTV and are on a similar scale (cm) with the ultrasound
beam-path.

On the co-registered PET-CT images, the MTV structure was fused into all the CT images so
that the MTV can be visibly recognized on the CT images, as indicated in Figure 4.2 (A, B).
These CT images were then exported as DICOM images and processed using MATLAB
(R2018a, Math Works, Natick, MA, USA) and Python 2 (Anaconda3-2019.10). This procedure
included the anonymization of patient information, modification of the DICOM header to be
compatible with the MRgHIFU treatment planning system, and rotation of the images.
Specifically, CT images were first flipped along the patients’ coronal plane to generate images
with patients in both supine and prone positions. Then, rotations of the CT images along the
patients’ longitudinal axis relative to the transducer were applied in degrees of 0°, ±5°, ±10°,
±15°, ±20°, ±25°, ±30°, ±35°, and ±40°, resulting in image sets representing 34 angles of
rotation.
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Figure 4. 2 Representative image processing.
Figure caption: (A) PET-CT in the axial view with the green contour indicating the location of
MTV. (B) Corresponding axial CT with MTV fused as highly-weighted volume. (C&D) Axial
(C) and sagittal (D) view of targeting posteriorly. The white line indicates the HIFU beam-path
and green cone-shaped area indicates the heating volume; the coccyx highlighted in yellow
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dashed line blocked the HIFU beam-path. (E&F) Axial (E) and sagittal (F) view of targeting
anteriorly. The depth of the MTV represented by the yellow dashed line is longer than 8 cm; the
PS highlighted by the yellow dashed contour blocked the HIFU beam-path. (G&H) Axial (G)
and sagittal (H) views of the CT images rotated clockwise for 30°. The depth of the MTV
represented by the yellow dashed line is less than 8 cm, and the distance between the bone and
HIFU beam-path is longer than 1 cm.

4.2.4 MRgHIFU treatment planning system
Each processed CT image set was then imported into a clinical MRgHIFU software program
(Sonalleve® Treatment Planning System R3.5.955.1215 L2; Profound Medical, Mississauga,
Canada). The Sonalleve® treatment planning program models the approximate geometries of the
HIFU-induced HT beam-path, and the dimensions of heating cross-sectional beam (cell)
diameter based on the vendor’s measurements. Treatment planning utilized HT cells of diameter
18-mm, 32-mm, and 44-mm corresponding to heating volumes of 16.5-ml, 44.1-ml, and 101.1ml, respectively [12]. Different cross-sectional beam diameters were used in this study since the
Sonalleve® is capable of administering HT with all of the above-mentioned cross-sectional
diameters [1,12].

4.2.5 Targetability evaluation
The CT image at each specific angle was evaluated in three dimensions to identify a potential
acoustic beam-path that accommodated the targeting of the MTV and/or MTV-LN(s) by
MRgHIFU-induced HT. HT cells were placed to cover the MTV as much as possible under the
prerequisite that no bony structure was within 1-cm of the range of the acoustic window.
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The MTV was not considered targetable if:

1. The depth of MTV was more than 9 cm from the skin surface. The Sonalleve® software
had a depth limitation of 8 cm for the placement of HT cell on the centermost plane used
for the feedback control, and the effective HT heating zone can extend 1 cm beyond the
target plane [213,256].

2. The HIFU beam-path was blocked by or within 1 cm of any bony structures/calcifications
[31,212,213].

3. The whole MTV was less than 1 cm away from the skin surface. Prohibiting targeting
this shallow would minimize the risk of skin burns. However, if part of the MTV was less
than 1 cm from the skin but other portions of the MTV are more than 1 cm, then this
MTV was considered targetable.

4. When administering HIFU anteriorly, the distance between the lower end of the
MTV/MTV-LN and the bladder was more than 2.39 cm [257]. This was based on
previous reports that the interposed bowel loops could potentially be displaced out of the
acoustic pathway by bladder filling, bowel massage, and/or uterine anteflexion maneuver
[257–263]. 2.39 cm was reported as the median distance that a bladder could distend by
filling per Ju et al [257].
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Duration targeting evaluation, the largest possible cell size was first evaluated. Next, if there was
bone blocking the beam path or any other criteria was violated, we switched to a smaller size. If
the tumor could not be targeted by the smallest 18 mm cell (i.e. comply with any of the
abovementioned untargetable criteria), then those tumors were defined as “untargetable”. All
assessments were performed in this way. Treatment plans were examined in three dimensions to
assess if any of the above rules were violated. The MTV/MTV-LN was considered targetable if
at least one HT cell could be placed to cover the MTV/MTV-LN without violating any one of the
criteria above. Of note, for anterior targeting, the existence of intestine, bowel, or rectum within
the beam-path was regarded as potentially targetable, since in clinical practice with MRgHIFU
treatments, there are several potential ways to displace the interposing bowel loops out of the
ultrasound beam-path, including: (1) sequential bladder filling, rectal filling, and bladder
emptying (referred as bladder-rectum-bladder bowel manipulation technique) [258,259,261,264];
(2) Trendelenburg position with bowel massage [258]; (3) use of a convex gel pad
[261,265,266]; and (4) manual uterine manipulation, i.e. repositioning of the uterus into
anteflexion by bladder filling, rectal filling and/or use of a vaginal speculum [258]. For posterior
targeting, similarly, a safe ultrasound beam-path could potentially be constructed by the use of a
rectal balloon filled with degassed ultrasound gel, as done in a clinical study for rectal cancer
patients treated with MRgHIFU-induced HT [1]. Based on the criteria stated above, for each CT
image set at a specific rotated angle, cervical cancer targets were categorized into 2 types:
potential targetable or non-targetable. Due to the potential need for intervention in almost all
cases, we did not include a class of “unconditionally targetable”.
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4.2.6 Statistical analysis
The statistical correlation between the demographic and/or anatomical factors (height, weight,
BMI, MTV, MHF, MAP, MRL, DMA, DMP, MC, MPS, AF, PF, DAP, RISC, LISC, ISCavg, and
DIS) and targetability were evaluated. Additionally, the correlations between the usable crosssectional beam diameter and all other parameters (including the above-mentioned anatomical
measurements and rotated angle) were also analyzed using a logistic regression model.

Mean and standard deviation (SD) of covariates such as height, weight, BMI, MTV, MHF, MAP,
MRL, DMA, DMP, MC, MPS, AF, PF, DAP, RISC, LISC, ISCavg, and DIS were calculated. The
Mann-Whitney U test was then applied to compare between the targetable patients and nontargetable patients. The significance level was chosen at 0.05. Additionally, nonlinear additive
transformation and restricted cubic splines were applied to impute the missing BMI values in the
dataset due to non-reported height values of ten patients [267].

Variable selection was conducted by parametric additive models that were determined by how
well each variable could be predicted from the remaining variables. Variables were dropped in a
stepwise fashion, removing the most predictable variable at each step. The remaining variables
were used to predict. We selected our objective covariates by setting R2 equal to or lower than
0.3 beforehand. Next, logit regression was applied to check the significance between each
selected covariate and anterior/posterior targetability. The odds ratio (OR), and the
corresponding 99%, 95%, and 90% confidence interval (CI) of each variable for the
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anterior/posterior targetability were provided. Finally, the mixed effect model was used to check
the correlation between the useable cross-sectional beam diameter and the aforementioned
parameters and targeting angles.

4.3 Results
4.3.1 Patient Demographics and lesion characteristics
Table 4.1 shows the patients’ demographics. Sixty-four out of seventy-nine patients received a
combination of EBRT and HDR; 13 patients received EBRT alone; and 2 patients received HDR
alone. The total dose of HDR ranged from 4.5 Gy–43.8 Gy in 1–8 fractions; and the total dose of
EBRT ranged from 19.8 Gy–70.2 Gy in 10–39 fractions. Except for a lack of ten patients’ height
information, all other information was retrieved from all 79 patients. 83% of cases were on stage
IIIB and 17% of cases were on stage IVA. The lesion characteristics of the anatomical
measurements in all patients were also presented in Supplementary Table 4.2.

Table 4. 1 Patient demographics.
Mean ± SD

Median (range)

Age (years)

59.96±14.67

53 (26–89)

Height (inch)

63.78±2.72

63 (59 –72)

Weight (lbs.)

166.70±54.44

149.50 (81.10–293.20)

Body mass index

28.25±8.68

26.53 (14.79–54.49)

Cervical cancer stage

IIIB (66) and IVA (13)
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Table 4. 2 Characteristics of cervical cancer lesions in all patients.
Mean ± SD

Median (Minimum – Maximum)

MTV (mm3)

83.2±95.7

50.3 (7.3 – 577.2)

MHF

54.8±21.2

52.9 (19.1–125.6)

MAP

53.1±22.1

48.8 (16.2–133.2)

MRL

48.8±18.6

45.0 (17.6–108.1)

DMA

93.5±27.8

89.6 (38.9 – 178.0)

DMP

68.0±19.7

68.9 (29.6 – 117.6)

MPS

35.6±14.5

34.9 (3.4 – 69.8)

MC

40.0±16.6

36.9 (8.6 – 114.4)

AF

33.8±16.5

33.0 (7.2 – 83.8)

PF

29.4±14.5

27.3 (5.7 – 85.4)

DAP

220.7±38.4

211.0 (160.2 – 319.7)

RISC

58.4±5.6

58.3 (45.9 – 74.1)

LISC

58.0±6.5

58.0 (43.5 – 78.3)

ISCavg

58.2±5.6

58.0 (44.7 – 72.5)

DIS

108.1±14.8

106.5 (89.9 – 217.2)

Caption: Statistical metrics are reported in millimeters (mm) unless otherwise noted.
Abbreviations: Metabolic tumor volume (MTV). The largest dimension of MTV in the head-foot
axis (MHF). The largest dimension of MTV in the anterior-posterior axis (MAP). The largest
dimension of the MTV in the right-left axis (MRL). Depth of the MTV anteriorly (DMA). Depth
of the MTV posteriorly (DMP). Distance from the lesion to the pubic symphysis (MPS).
Distance from the MTV to the coccyx (MC). Thickness of the anterior subcutaneous fat layer at
the level of the lesion (AF). Thickness of the posterior subcutaneous fat layer at the level of the
lesion (PF). Distance of the body from the anterior to the posterior skin surface (DAP). Distance
from the right ischial spine to the coccyx (RISC). Distance from the left ischial spine to the
coccyx (LISC). Average of RISC and LISC (ISCavg). Distance from the right ischial spine to the
left ischial spine (DIS). (See Figure 4.1 for metrics definitions)

4.3.2 Targetability at different angles
Of the seventy-nine patients, fifty-seven (72.15%) were targetable from at least one angle.
Among them, thirty-nine (49.37%) were targetable posteriorly and thirty-one (39.24%) were
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targetable anteriorly. Figure 4.2 presents a representative CT image, which is not targetable with
0° rotation both posteriorly (Figure 4.2 C, D) and anteriorly (Figure 4.2 E, F), but targetable
posteriorly with a clockwise rotation of 30° (Figure 4.2 G, H). After evaluation of 34 different
angles of each patient, the targetability of patients rotated from 0-40° along the longitudinal axis
in prone (targeting from anterior, Figure 4.3 A) and supine (targeting from posterior, Figure 4.3
B) orientations was calculated. Due to the reasonable symmetry of the pelvic girdle anatomy, we
averaged the number of targetable patients by clockwise- and counterclockwise- rotations, as
shown in Figure 4.3(C). In the prone position, 0° rotation resulted in the maximum number of
targetable patients, while in the anterior position, rotations of 25° and 30° resulted in the
maximum number of targetable patients.
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Figure 4. 3 Targetability analysis in different HIFU angles.
Figure caption: (A, B) Targetability of patients in different angles (rotated from 0° to 40° in both
clockwise and counterclockwise directions) in both prone position (targeting from anterior, A)
and supine position (targeting from posterior, B). (C) The average number of targetable MTV at
each clockwise and counterclockwise rotated angle.
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Of the 53 patients with at least one MTV-LN, 18 patients (33.96%) had targetable MTV-LN(s).
Thirty four patients presented MTV-LN(s) only within the pelvic region; 9 patients presented
MTV-LN(s) only in adjacent to the lumbar vertebrae; and 10 patients had MTV-LN(s) that were
located both in pelvic region and close to lumbar vertebrae region. No MTV-LN adjacent to
lumbar vertebrae region were targetable. All 18 cases with targetable MTV-LN(s) were located
within the pelvic regions. The D-LN of the targetable (65.4±31.7mm) and non-targetable patients
(95.6±28.7mm) were significantly different (p<0.05). The BD-LN of the targetable (6.7±7.6
mm) and non-targetable patients (9.7±6.9mm) were not significantly different (p=0.96).

4.3.3 Logit correlations of the anatomical measurements and targetability
Table 4.3 presents the comparisons of the parameters (height, weight, BMI, MTV, MHF, MAP,
MRL, DMA, DMP, MC, MPS, AF, PF, DAP, RISC, LISC, ISCavg, and DIS) between the
targetable patients and non-targetable patients. For anterior targeting, there was a significant
difference (p<0.05) in weight, BMI, MTV, DMA, AF, and DAP between the targetable and nontargetable patients. For posterior targeting, there was a significant difference (p<0.05) in height,
weight, BMI, DMP, MC, AF, PF, DAP, LISC, and ISCavg between the targetable and nontargetable patients.
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Table 4. 3 Characteristics of cervical cancer lesions in all patients.
Anterior

Targetable

Non-

Posterior

Test Statistic

Targetable

targetable

Non-

Test Statistic

targetable

BMI

25.6±6.2

30.6±9.8

p=0.029

24.5±6.7

31.9±8.9

p<0.001

Height (inch)

64.0±2.5

63.6±2.6

p=0.451

63.2±2.4

64.40±2.9

p=0.035

Weight (lbs.)

150.0±41.6

177.5±59.2

p=0.046

145.8±47.0

187.1±53.9

p<0.001

MTV

102.6±97.4

70.7±93.4

p=0.020

91.2±103.2

75.4±88.3

p=0.335

MHF

57.7±20.8

53.0±21.5

p=0.376

56.5±20.0

53.2±22.4

p=0.355

MAP

56.4±19.4

50.9±23.6

p=0.111

55.1±26.1

51.1±17.4

p=0.981

MRL

52.0±18.4

46.8±18.7

p=0.208

52.0±19.7

45.8±17.2

p=0.151

DMA

76.7±20.8

104.2±26.3

p<0.001

89.2±19.8

97.6±33.3

p=0.264

DMP

65.9±18.5

70.1±21.1

p=0.470

53.5±12.1

83.0±14.9

p<0.001

MPS

36.4±15.2

34.4±14.6

p=0.464

38.3±13.3

32.2±15.7

p=0.083

MC

40.6±16.8

40.0±16.6

p=0.988

31.9±12.1

48.4±16.5

p<0.001

AF

27.0±11.4

38.6±17.9

p=0.001

29.4±13.5

38.57±18.20

p=0.032

PF

26.6±11.0

31.3±16.1

p=0.265

24.8±11.8

34.02±15.44

p=0.008

DAP

207.4±26.2

230.0±42.5

p=0.023

203.9±30.6

237.9±38.1

p=0.001

RISC

57.8±5.3

58.7±5.9

p=0.842

59.2±6.1

57.6±5.1

p=0.299

LISC

57.6±6.2

58.3±6.8

p=0.964

60.2±5.8

55.9±6.6

p=0.003

ISCavg

57.7±5.2

58.5±5.8

p=0.807

59.7±5.5

56.8±5.3

p=0.017

DIS

109±21.4

106.9±8.1

p=0.662

108.5±7.5

107.4±19.4

p=0.056

Notes: Statistical metrics are reported in the unit of millimeter (mm). Abbreviations: Metabolic
tumor volume (MTV). Depth of the MTV anteriorly (DMA). Depth of the MTV posteriorly
(DMP). Distance from the MTV to the coccyx (MC). Distance from the lesion to the pubic
symphysis (MPS). Thickness of the anterior subcutaneous fat layer at the level of the lesion
(AF). Thickness of the posterior subcutaneous fat layer at the level of the lesion (PF). Distance of
the body from the anterior to the posterior skin surface (DAP). Distance from the left ischial
spine to the coccyx (LISC). Distance from the left ischial spine to the coccyx (LISC). Distance
from the left ischial spine to the coccyx (LISC). Distance from the left ischial spine to the coccyx
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(ISCavg). Distance from the right ischial spine to the left ischial spine (DIS). A statistically
significant difference was presented as the bold character.
Table 4.4, Figure 4.4, and Figure 4.5 show the statistical correlations between the anatomical
measurements and targetability. Figure 4.4 depicts the OR with 90%, 95%, and 99% CI of each
variable. As showing in Table 4.4 and Figure 4.5, for targeting anteriorly, the DMA was
significantly correlated with the anterior targetability (χ2=14.3, p<0.001, OR =1.064 with 95% CI
(1.034, 1.103)). This represents that the odds of anterior targetability significantly increased
when the DMA decreased. Neither MPS (χ2=3.1, p=0.080) nor MHF (χ2=1.2, p=0.278) were
significantly correlated with the anterior targetability. For posterior targetability, MC had a
significant correlation with the posterior targetability (χ2=12.7, p<0.001, OR=1.101 with 95% CI
(1.049, 1.167)). This represents the odds of posterior targetability decreased when MC increases.
The posterior targetability was not significantly correlated with PF (χ2=1.4, p=0.232), DIS (χ2=0,
p=0.973), or MHF (χ2=0.1, p=0.738).
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Table 4. 4 Correlation between anatomical landmarks/demographic informatin on and the
targetability/usable cross-sectional beam diameter.

anterior targetability

posterior targetability

anterior usable crosssectional beam
diameter

posterior usable
cross-sectional beam
diameter

DMA
MPS
MHF
MC
PF
DIS
MHF
Angle
MPS
DMA
MHF
Angle
Weight
MC
MRL

Odds ratio [95% CI]

P-value

1.064 [1.034–1.103]
0.962 [0.920–1.003]
1.005 [0.978–1.033]
1.101 [1.049–1.167]
1.027 [0.986–1.078]
1.001 [0.963–1.038]
1.005 [0.978–1.033]
0.856 [0.835–0.878]
0.947 [0.862–1.039]
0.901 [0.846–0.959]
1.046 [0.969–1.129]
1.004 [0.997–1.012]
0.997 [0.990–1.004]
0.968 [0.942–0.996]
1.028 [1.011–1.044]

<0.001
0.080
0.277
<0.001
0.232
0.973
0.738
<0.001
0.248
0.001
0.247
0.264
0.355
0.026
<0.001
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Figure 4. 4 (A). The odds ratio (OR) and different confidential intervals (CIs) of the depth of the
metabolic tumor volume anteriorly (DMA), distance from the lesion to the pubic symphysis
(MPS), and the largest dimension of MTV in the head-foot axis (MHF) for the anterior
targetability. (B). The OR and different CIs of the distance from the MTV to the coccyx (MC),
the thickness of the posterior subcutaneous fat layer at the level of the MTV (PF), the distance
from the right ischial spine to the left ischial spine (DIS) for the posterior targetability, and the
MHF.
Figure caption: The red, blue, and green color represent the 99% CI, 95% CI and 90% CI,
respectively. The triangles indicate the overall OR of the corresponding covariate. The names of
the geometrical measurement with the 3rd quantile (75% percentile) and the 1st quantile (25%
percentile) are presented on the left side.
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Figure 4. 5 (A). The odds ratio (OR) of the distance from the metabolic tumor volumes (MTV) to
the pubic symphysis (MPS), the largest dimension of MTV in the head-foot axis (MHF), and the
anterior (ventral) depth of the MTV (DMA) for the anterior targetability, respectively. (B). The
OR of the distance from the right ischial spine to the left ischial spine (DIS), the distance from
the MTV to the coccyx (MC), MHF, and the thickness of the posterior subcutaneous fat layer at
the level of the MTV (PF) for posterior targetability, respectively.
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4.3.4 Logit correlations between the anatomical measurements and targeting
cross-section diameter
Table 4.4 and Figure 4.6 present the statistical correlations between the
anatomic/demographic/angle information and useable cross-sectional beam diameters. For
anterior targetability, angle (p<0.001, OR= 0.856 with 95% CI (0.835–0.878)) and DMA
(p=0.001, OR= 0.901 with 95% CI (0.846–0.959)) were significantly correlated with the anterior
usable cross-section beam diameter. Neither MHF (p=0.247, OR=1.046 with 95% CI (0.969–
1.129)) nor MPS (p=0.248, OR= 0.947 with 95% CI (0.862–1.039)) were significantly correlated
with the anterior targetability. These results illustrate that when increasing the targeting angle by
5°, the odds of being able to use a greater size of the cross-sectional beam diameter decreased by
0.856 times compared to the odds of using a smaller targeting diameter. When the DMA
increased by 1 mm, the odds of using a larger cross-sectional beam diameter decreased by 0.901
times compared to the odds of using a smaller targeting diameter.
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Figure 4. 6 (A). The odds ratio (OR) of the anterior (ventral) depth of the MTV (DMA), the
distance from the MTV to the pubic symphysis (MPS), the largest dimension of MTV in the
head-foot axis (MHF), and angle for the anterior useable cross-sectional beam diameters. (B).
The OR of weight, the distance from the MTV to the coccyx (MC), the largest dimension of the
MTV in the right-left axis (MRL), and angle for the posterior useable cross-sectional beam
diameters.
Figure caption: Asterisks indicate the statistical significance. (*p<0.05; **p<0.01; ***p<0.001)
For the posterior targetability, the MRL (p<0.001, OR=1.028 with 95% CI (1.011–1.044)) and
MC (p=0.026, OR=0.968 with 95% CI (0.942–0.996)) were significantly correlated with the
usable cross-sectional beam diameter, while neither the rotated angle (p=0.264, OR=1.004 with
95% CI (0.997–1.012)) nor weight (p=0.355, OR=0.997 with 95% CI (0.990–1.004)) were
significantly correlated with the posterior useable cross-sectional beam diameter. The results
indicated that for posterior targeting, when the MRL increased by 1 mm, the odds of being able
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to use a larger beam diameter increased by 1.028 times compared to the odds of using a smaller
targeting diameter; when increasing the MC by 1 mm, the odds of using a larger targeting
diameter decreased by 0.968 times compared to the odds of using a smaller beam cross-sectional
diameter.

4.4 Discussions
For the cases analyzed in this study, over 70% of the cervical cancer patients (stage IIIB–IVA)
had a potentially targetable primary lesion by MRgHIFU-induced HT from at least one angle
with no or minimal intervention. These results support proceeding into clinical trials to further
evaluate the efficacy of MRgHIFU HT in the treatment of late-stage cervical cancer patients. No
rotation (in the prone orientation) or a rotation of 25°–30° (in the supine orientation) had the
highest anterior or posterior targetability rate, respectively. Additionally, the anterior
targetability was statistically correlated with the DMA. The posterior targetability was
statistically correlated with the MC. In an anterior setup, the usable beam cross-sectional
diameter was statistically correlated with the rotated angle and DMA. In the posterior setup, the
usable cross-sectional beam diameter was statistically correlated with the MC and the MRL. This
analysis provides potential guidance for optimal patient setup and treatment workflow, as well as
metrics which could be useful for screening patients from pre-treatment images.

Our study provides a method for virtual treatment planning utilizing the pre-existing PET-CT
images in the place of standard MRI for MRgHIFU-induced HT in the evaluation of both
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primary cervical cancer lesions and metastatic lymph nodes. By reviewing the diagnostic/pretreatment images, this strategy potentially spares patients from additional imaging or
administration of sedative drugs or contrast agents. In this way, we created a potentially useful
workflow for determining an optimal treatment setup that could facilitate the evaluation of the
targetability of the MRgHIFU HT in late-stage cervical cancer patients. Additionally, we
analyzed the potential correlation between anatomical landmarks of the pelvic girdle and the
targetability, so that some simple measurements might provide useful information to clinicians
when screening candidates of MRgHIFU HT or gauging the targetability. Although the approach
and the predictability of selected anatomical measurements still need to be tested on a treated
patient population, the accurate delineation of the target lesion (MTV) by PET and the stark
contrast of bony structures in CT facilitate the recognition of any obstructive bony structures
within ultrasound beam-path.

Overall, our study showed that 72.15% of the patients had targetable primary pelvic lesions,
higher than reported in a previous study by Giles et al. [247] that evaluated recurrent
gynecological tumors and reported that 55% of patients were targetable by MRgHIFU thermal
ablation when bladder and/or rectum filling were assumed. Several factors might be related to
this variation. First, the treatment objective of Giles et al. [247] was ablation. Usable beam sizes
were different with the Sonalleve® system providing 4-mm, 8-mm, 12-mm, or 16-mm as the
axial diameters for the ablation therapy and 18-mm, 32-mm, 44-mm, or 58-mm the selectable
diameters for HT. The HIFU beam-path requirements (i.e. useable cross-sectional beam
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diameter, angle) also differed between the thermal ablation and HT studies. Furthermore, the
allowed set-up position(s) in the previous study were more limited than this one. Specifically,
Giles et al. only analyzed one treatment position per patient by minimizing the distance between
the target lesion and the transducer. In contrast, our study systematically evaluated the
targetability at 34 different angles, which subsequently increased the probability of obtaining a
targetable cell. The previous study also covered all recurrent gynecological tumors while our
study only focused on late-stage cervical cancer. Finally, the previous prospective study recruited
a smaller cohort than this study which might have introduced a higher degree of sample bias.

Another study by J Shim et al. [213] addressed virtual treatment planning of MRgHIFU thermal
ablation in pediatric tumors including a sub-cohort of pelvic tumors. The targetability of the
pelvis tumor was 95% (N=28, primary sarcoma) [213]. The difference between J Shim et al. and
our study could be the intrinsic difference in anatomical locations or sizes between sarcoma
(surrounding the bone) and cervical cancer (within the pelvic girdle) as well as differences in the
treatment regimen (HIFU thermal ablation vs. HT) as discussed above. Additionally, J Shim et
al. only evaluated two orthogonal (two-dimensional) images for assessing the ultrasound beampath compared to our three-dimensional evaluation.

Our results also demonstrated that a rotation of 0°–5°and 25°–30° had the highest anterior and
posterior targetability rate, respectively. These results imply that when targeting from the
anterior direction, the optimal prone position might be lying flat. In contrast, when targeting
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posteriorly, a slight decubitus rotation was needed to optimize the accommodation of an acoustic
beam-path without blockage, and to provide a good coupling of the patients’ skin surface with
the transducer. Both setups are potentially feasible to implement in the clinic.

In addition, this study further evaluated possible relationships between anatomical structures and
targetability by statistical comparison. Two different statistical analyses were performed. The
Mann-Whitney U test evaluated statistical differences between targetable vs. non-targetable
cohorts. This analysis revealed statistically significant differences in the weight, BMI, MTV,
DMA, AF, and DAP between targetable and non-targetable patients when focusing on the
anterior targetability (Table 4.3). Most anteriorly targetable patients either had a relatively
smaller body mass/dimension and/or a larger MTV. For posterior targetability, the height,
weight, BMI, DMP, MC, AF, PF, DAP, LISC, and ISCavg all showed statistically significant
differences between targetable and non-targetable patients. We could explain these differences in
two ways. Similar to the anterior targetability, a lower weight, height, BMI, DMP, AF, and PF
might reflect the ability of the ultrasound beam-path to reach the MTV target. Furthermore, a
shorter MC and/or a larger LISC/ISCavg implied a larger acoustic window between the bony
structures, thus allowing greater treatment access to the target.

As opposed to the Mann-Whitney U test, the logit regression model illustrated a statistical
correlation for assessing the predictability of targetability/utilizable cross-sectional diameter by
anatomical measurement/demographic information. A larger DMA or MC was statistically
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correlated with lower odds of targetability from an anterior or posterior orientation, respectively.
A smaller rotated angle or a shorter DMA was statistically correlated with a larger usable crosssectional beam diameter. A shorter MC or a larger MRL were statistically correlated with a
larger usable cross-sectional beam diameter. The results were as expected, since a larger MRL
implies an increased dimension of the MTV in the coronal axis, which in turn, allows for a larger
useable cross-sectional beam diameter. Similarly, a shorter DMA, smaller rotated angle, and/or
shorter MC all potentially shorten the relative distance from the transducer to the MTV, thus
allowing a larger usable beam diameter. These results illustrate a consistent statistical correlation
between geometrical measurements and targetability, thus implying that a careful evaluation of
the bony anatomy relative to the primary tumor could potentially provide useful information to
clinicians when determining targetability by MRgHIFU-mediated HT.

This study also demonstrated that in patients with MTV-LNs, 33.6% were targetable by
MRgHIFU-induced HT, lower than the primary MTV. Possible reasons might include that the
MTV-LN were more likely to be located adjacent to the lumbar vertebra (N=19) or the pelvic
girdle (N=44), for which an adequate acoustic pathway was difficult to define. Bing et al. [246]
analyzed the targetability of metastases lesions located in proximity to the vertebra [246], and
included additional interventions (articular hydro-dissection, bone-consolidation) that we did not
consider. Such interventions could potentially increase the targetability of the MTV-LNs located
adjacent to the lumbar vertebra. We did not include assessment of patient rotation in the
targetability of the MTV-LNs because 35.84% of the MTV-LNs were located close to the lumbar
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vertebrae, thus no amount of rotation could enhance the targetability. Furthermore, a smaller
sample size (53 patients) and location variability of MTV-LNs decreased the applicability of the
logit regression model, so we did assess the logit correlation between the targetability of the
lymph nodes and the geometrical measurements. Furthermore, due to the extended duration
required for HT, it might be infeasible and inefficient to perform HT on all MTV-LNs with the
current system. With that said, as the 10-year overall survival rate for locally advanced cervical
cancer patients receiving chemo-RT with LN size < 10 mm and ≥ 10mm was 89.2% and 64.1%
(p<0.05), respectively [268], applying HT to the primary lesion and lymph nodes ≥10 mm could
potentially reduce the tumor burden and have clinical benefit.

Our study has several limitations. First, the analyzed cohort was limited to late-stage cervical
cancer patients receiving RT at a single treatment center, so this might limit the generalizability
of our results and applicability to the greater cervical cancer patient population at different stages
and/or other institutions. However, this study was reasonably representative of a specific patient
population (stage IIIB to IVA) that could benefit from additional treatment options, in contrast to
early stage cervical cancer patients, who have a relatively satisfactory prognosis after surgery
and/or RT [269,270]. Second, our analysis did not calculate the targetable volumes of each tumor
but only calculated the percentage of the targetable patients by the treatment planning system.
While calculating the targetable volume might be useful, the heating distributions of HT can
differ in various scenarios. For example, neighboring structures, physiological motion, and the
utilized interventions might all exert different effects on the heating dimensions in practice.
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Hence the achievable heating volume needs to be assessed on a case-by-case basis. Other
advanced possible interventions, such as respiratory/cardiovascular motion compensation,
adjunctive hydro-carbo-dissection, or consolidation, etc., were also not considered. This was due
to the fact that previous studies had shown that MRgHIFU induced HT could be performed in the
pelvic region without the above mentioned interventions in porcine models [1,210] and human
patients [158]. MRgHIFU HT with minimal intervention was preferable as it limits the patients’
risk and potentially increases patient comfort, which might lead to higher compliance.

Furthermore, we analyzed the targetability under the assumption that heating part of the tumor
might have therapeutic benefits for the tumor response, so we did not intend to cover the whole
tumor volume in one HT session. This method was selected for several reasons. In a previous
clinical trial [271], when heating tumors, HT was only directed to the most bulky area. This
targeting strategy (aiming to heat only part of the tumor in one HT session) is also adopted in an
ongoing clinical trial using MRgHIFU induced HT for rectal cancer therapy [158]. Furthermore,
the irregular shape (different from the cone shape of the heating volume of the heated cell of
Sonalleve®), depth of the lesion, and pelvic bone all make it challenging to cover the whole
tumor without heating the surrounding normal tissues in one session. It is also well-established in
pre-clinical studies that ultrasound induced HT is able to activate the immune system by
accelerating antigens presentation and releasing of anti-tumor cytokines [227]. Finally, in our
planned subsequent phase I clinical study, we intend to cover the target lesions in separate HT
sessions and treat different areas throughout the patients’ course of treatment. Therefore, we
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choose to only heat a portion of the tumor as a constant criteria in this study. Nevertheless,
further studies should be performed to evaluate the percentage of the heatable tumor volume
and/or the impact of partial target therapy.

Another issue is that, as ultrasound waves cannot penetrate air, acoustic mismatches near the
interfaces between air (or air containing structures) and tissue can cause unwanted heating of
sensitive tissue layers [1,266]. As this can result in undesired burning of the surrounding normal
tissue, potentially air-containing bowel loops cannot be present within the acoustic beampath and
have to be displaced out of ultrasound pathway [258–260]. However, we assumed that patients
with digestive tracts present in the acoustic pathway were targetable after bowel manipulation
[258–261,264]. This assumption was based on previous studies which have proposed and used
an array of bowel manipulation techniques that could displace the bowel loops out of the way of
the ultrasound beampath and increase patients’ eligibility rates from 66.7% – 82% to 89.3% –
100% [258,259]. While it is still possible that a small portion of patients might have bowels that
could not be displaced out of the beam path by any manipulation technique, we believe our
analysis represents the majority of the patient population. With that said, the feasibility and
effectiveness of these relatively newly-emerged bowel manipulation techniques requires further
validation and optimization, which are out of the scope of this study.

Furthermore, in this study, we also did not evaluate any practical method of applying RT and HT
simultaneously, but only discussed the targetability of MRgHIFU induced HT. In past clinical
133

studies utilizing HT, pre-RT [140,142,143,153,154,228], simultaneous [141,146–152], and postRT [13,119,121,143–145,154,155] HT have all been applied and radiosensitization effects have
been demonstrated in all of these sequences. Thus, HT is not required to be applied with RT
simultaneously to exert radiosensitization, as long as the time interval between RT and HT is
relatively short (<4 hours). The time of the transmission from one area to another area could
depend on a number of factors. Moving from one site to another depends on the time needed to
adjust the patients’ position with satisfactory compliance and comfort, as well as the time the
operators need to find an accessible ultrasound pathway to the tumor. This includes performing a
coupling using gel pads, acquiring the planning MR images, and making positional
adjustments/manipulations based on any structures in the ultrasound beampath). For multiple HT
sessions in the same patient, different sessions could be performed on different days throughout
the treatment course [146]. It should also be noted that to apply RT+HT simultaneously, an MRguided RT capable treatment unit would need to be merged with MRgHIFU induced HT devices.
Currently, no such device exists on the market, and, although we believe this hardware
combination deserves further study (i.e. design of the equipment room, building materials, etc.),
this is out of the scope of the current chapter.

Another issue is the posterior potion of the pelvic cavity is rich in nerve bundles, so targeting
from the posterior direction requires extra caution (good coupling, careful examination of
acoustic pathway). Otherwise, nerve injury is possible, especially when ablative temperatures
(~80°C) are required for protein denaturation. Despite this, we expect that MRgHIFU induced
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HT can feasibly be performed in late stage cervical cancer for a number of reasons. First, we
utilized a relatively mild temperature (40°C – 45°C), a continuous ultrasound wave, and passive
cavitation monitoring in the transducer that disables sonication when detecting cavitation above a
threshold, all of which create multiple overlapping layers of protection to decrease the
probability of accidental burning injuries/mechanical damage. Another reason is we intend to
treat patients consciously in line with other clinical trials [158,265,266]. Patient alertness
decreases the likelihood of nerve burning injury since the sonication power can be immediately
cut off if they feel any uncomfortable sensation via a patient held trigger which immediately
stops the sonication. Additionally, the relative safety of heating patients posteriorly has been
evaluated by a group of researchers who have adopted this position and noted its feasibility in the
treatment of recurrent rectal cancer patients without reporting severe nerve complications
[1,2,158]. Furthermore, in our previous study, 30-min HT was also performed to porcine pelvic
muscles [210] in an orientation reflective of a human patient prone position without showing any
burning injury to the surrounding tissue or nerve injury. These results thus imply the feasibility
and safety of targeting in the supine position (posteriorly) in clinical practice. Finally, we did not
take into account the possible tumor volume shrinkage during/after RT, but only evaluated the
targetability based on the pre-treatment/diagnostic PET-CT images. Future work is required to
assess the targetability during the course of RT due to potential tumor regression/shrinkage.

Despite these limitations, the results of this study provide important evidence that most late-stage
cervical cancer primaries are targetable by MRgHIFU HT which supports the progression into a
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clinical trial. We have evaluated the feasibility and safety of applying MRgHIFU induced HT for
a variety of clinically-mimicking pelvic geometries in a porcine model [210], and also
characterized the heating volume of the MRgHIFU-induced HT [272]. Furthermore, the
feasibility of using MRgHIFU for treating rectal cancer patients was also evaluated by Chu et al.
[158]. Based on these results [158,210], it is our intention to perform a subsequent phase I
clinical trial for safety evaluation, applying HT for 30 min – 60 min in locally advanced cervical
cancer patients who are also receiving RT. Targeting the metastatic lymph nodes by MRgHIFUinduced HT might require further evaluation or a different approach. Our results also provide
clinical guidance for potentially optimal patient setup and alignment for the MRgHIFU HT. The
results also suggest that simple measurements from the patients’ images/demographics might be
useful as a screening tool to assess patients’ targetability by MRgHIFU HT. Overall, the results
of this study promote the use of MRgHIFU to treat late-stage cervical cancer.

4.5 Conclusions
Most late-stage cervical cancer was targetable by MRgHIFU-induced HT in at least one
orientation/angle assuming minimal intervention. No rotation had the highest chance of anterior
targetability, while a rotation of 25°–30° had the highest chance of posterior targetability. Patient
characteristics and anatomical geometric factors could be used to predict the anterior or posterior
targetability and the targeting cross-sectional diameter. The results of this study support
proceeding into human clinical trials to further evaluate the efficacy of MRgHIFU HT in the
treatment of late-stage cervical cancer patients.
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Chapter 5 Future research directions of
MRgHIFU induced HT
5.1 introduction
Our results in chapter 2 and chapter 3 demonstrated that MRgHIFU could feasibly deliver HT to
(1) a variety of pelvic target geometries with an 18-mm cell (chapter 2) and (2) the hind leg
muscle with a 58-mm cell in vivo in a porcine model (chapter 3) with satisfactory temperature
profile. We have also demonstrated that fifty-seven out of seventy-nine patients with late-stage
cancer primaries from our single clinic center were potentially targetable by MRgHIFU induced
HT with no or minimal intervention, based on pre-treatment PET-CT images. To broaden the
application of MRgHIFU induced HT in clinic, we would need further research to develop and
validate the feasibility, reliability, and safety of this method. In this chapter, we will discuss
future research directions regarding MRgHIFU induced HT in both pre-clinical and clinical
aspects.

5.2 Future pre-clinical research
5.2.1 Feasibility and safety of the MRgHIFU HT
In chapter 2, we have demonstrated that MRgHIFU is able to deliver HT to a variety of pelvic
target geometries in vivo in a porcine model with satisfactory temperature characterization. For
each target geometry, the analyzed temperature profile, including accuracy, precision,
uniformity, and temporal variation, matched with previously published results [1,12] and clinical
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guideline [94]. Built on this work, a number of experiments could be conducted to broaden and
optimize the clinical application of MRgHIFU HT.
First, as clinical evidence suggests that the addition of HT to RT could increase the survival rate
for patients with cancer located in the genitalia [147–151], this methodology developed in our
study could also be used for MRgHIFU induced HT in a broader array of pelvic
organs/geometries. For example, prostate, scrotum, penis (male), ovary, or vulva (female) could
be the target. Specifically, we could use similar parameters as described in chapter 2, but perform
studies with older/larger pigs (compared to the current study) with targets that would
accommodate larger than 18-mm tROIs. In addition, for successful HT implementation, animals
may need to be set in different positions in order to increase the accessibility of target organs to
the transducer. As we discussed in chapter 1, there are other sites (apart from pelvis) for which
HT might be beneficial, including head and neck, central nervous system, breast, chest wall,
skin, etc. For the application of HT in these locations, the methodology developed in this study
could be further evaluated and broadened.
Second, in this study, we did not consider utilizing any additional techniques to address
physiological motion, such as respiration, peristalsis, and bladder filling, among others. It has
been reported that the amplitude of the organ movement during respiration could be up to 2 cm
[273–276]. In previous studies, several methods have been used to control the respiratory motion
during HIFU ablation, including breath holding (use ventilator-controlled breath-holds for
anesthetized patients) [277,278], MR-based motion tracking (steering the ultrasound beam
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during uninterrupted breathing while tracking the organs motion) [279–281], ultrasound based
motion tracking (mainly for ultrasound guided ultrasound therapy system, using ultrasound
techniques to track the 3D motion of biological tissue) [282–285], and motion compensation by
electronic beam steering (electronically steering the ultrasonic beam to compensate the 3D
movement of the organ after measuring the tissue motion) [286–288]. In future studies, the
above-mentioned interventions [289–291] could potentially be applied or modified to be used in
MRgHIFU HT. In this way, a larger variety of organs, including those located in the upper
abdomen (i.e. liver) and flank (i.e. kidney) that were affected by respiration, could potentially be
treated. In addition, as we mentioned in chapter 4, the bladder and/or rectal filling could be
applied to relieve the physiological motion from bladder filling and/or rectal peristalsis, and the
safety of any of the additional intervention warrants further validation.
For the next step of the experiment, researchers could evaluate the tolerability in healthy
volunteers or cervical cancer patients. For example, for anterior targeting, if patients do not have
urinary incontinence or discomfort, researchers could encourage them to drink more water and
refrain from micturition. Otherwise, researchers could determine if it is feasible to perform the
intervention as we described in Chapter 4 [247], including filling their bladder with 200–500 ml
normal saline via Foley catheter, lower abdominal massage, and/or use a plastic vaginal
speculum to fix the uterus position [258]. For posterior targeting, researchers could fill the
rectum with ultrasound gel [258]. After the bowel/bladder preparation, researchers could acquire
a MR imaging series to evaluate if such interventions could facilitate the MRgHIFU targeting
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under good patients’ tolerance, and/or quantify the level of patients’ discomfort for each
intervention.
As we summarized in chapter 1, in previous clinical studies utilizing ultrasound induced HT,
treatment toxicity caused by ultrasound and/or RT included peculiar burning [140], hot sensation
[119], severe soft tissue necrosis [13], skin pigmentation [144], tumor ulceration [145], moist
desquamation [146], or hematuria (when treating prostate) [148]. When conducting the
experiment for the next step using MRgHIFU induced HT, researchers should observe and
evaluate if similar reported side effects occur. In addition, to enhance safety, future studies
should also explore procedures that could potentially prevent or alleviate adverse events. For
example, in previous clinical studies using HIFU ablation, a cooling interval of 2–3 s between
every 2 s of ablation was required to prevent overheating of the target tissue [292]. Also, cold
saline was utilized to wash and cool down the bladder immediately after ablation [293]. Nonsteroid anti-inflammatory drugs (NSAIDs) were used as needed to relive post-therapy pain (if
any) [293], and oral antibiotics were prescribed for one week post-therapy to prevent potential
infection [294]. These safety precautions utilized in previous clinical studies might be adopted if
needed, and their efficacy could further be evaluated in future research.
Third, in the current study, only one set of parameters (power of 100 W, frequency of 1.0 MHz,
heating duration of 30 minutes, target temperature of 42°C, and the maximal violation
temperature of 44°C, tROI of 18 mm) was used. There are a number of adjustable parameters of
the system (i.e. power, duration, frequency, targeting temperature and depth, threshold
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temperature, and the diameter of heating focus) and future studies could evaluate if each
parameter has a practically usable range and/or an optimal level for heating cervical cancer or
cancer located in the pelvis. For example, research by other groups [12,295] demonstrated the
feasibility of in vivo MRgHIFU-HT with a tROI Ø of 32-mm and 44-mm with different power
level (100W –180W), frequency (0.8MHz –1.0MHz), and sonication duration (10 min–60 min),
but for each parameter set, only 1–2 experiments were repeated [12]. In future studies, more
studies (n≥3) with the same parameter could be performed to assess the robustness of this system
when using tROI Ø of 32-mm and 44-mm. In addition, in a preliminary, phantom-based test, we
found that with a power of 20 W and the diameter of 58 mm, the average temperature was not
able to reach the target temperature of 42°C even after we waited for an extended period of time
(>20 min) when heating a phantom. Thus, we speculated that when the power is below a
threshold (i.e. as low as 20W), the temperature could not rise to the ideal level no matter how
long the heating duration lasts (i.e. >20 min). Future studies could be performed to investigate
the usable threshold power level in the pelvic targets for each diameter of heating focus. Next,
the time needed for the average temperature to reach the target temperature at different power
levels (i.e. 40 W, 160 W, 200 W) could be investigated, in order to provide future researchers
guidance to select an optimal power level for different HT durations. In addition, the temperature
metrics, including the precision, accuracy, uniformity, and temporal variation could be quantified
and compared under different power/frequency levels, and the optimal parameters for different
application should be reported that could potentially be employed in future experiments.
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Another aspect to note is that when comparing the histological results when using (1) 18 mm +
100 W (no irreversible damage, as shown in chapter 2) with (2) 58 mm + 200W (with
irreversible damage, as shown in chapter 3), we observed a discrepancy in the tissue histological
analysis. Future studies could be performed to explore the threshold of MRgHIFU HT that could
cause tissue injury. For example, future studies could evaluate the safety profile of the muscle
tissues when they received different levels of power (i.e. 140 W, 160 W, and 200 W) of
MRgHIFU induced HT in order to find out whether muscle damage could result from the 18-mm
HT under these higher power levels (>100W as we used in chapter 2). Experiments could also be
performed using 100 W HT with different heating diameters (i.e. 32 mm, 44 mm, and 58 mm
each for more than three times to perform statistical analysis) to see if using a larger heating
diameter could lead to irreversible tissue damage.
Fourth, in chapter 2, we evaluated the safety profile for MRgHIFU HT using an 18 mm diameter
heating focus. While we did not detect any irreversible damage to the muscle receiving HT, we
drew our conclusion solely under the condition that only 100 W of power was used. Thus, further
studies are still needed to fully evaluate whether there is any potential tissue injury resulted from
18 mm diameter MRgHIFU induced HT when using higher power levels (i.e. up to 200 W), a
greater range of frequency levels (i.e. 1.2 MHz or 0.8 MHz), and/or for longer heating durations
(i.e. up to 1.5 hours).
Fifth, we only collected tissues at the center of the heated region for H&E staining without
examination of the tissues on the periphery of the heating region and/or using other
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histopathological staining techniques. Future studies might involve performing the histological
examination in larger areas related to the HT therapy, as well as exploring other
immunohistochemistry methods (i.e. heat shock protein, E-selectin, etc.) to further examine the
cellular response and protein expression post-HT therapy. Future studies could develop and
utilize some injectable imaging fiducial marker, similar to the injectable nonmetallic fiducial
markers used in the cone beam CT imaging [296] to further increase co-localization of the
collected tissue with the tissue that received HT. This injectable fiducial marker should be visible
on MR images, not interfere with ultrasound wave, biodegradable, and it could have the property
to quickly transform into solid after subcutaneous injection. The marker can be used as a
reference for HT planning and tissue collection. Second, we only performed staining and
histological analysis at the very center of the collected tissue block. In future studies,
pathological analysis could include collecting a wider range of tissue (e.g., collecting an average
of five blocks of tissue on a dimension of 20 mm to cover the periphery region).
Lastly, future studies should also entail establishing a porcine tumor model, including implanting
tumor tissue (i.e. cervical cancer or other relevant tissues) into healthy porcine muscle or use
genetically modified cancer models to facilitate the wider translation of this technology into
human patients. After the tumors reach a certain size, (1) MRgHIFU induced HT in combination
with RT or (2) RT alone could be used to treat the tumors. We could further demonstrate the
efficacy of the adjuvant effect by MRgHIFU induced HT in the animal tumor model by
comparing the efficacy (i.e. tumor shrinkage or overall survival time) of administration of
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HT+RT with RT alone. In addition, ultrasound stimulated immune responses has been reported
[71,227,297]. This model could also be used for investigating if any anti-tumor immune response
could be stimulated by ultrasound.

5.2.2 Characterization of temperature field and tissue damage
In chapter 3, we characterized the temperature fields and tissue injury of MRgHIFU induced HT
with the largest cell diameter (58 mm) in porcine thigh muscles using different threshold-planes
and target locations. However, we did not provide the exact dimension of the injured tissue.
While the results in chapter 3 could be a basis for a subsequent phase I clinical study, further
technical optimization can facilitate a greater optimization of clinical use and/or broader
opportunities for clinical utility.
The current study only heated healthy muscle tissue which is different from the tumor tissue in
patients. It is more ideal to perform the temperature characterization on tumor tissue in vivo in
future experiments due to the differences in tissue architecture, perfusion rate, and
sensitivity/response to heat between tumor and normal tissue. It would be ideal to implant tumor
tissues to animals to establish in vivo tumor models, in order to mimic the physiology of tumor
tissue, as we have discussed in the last section (5.2.1).
We only provided histopathology analysis of the tissues within the tROI, and at 2 cm beyond the
tROI region, as well as skin and subcutaneous tissue overlaying in the heating pathway. We were
not able to draw a definite boundary between the heated/injured tissue and the unaffected tissues
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(i.e. the exact volume of the damage). More in-depth studies are needed to investigate the
extension of the injury zone in the target volume to provide more detailed instructions for the
clinical practice to avoid tissue damage to sensitive critical structures. This could be achieved
through H&E staining sections at more extended areas in proximity to the heated region (e.g., in
a 58mm × 58mm × 150 mm tissue block, cut 1–2 sections in every 2–5 mm distance behind the
tROI). A larger number of examined tissues could increase the possibility of discovering the
damaged tissue. It will also give the researchers a higher chance of capturing the boundary
between the damaged and healthy tissue.
Future research should also investigate the impact of the parameter space on the performance of
the 58 mm MRgHIFU induced HT. In chapter 3, we used the same power as the first aim(100
W), frequency (1.0 MHz), heating duration (30 min), and target temperature (42°C). However,
previous studies showed a variation in the target temperatures of interest. For example, in clinical
practice, the target temperature might vary when HT is used for different applications such as
RT, chemotherapy, chemo-RT, or for the delivery of thermo-sensitive agents. For RT+HT,
published target goal temperatures included 41.0°C [146], 42.0°C [144], 42.5°C [147,153],
43.0°C [143,159,228]; for chemotherapy, the objective temperatures included 42.0°C
[208,229,230] or the range of 41°C–43°C [20,231]. One study has the target temperature of
42.5°C–43°C (T90) [232] for chemotherapy + RT + HT.
The difference in choosing the different target temperatures for different applications might be
due to the various biological mechanisms of the HT. For HT assisted localized drug delivery, the
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main mechanism involved is related to the increased blood flow and oxygenation that start to rise
at a lower temperature (i.e. 39°C), reach the maximum, and decrease again after the temperature
becomes higher than the thermal threshold of stasis [163]. However, a slightly higher
temperature (i.e. 42°C) might be required for HT-induced DNA repair impairment. Similarly, the
acoustic power might need to be increased to compensate for the intensity lost due to the
increased depth or multiple threshold-plane for deep HT that used multiple threshold-planes.
Hence, power optimization might be needed in order to achieve a more consistent system
performance when heating targets in different depths. Specifically, the following procedure
could be performed as the next step of this study. First, a variety of power levels (including 100
W, 150 W, 200 W) could be applied to (1) deep HT with near-field plane as threshold-plane, (2)
deep HT with both near field and far field as threshold-planes, (3) superficial HT with near-field
as threshold-plane, and (4) superficial HT with both near field and far field as threshold planes.
With each parameter, the experiment should be performed ≥3 times to demonstrate the systems’
robustness. Then, we could potentially find the optimal power levels (for each treatment
condition) that could reach a more consistent temperature distribution by comparing the achieved
temperature from each group. After calculating the “compensated” power level from each group,
this “power compensation” by the depth or threshold-plane could potentially be integrated into
the Sonalleve® system if the treatment goal is for a more consistent temperature distribution for
the HT at different depths.
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In Chapter 3, we demonstrated a proof-of-concept in the ability to change the shape of the
temperature distribution by manipulating the threshold-plane. In future studies, we could
potentially place the near-field or far field at a different distance to the tROI (i.e. with the
distance of 1 cm, 2 cm, and 3 cm to the tROI), and then apply the threshold-plane to either nearfield, far-field, or both fields. We could fully characterize the expected heating volume in each
heating condition after applying HT in pigs. Then, we might be able to find the relationship
between the location of the threshold-plane and the adjustable heating volume by performing a
correlation between the distances from the threshold-plane to the tROI with the reduced heating
volume. This study could also utilize different maximum temperatures in the threshold-planes,
and compare (1) the extent of the modified TIR dimensions and (2) the changed thermal dose
distribution resulting from either different maximum temperature or different locations for the
threshold-plane. Future clinicians could potentially use the planes to shape the heating
distributions in the treatment of patients.
Furthermore, as mentioned in Chapter 3, there is a lack of correlation between the
histopathological results and the contrast-enhanced MR images or the highest temperature
metrics (Tmax/T10/CEM43Tavg). This lack of correlation suggests a number of additional
investigations might be needed. First, the contrast enhanced MRI sequence we used was
originally designed for the detection of the non-perfused area achieved in the ablation application
that is indicative for the non-perfused ablative volume (NPV), a sign of severe tissue damage.
The HT-induced lesions were less likely to be severe injuries. Thus, an MRI sequence that is
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more sensitive to the HT-induced lesion could potentially be developed and integrated into the
MRgHIFU HT application. Second, the diameter of the heating area is about 5.8 cm, but the
dimension of the H&E staining section is 2.5 cm×2.0 cm, which is smaller than the heating
dimension. Further studies could also examine a larger extent of tissue within the target area. The
sectioned area could have a higher chance of revealing the damaged tissues corresponding to the
detected lesion in the contrast enhanced MR images.

5.2.3 Optimization of patient setup/angles
In chapter 4, we retrospectively analyzed the optimal patients’ setup to receive the MRgHIFU
HT treatment by analyzing the targetability from different angles. Future studies could improve
upon our experiment by adopting alternate methods or performing additional evaluations.
First, the interposed bowel loops were a frequent reason for ineligibility and/or failure of HIFU
treatment in uterine disease [258–261,264]. In chapter 4, we assumed that the interposed bowel
loops in most of the cases could be displaced out of the acoustic beam path. This assumption is
based on effective techniques reported in previous clinical studies to displace the bowel loops out
of the way of the ultrasound beampath which may enhance patients’ eligibility rate. In one
example, Park et al. [259] first introduced a bowel-manipulation technique by sequentially (1)
filling the bladder with 200–500 ml normal saline via Foley catheter, (2) filling the rectum with
100-ml ultrasound coupling gel via an enema syringe, and (3) emptying the urinary bladder.
They reported the adoption of this technique resulted in the screening failure rate dropping from
33.3% (30/90) to 10.7% (15/140) when using the Sonalleve® system. Kim et al. [260] further
148

verified the feasibility of this unique bowel displacement technique by applying it to 60 patients,
and MRgHIFU could successfully be initiated in 57 out of the 60 patients (57/60, 95%).
Verpalen et al. [258] implemented a newly developed 3-step modified manipulation protocol in
2020 that further decreased the rate of patients’ ineligibility for MRgHIFU due to bowel
interference or inaccessible fibroids from 18% (16/88) to 0% (0/77), and also decreased the
treatment failure rate from 20% to 2%. These procedures were utilized prior to the HIFU ablation
of human leiomyoma, which shared some geometrical proximity with cervical cancer lesions. As
a result of these techniques, we assumed in Chapter 4 that any presence of bowel in the beam
path could potentially be manipulated utilizing one of the published techniques and would not
decrease the patients’ eligibility for MRgHIFU. However, the feasibility and safety of these
manipulation techniques still needs further validation due to the relatively recent emergence of
these technique and the small patient’s population in these clinical studies. First, since cervical
cancer is located more towards the caudal (closer to the pubis), the cervix is more likely to be
blocked by the pubic symphysis. It is possible that the successful rate of these techniques in
cervical cancer is lower than for treatment of uterine fibrosis. Thus, future studies should
investigate whether the above-mentioned techniques would result in comparable success when
applied to cervical cancer. Second, the interposed bowel could block the acoustic pathway on the
treatment day, despite no interposed bowel seen during MR screening in some patients [259].
This implies that the presence of interposed bowel may require manipulation at different time
points before and/or during the course of treatment. Therefore, future studies are needed to
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evaluate whether the published techniques could work successfully during both simulation
evaluation and on the treatment day.
Second, the optimal angle for targeting the cervical cancer posteriorly had a rotation of 25°–30°.
However, we only drew this conclusion based on our assessment from the PET-CT images. This
rotation angle in patients still needs to be evaluated in cervical patients with the goal of
evaluating the targetability with real-time imaging (without heating). As such, future research
should include a simulation in healthy volunteers or cervical cancer patients using a supine setup
with angular rotations similar to that analyzed Chapter 4. We could first perform the abovementioned intervention (i.e. fill the bladder/rectum, bowel message, fix the uterus, etc.[258]) to
the recruited subjects, and then scan them in the supine position with either (1) no rotation, or (2)
a rotation of 25°–30° to validate whether this rotated angle could facilitate the posterior
targetability of the cervix (in healthy volunteers) or tumor (in cervical cancer patients). If the
subjects have good tolerance for more MR scanning, they could (preferably) be scanned in more
rotation angles including ±10°, ±20°, and ±30° in their supine position. A more definite
conclusion about the optimal targeting angle when targeting posteriorly could be reached by
comparing the targetable cervix (in healthy volunteers) or tumor (in cervical cancer patients)
from different targeting angles.
Third, the heatable volume could potentially be analyzed by the computational heating transfer
model and then cross-verified in human patients. The thermal properties of various types of
tissues (blood vessels, adipose tissues, ligaments, fascia, skin, etc.) should be taken into
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consideration, as well as the neighboring structures, physiological motion, and the utilized
interventions.
Fourth, in chapter 4, we only aimed to cover part of the tumor lesion due to the irregularly-shape
of the lesion, the cone-shape heating volume of our system, the challenging geometry for HT
targeting, and similar strategies reported in a previous study [271]. However, for the treatment of
cervical cancer by MRgHIFU HT, it is still unknown whether covering the whole tumor will
result in a better clinical outcome compared with only heating part of the tumor. Thus,
comparing the efficacy of RT and RT+HT, with HT only partially covering the tumor volume
still deserves further study. Specifically, future researchers should perform a prospective
randomized control trial for treating locally advanced cervical cancer patients including one arm
receiving only RT and the other arm receiving RT+HT with partial target coverage. The clinical
benefit of the addition of HT could be evaluated by comparing the CRR, PRR, and overall
survival rate.
Fifth, we observed in the MR images that many nerves exist in the posterior pelvic cavity. It is
possible to cause nerve damage if the heated area is too close to nerve tissues. During the study
in Chapter 3, we observed that two animals had their hind limb jerking while receiving the HT
under anesthesia when applying HT to the thigh muscle close to the nerve bundle. This raises
concerns that even a relative mild temperature (40°C – 45°C) might lead to nerve stimulation
when the heating zone is relatively close to the nerve tissue. Future in vivo animal studies could
heat the nerve bundle while using electromyography for evaluating and recording the electrical
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activity produced by skeletal muscles to fully evaluate if HT could lead to nerve stimulation. If
the electromyography shows any electrical activation, future researchers could heat the muscle
adjacent to the nerve bundle (i.e. muscles that are 3 cm, 2 cm, 1 cm away from the nerve tissue)
to detect if there is a safety boundary that is needed to keep away from the nerve tissues to avoid
similar nerve activation.
Sixth, it will be ideal to develop equipment that can perform MRgHIFU and RT at the same time
since simultaneous application of MRgHIFU induced HT with RT can potentially result in a
maximal radiosensitization effect [93]. An MR-guided RT capable treatment unit would need to
be merged with MRgHIFU induced HT devices. Currently, no such device exists on the market.
Therefore, development of this hardware combination (i.e. design of the equipment room,
building materials, etc.) could potentially help increase the efficacy of MRgHIFU induced
HT+RT.

5.3 Future clinical research
The completion of this dissertation has directly paved the way for a phase I clinical study for late
stage cervical cancer as well as other clinical studies for the treatment of cancer located in the
pelvis (i.e. vulva, prostate, scrotum, etc.).
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As a preliminary study, the phase I clinical trial should focus on the treatment safety and
feasibility of MRgHIFU induced HT. More than ten patients [298] with locally advance cervical
cancer (stage IIIB –IVA) that received RT could be recruited in a single treatment arm. For all
patients, the distance between their anatomical landmarks (in chapter 4) could be measured, and
their pre-treatment PET-CT images could be imported into the MRgHIFU system to evaluate
their targetability.

Before performing the HT study, researchers could first perform an MR scanning using the
MRgHIFU system. During the imaging study, patients could be placed in the targetable position
as shown in the prior imaging analysis. If researchers plan to target from anterior direction, they
could encourage patients to drink more water and refrain from micturition prior to scanning, in
order to distend the bladder and push the bowel loops out of the ultrasound beam path (provided
the researchers think it is helpful to target the lesion with these approaches). However, this
procedure might not be suitable for them if patients have urinary incontinence or discomfort
during bladder distension. Instead, filling the bladder with a urinary catheter (as performed in
chapter 2) could aid in displacing the bowel loops out of the ultrasound beampath. Rectal filling
might be required to stabilize the peristaltic motion and construct an acoustic window if the plan
is to target from a posterior position. The diameter of the heating focus could be chosen based on
the dimension of the cervical lesion and the available acoustic window during the treatment.
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HT could target a temperature of 41°C – 42°C for 30 min – 60 min per session in proximity to
the patient’s standard RT treatment (i.e. a separation between the two of less than or equal to 4
hours). After the treatment, the temperature metrics including the accuracy, precision, temporal
variation, uniformity, the time needed for the average temperature to reach 41°C, and CEM43T90
could be recorded and compared with HT in the porcine model. Despite some similarities, the
pig model used in this study does not correlate perfectly with human anatomy. For example, the
3-month-old pigs have a thinner subcutaneous fat layer (6 to 8 mm) than most humans (7.2 to
83.8 mm as shown in chapter 4). Future studies should investigate whether the potentially thicker
adipose tissue impacts temperature monitoring. Additional aspects may need further evaluation
in clinical studies.

The patients’ tolerance or adverse events resulting from MRgHIFU induced HT still needs to be
evaluated. In the studies in Chapters 2 and 3, the pigs’ muscle tissue was heated after intubation
(under general anesthesia) which is not representative of the preferred scenario for patient
heating. Previous clinical studies treated patients under conscious sedation which is preferable
for safety concerns [299]. However, to heat patients continuously for up to 1 hour requires the
patients’ obedience and tolerance. According to a previous clinical study [121] using ultrasound
induced HT, 9.09% of the HT sessions were terminated due to pain and discomfort during
treatment. Most of the published clinical studies reported skin lesions (i.e. burning [140], hot
sensation [119], pigmentation [144], ulceration [145], or moist desquamation [146]). Extra care
should be taken to protect the skin when applying HT. For example, during the therapy, a
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relatively lower target temperature (i.e. 41°C) or a smaller heating focus (i.e. 18 mm) could be
aimed, and a relatively longer HT (i.e.1 h) could be broken down into two subsequent sessions
(i.e. 30 min) as previous study showed the thermal skin damage is time-temperature dependent
[300]. Additionally, before placing the patients on the HIFU tabletop, their skin should be
cleaned by cotton soaked by alcohol. Suction should also be performed to remove any dermal
micro bubbles in the hair follicles. The range of skin preparation should extend at least 8 cm
beyond the tumor borders [301]. The gel pad in contact with the patients should be cautiously
examined to prevent any small bubbles. In addition, the direct skin cooling (DISC) could be
utilized during heating to prevent the skin temperature overshoot [134]. After treatment, as
reported in other clinical studies using HIFU to ablate uterine fibrosis, cold saline might be used
to fill the bladder to cool down the bladder post-ablation [293], oral antibiotics, as were used in
ablation studies, taken after treatment for 7 days might be prescribed as an infection prophylaxis
[294] or NSAIDs for pain relief [293]. Future studies could utilize the above-mentioned
strategies to protect the overlaying skin tissues and potentially alleviate other adverse events.

Several methods have been introduced in other publications for HIFU ablation application for
displacement of the digestive tract out of the ultrasound beam path [258,259,261,264–266].
However, these techniques might need further assessment and refinement for HT applications as
the duration of HT is longer than ablation, and the gradual filling of the bladder during the
treatment could lead to an over-distended bladder wall and patient discomfort or even organ
injury.
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Finally, this study demonstrated a method to assessing safety and feasibility for MRgHIFU
induced HT to for cervical cancer. The feasibility and/or efficacy for other potential pelvic
targets, (i.e. cervical intraepithelial neoplasia, or CIN) and/or cancerous lesions located in the
pelvis (i.e. vulvar carcinoma or testicular tumors), could also be investigated. For example, one
study [302] reported the transvaginal high-frequency FUS for treatment of CIN 1, and reported a
cure rate of 90%. In addition, 24 out of 28 patients HPV (+) pre-FUS converted to negative after
the treatment. The methods we have developed in this dissertation could potentially be applied to
MRgHIFU HIFU ablation of CIN. Patients should be followed with intensified screening since
invasive surgery for biopsy-proven CIN 1 patients is not indicated [303]. Diagnostic excision of
the transformation zone should only be performed if the risk of underlying high-grade disease is
high [303]. Thus, the advantages, drawbacks, cost-efficiency, and the appropriate time-point to
use transvaginal FUS and/or extracorporeal HIFU in the management of CIN still warrants
further evaluation.

Ultimately, it should be feasible to proceed into a stage I trial for treating locally advance
cervical cancer (stage IIIB –IVA) with MRgHIFU induced HT based on the results of this study
seen in Chapters 2-4 and the discussion above. However, several elements warrant further
investigation to improve or optimize the implementation of MRgHIFU induced HT both in
porcine models in vivo and human patients with cervical cancer or other disease.
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Chapter 6 Summary
With the goal of pushing the MRgHIFU HT technique into human late stage cervical cancer
patients’ treatment in a phase I clinical trial, we have evaluated the current status of ultrasound
induced HT in clinical studies for cancer therapy (chapter 1), evaluated the feasibility, safety of
this technique (chapter 2), explored possible parameters optimization (chapter 3), retrospectively
assessed the targetability of this technique in advance-stage cervical cancer patients using PETCT images (chapter 4), and discussed future research directions (chapter 5). The contributions
are summarized as followed.

HT, as one of the most effective sensitizers for RT [11,24], has been used for treating cancer
with a long history from pre-Christian times [25–27]. Chapter 1 presented the history overview/
mechanisms/ usable technique of HT, currently recommended thermal dosimetry requirement
and quality assurance procedure of HT practice, the image guidance techniques of HT, and the
evolution of ultrasound technology to induce HT, previous clinical studies using ultrasound
induced HT, and the challenges of ultrasound induced HT in current clinical practice. This
chapter gave a comprehensive overview of the advantages and challenges of ultrasound induced
HT in clinical studies. It also emphasized that MRgHIFU induced HT provides more control
over the power deposition pattern, thus translating into adjustable temperature distributions. This
manipulation of the temperature field is one advancement of the HT technique, and could not be
achieved by using traditional isolated thermocouple(s). Furthermore, this chapter showed the
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unmet needs (e.g., evaluate the feasibility and safety of MRgHIFU HT techniques and optimize
the parameters for better controlling the temperature distribution) for ultrasound induced HT for
the optimal translation into clinical trials, and illustrates the significance of the studies we
performed in the following chapters.

To propel the implementation of MRgHIFU induced HT into treatment for human patients, the
second chapter evaluated the feasibility and assessed safety parameters of MRgHIFU induced
HT for heating different geometries of pelvic locations (muscles close to the bladder and uterus)
in a porcine model in vivo. We demonstrated the feasibility of performing MRgHIFU induced
HT (ø=18 mm) to a set of clinically mimicking pelvic targets with satisfactory safety parameters
(including contrast-enhanced MRI, macroscopic tissue observations, and contrast-enhanced
MRI). Therefore, the results from this chapter support proceeding into a human clinical trial
(with the smallest 18 mm cell size). However, for HT using larger heating diameters (up to 58
mm), the temperature statistics and safety profile still needed further evaluation.

In the third chapter, we characterized the temperature distribution and tissue damage profile of
large-volume (ø=58 mm) HT in both deep (i.e., 6-cm) and superficial (i.e., 2-cm) locations by
applying a series of HT in vivo with different user-definable parameters. The results showed
MRgHIFU induced HT could feasibly be delivered to both depths with satisfactory temperature
characteristics. Target tissue histology showed some tissue damage within the HT target volume
but no damage to the surrounding tissues, implying a satisfactory safety profile for the tissues
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surrounding the target. These results, along with the results we obtained in chapter 2, support the
proceeding into a clinical study using MRgHIFU HT for the patients with cancer located in the
pelvis or thigh muscle. However, due to the different anatomy between the human and pigs, the
targetability of the pelvic targets by MRgHIFU induced HT still required further evaluation.

To evaluate the targetability of MRgHIFU induced HT in human patients, chapter 4 evaluated
the percentage of primary lesions and metastatic lymph nodes in late-stage cervical cancer (stage
IIIB–IVA) patients that can be targeted by a clinical MRgHIFU device; assessed optimal patient
positioning for the highest targetability rate; and analyzed any statistical correlation between the
patients’ anatomical geometries/demographics and the targetability. The results showed that
most (72.15%) of the primary cervical cancer could be targeted by the MRgHIFU induced HT
with no/minimal intervention, with a rotation of 0° or 25°–30° relative to the transducer might
benefit posterior and anterior targetability, respectively. Certain demographic/anatomic
parameters might be useful in screening patients for treatability. Build upon the results acquired
from chapters 2, 3, and 4, we have demonstrated that MRgHIFU induced HT could be feasibly
and safely delivered to most of the late-stage cervical cancer primaries while achieving
satisfactory temperature distributions and without damaging the normal surrounding tissues.

In the fifth chapter, we discussed the future research directions in both pre-clinical and clinical
studies related to MRgHIFU induced HT. For pre-clinical studies, more ultrasound parameters
(including power, heating duration, threshold planes, frequency, and target temperature) space
159

could be explored and optimized for different applications; the feasibility of heating more pelvic
organs (vulva, prostate, penis) could be evaluated; additional interventions (to reduce the
physiological motion) could be applied to broaden the usage of MRgHIFU induced HT; and
more staining techniques could be examined for evaluating the tissue damage. In addition, future
studies could establish the tumor models to further evaluate the heating distribution, local tumor
response, and overall survival benefit resulted from MRgHIFU induced HT. For clinical studies,
the completion of this dissertation pave the way for a phase I clinical study for late stage cervical
cancer. And a couple of issues should be addressed, including the patients’ tolerance [121], the
feasibility of using the proposed technique [121,258,259,261,264–266] to displace the digestive
tracts out of the ultrasound beam path, and the efficacy of HT for cancer located in the pelvis,
including late-stage cervical cancer.

In conclusion, this dissertation reviewed previously developed ultrasound induced HT
technology in clinical trials, demonstrated the feasibility and assessed the safety profile of
MRgHIFU HT and investigated the parameter optimization of MRgHIFU HT in a porcine
model. The targetability of cervical cancer in real patients by MRgHIFU HT was evaluated in a
retrospective treatment planning study, finding the preponderance of targets were potentially
accessible by MRgHIFU HT. These results support proceeding into a Phase I clinical trial using
MRgHIFU HT for treating cervical cancer.
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